Compositions and methods for RNA-encoded DNA replacement of alleles
Patent Information
- Application Number
- JP2023527427
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2041-11-05
AI Technical Summary
Current base editing tools have limitations in editing thymine and guanine residues and are restricted by a small editing window, necessitating the development of new editing tools to expand the range of edits possible in various organisms.
The use of recombinant nucleic acid constructs comprising CRISPR-Cas effector proteins, reverse transcriptases, and extended guide nucleic acids to modify target nucleic acids, including the introduction of expression cassettes optimized for plant expression, which facilitate precise nucleic acid editing by coordinating the functions of these components to enhance editing efficiency.
This approach allows for more comprehensive nucleic acid editing by expanding the range of editable residues beyond cytosine and adenine, improving editing efficiency and precision in plants and other organisms.
Abstract
Description
Technical Field
[0001] Statement Regarding the Electronic File of the Sequence Listing Provide, in lieu of a paper copy, the sequence listing in ASCII text format submitted via EFS-Web on November 5, 2021, having a size of 1,043,362 bytes, titled 1499.57.WO_ST25.txt, submitted in accordance with 37 C.F.R.§1.821. This sequence listing is incorporated herein by reference for its disclosure.
[0002] Statement of Priority This application claims the benefit of U.S. Provisional Patent Application No. 63 / 110,386, filed on November 6, 2020, under 35 U.S.C.§119(e), the entire content of which is incorporated herein by reference.
[0003] Field of the Invention The present invention relates to recombinant nucleic acid constructs comprising CRISPR-Cas effector proteins, reverse transcriptases, and extended guide nucleic acids for modifying nucleic acids in plants, and methods of using the same.
Background Art
[0004] Base editing has been shown to be an efficient way to change cytosine and adenine residues to thymine and guanine, respectively. These tools are powerful, but have several limitations, such as limited access to trait-related targets due to small base editing windows, inability to convert cytosine and adenine to other residues, and inability to edit thymine or guanine residues, unless bisulfite bases and enzymes with high PAM density are available for compensation. Thus, currently available tools for base editing are limited. Therefore, new editing tools are needed to broaden the range of possible edits for more organisms and make nucleic acid editing more useful.
Summary of the Invention
[0005] In a first embodiment, a method for modifying a target nucleic acid is provided, comprising contacting the target nucleic acid with (a) a type V CRISPR-Cas effector protein or a type II CRISPR-Cas effector protein; (b) a reverse transcriptase; and (c) an extended guide nucleic acid (e.g., extended type II or V CRISPR RNA, extended type II or V CRISPR DNA, extended type II or V crRNA, extended type II or V crDNA), thereby modifying the target nucleic acid.
[0006] In a second embodiment, a method for modifying a target nucleic acid is provided, comprising contacting the target nucleic acid at a first site with (a)(i) a first CRISPR-Cas effector protein; and (ii) a first extended guide nucleic acid (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA); and (b)(i) a second CRISPR-Cas effector protein, (ii) a first reverse transcriptase; and (ii) a first guide nucleic acid, thereby modifying the target nucleic acid.
[0007] A third embodiment provides a method for modifying a target nucleic acid in a plant or plant cell, comprising introducing an expression cassette of the present invention into a plant or plant cell, thereby modifying a target nucleic acid in the plant or plant cell, and generating a plant or plant cell containing the modified target nucleic acid.
[0008] A fourth embodiment provides a complex comprising (a) a type V CRISPR-Cas effector protein or a type II CRISPR-Cas effector protein; (b) a reverse transcriptase; and (c) an extended guide nucleic acid (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA, e.g., a targeted allele guide (tag) nucleic acid (i.e., tagDNA, tagRNA)).
[0009] In a fifth embodiment, a codon-optimized expression cassette for expression in an organism is provided, comprising (a) a polynucleotide encoding a plant-specific promoter sequence (e.g., ZmUbi1, MtUb2, RNA polymerase II (Pol II)) in a 5' to 3' orientation; (b) a plant codon-optimized polynucleotide encoding a type V CRISPR-Cas nuclease (e.g., Cpf1 (Cas12a), dCas12a, etc.); (c) a linker sequence; and (d) a plant codon-optimized polynucleotide encoding a reverse transcriptase.
[0010] In a sixth embodiment, an expression cassette is provided which is codon-optimized for expression in an organism, comprising (a) a polynucleotide encoding a promoter sequence and (b) an extended RNA guide sequence, wherein the extended guide nucleic acid comprises an extended portion having a primer binding site and an edit portion incorporated into a target nucleic acid at its 3' end (e.g., a template for reverse transcriptase), and optionally the extended guide nucleic acid is included in the expression cassette, and optionally the extended guide nucleic acid is operably ligated to a Pol II promoter.
[0011] The present invention further provides cells, including plant cells, bacterial cells, archaeal cells, fungal cells, and animal cells, that contain target nucleic acids modified by the method of the present invention, and organisms, including plants, bacteria, archaea, fungi, and animals, that contain such cells. Furthermore, the present invention provides a kit comprising the polynucleotides, polypeptides, and expression cassettes of the present invention.
[0012] These and other aspects of the present invention are described in more detail in the following description of the invention. [Brief explanation of the drawing]
[0013] [Figure 1]Figure 1 is a schematic diagram illustrating the generation of a DNA sequence by reverse transcription of crRNA and its subsequent integration into a nick site. The extended guide crRNA (tagRNA) binds to Cpf1 nickase (cas12a nickase) (nCpf1, upper left). Alternatively, the extended portion encoding the editing template may be located at 5' of the crRNA. The 3' end of the crRNA is complementary to the DNA at the nick site (non-bold pairing line, upper left). nCpf1 may be covalently bound to reverse transcriptase (RT), or RT may be recruited to nCpf1, in which case multiple reverse transcriptase proteins may be recruited to nCpf1. RT polymerizes DNA from the 3' end of the DNA nick on the second strand to generate a DNA sequence complementary to the crRNA, which has complementary nucleotides (non-bold pairing line, upper right) followed by nucleotides (non-bold pairing line, upper right) that are not complementary to the genome (bold pairing line, curly braces, upper right). Upon dissociation, the resulting DNA has an extended ssDNA with a 3' overhang, which has a nearly identical sequence to the original DNA (non-bold pairing line, bottom right) but contains several non-native nucleotides (bold pairing line, curly braces, bottom right). This flap is in equilibrium with a structure (bottom left) that has a 5' overhang in which mismatched nucleotides are incorporated into the DNA. Equilibrium can shift towards the left structure by reduction of mismatch repair, removal of the 5' flap during repair and replication, and by nicking of the first strand as described herein. [Figure 2]Figure 2 is a schematic diagram illustrating a method for reducing mismatch repair. To promote an equilibrium more favorable to the formation of the final product having modified nucleotides (bold, curly braces), nickase is guided (via guide nucleic acid) to cleave the first strand (e.g., the target strand or the lower strand) of the target nucleic acid at a distance from the nick in the region outside the RT-editing region (lightning bolt) – the second strand (e.g., the target strand or the upper strand). The nCpf1:crRNA molecule may be on either side of the editing bubble or on both sides. Nicking the first strand (dashed line) indicates to the cell that the newly incorporated nucleotide during mismatch repair and replication is the correct nucleotide, and therefore favorable to the final product having the new nucleotide. Other possible methods for maintaining equilibrium toward the desired product may include the removal of the 5' flap. [Figure 3] Figure 3 illustrates an alternative method of nucleic acid modification using the composition of the present invention, in which two nicks are introduced into the second strand, and the sequence introduced by RT is replaced by a double-nicked WT sequence, thereby enabling more efficient integration into the genome. [Figure 4] LbCas12a_R1138A is cleaved on a 1% TAE-agarose gel and is a nickase, as demonstrated in vitro. A supercoiled 2.8kB plasmid migrated with an apparent size of 2.0kB (lane 2) until double-strand breaks were induced by wild-type LbCas12a (lane 3). [Figure 5] Figure 5 shows the configuration of the REDRAW editor tested with E. coli (see Example 1). [Figure 6] Figure 6 shows the conformation of the tagRNA tested in the first library. [Figure 7] Figure 7 shows the structure of an example hairpin array (sequence number 203) designed for use in REDRAW editing. [Figure 8]Figure 8 shows the Sanger sequencing results demonstrating TGA>CTG editing that restored antibiotic resistance in the non-functional aadA gene (SEQ ID NOs. 204-208). The editing was observed in the SV40-MMLV-RT-XTEN-nLbCas12a-SV40 protein composition from colonies of selection 10 (SEQ ID NO: 71). [Figure 9] Figure 9 shows the results of Sanger sequencing of the rpsL gene in the E. coli genome, which confers resistance to the antibiotic streptomycin (SEQ ID NOs. 209-211). The editing was observed in the SV40-MMLV-RT-XTEN-nRVRLbCas12a(H759A)-SV40 protein composition from colonies of selection 2.5 (SEQ ID NO: 79). [Figure 10] Figure 10 shows the Sanger sequencing results demonstrating TGA>GAT editing that restored antibiotic resistance in the non-functional aadA gene (SEQ ID NOs. 212-215). The editing was observed in the SV40-nLbCas12a-XTEN-MMLV-RT-SV40 protein composition from a selection of 2.25 colonies (SEQ ID NOs. 73). [Figure 11] Figure 11 shows the Sanger sequencing results demonstrating TGA>GAT editing that restored antibiotic resistance in the non-functional aadA gene (SEQ ID NOs: 212-215). The editing was observed in the SV40-MMLV-RT-XTEN-nLbCas12a(H759A)-SV40 protein composition from colonies of selection 2.31 (SEQ ID NO: 83). [Figure 12]Figure 12 shows an example of an editing method performed in human cells (see Example 2). Panel A shows a double-stranded target nucleic acid. The Cas12a complex (the complex includes an extended guide nucleic acid, not shown) is recruited to the first strand (target strand, bottom strand), and the second strand (top strand, non-target strand) has a 5' flap which may be removed by a 5'-3' exonuclease (Panel B). Panel C shows the reverse transcriptase MMuLV-RT(5M) (SEQ ID NO: 53) extending from a priming site or primer (complementary to the primer binding site) on the target nucleic acid (dashed line = extension). Panels D and E show the resolution of the DNA intermediate by mismatch repair and DNA ligation, and the generation of a new edited DNA strand. [Figure 13] Figure 13 shows precise editing of the FANCF1 site in HEK293T cells using various guide conformations. The construct is named Cas12a(H759A)+RT(5M)+RecE FANCF1. [Figure 14] Figure 14 shows precise editing of the DMNT1 site in HEK293T cells using various guide conformations. The construct is named Cas12a(H759A)+RT(5M). [Figure 15] Figure 15 shows the effect of exonuclease transfection on precise editing activity at the DMNT1 site (normalized to no exonuclease treatment; pUC19=1). [Figure 16]Figure 16 shows various forms of the REDRAW architecture (i.e., the constructs of the present invention) and the respective rates of precise editing. The left panel shows reverse transcriptase (RT) provided by a trans (without recruitment). The central panel shows, as an example, the recruitment of RT using a SunTag (e.g., GCN4, e.g., SEQ ID NO: 23) fused to the C-terminus of LbCpf1 (LBCas12a) (LBCpf1-SunTag), which can recruit an antibody (scFv-RT(5M)) (e.g., scFv, SEQ ID NO: 25) fused to the N-terminus of RT(5M). The right panel shows a fusion protein of RT and lbCpf1. The left side of the right panel shows the result of fusing RT to the C-terminus of LbCpf1, and the right side of the right panel shows the result of fusing RT to the N-terminus of LbCpf1. [Figure 17] Figure 17 provides a schematic diagram of the use of a 5'-3' exonuclease to degrade the DNA at both ends of the double-strand break generated during the REDRAW process. [Figure 18] Figure 18 shows the rates of precise editing of REDRAW using a 5'-3' exonuclease (RecE (SEQ ID NO: 129), RecJ (SEQ ID NO: 130), T5_Exo (SEQ ID NO: 131), T7_Exo (SEQ ID NO: 132)) fused to the C-terminus of a Cas polypeptide (LbCpf1). In this configuration, RT(5M) (SEQ ID NO: 53) is expressed in trans (without recruitment). [Figure 19] Figure 19 shows the rates of precise editing of REDRAW using either the 5'-3' exonuclease sbcB (SEQ ID NO: 134) or the 5'-3' exonuclease Exo (SEQ ID NO: 135) each fused to the C-terminus of a Cas polypeptide (LbCpf1). RT(5M) is expressed in trans (without recruitment). [Figure 20]Figure 20 shows the rate of precise editing of REDRAW using the transient expression of exonuclease. LbCpf1 and RT are provided as a fusion protein. The right side of Figure 20 shows the result of fusing RT to the N-terminus of LbCpf1 (RT(5M)-LbCpf1(H759A)), and the left side of the figure shows the result of fusing RT to the C-terminus of LbCpf1 (LbCpf1(H759A)-RT(5M)). [Figure 21] Figure 21 shows the effect of exemplary mutations of Cas12a (LbCpf1) in the REDRAW process on the rate of precise editing of REDRAW. The exemplary mutations tested included K167A, K272A, K349A, K167A+K272A, K167A+K349A, K272A+K349A, and K167A+K272A+K349A (relative positions to the LbCas12a(H759A) SEQ ID NO: 148). [Figure 22] Figure 22 shows the rate of precise editing of REDRAW in the presence of a single-stranded DNA binding protein (ssDNA BP). The ssDNA BP was expressed in trans in the presence of a CRISPR-Cas effector polypeptide (e.g., LbCpf1(H759A)), RT(5M) and tagRNA1. In this example, RT and LbCpf1(H759A) were also expressed in trans. The ssDNA BPs tested were hRad51_s208E_A2'09D, hRad52, BsRecA, EcRecA, and T4SSB. The mock was without ssDNA BP. [Figure 23] Figure 23 shows the rate of precise editing of REDRAW in the presence of a single-stranded DNA binding protein (ssDNA BP) when fused to a CRISPR-Cas effector polypeptide (e.g., LbCas12a H759A). The single-stranded DNA binding proteins (hRad51, hRad52, BsRecA, EcRecA, T4SSB, Brex27) were fused to the N-terminus or C-terminus of LbCpf1(H759A). RT(5M) and tagRNA were expressed in trans. [Figure 24]Figure 24 shows the effect on the percentage of indels produced when REDRAW is performed in the presence of a polypeptide that prevents NHEJ. In this example, the polypeptide that prevents NHEJ is the Gam protein (Escherichia phage Mu Gam protein) (SEQ ID NO: 147), and the reverse transcriptase is expressed in trans, either as the native sequence (e.g., RT(5M)) or with Gam fused to the N-terminus of RT (e.g., Gam-RT(5M)). These constructs are expressed concurrently with LbCas12a(H759A) or LbCas12a(H759A) having the Gam protein fused to its N-terminus (e.g., Gam-LbCas12a H759A). [Figure 25] Figure 25 shows the percentage of REDRAW precision editing in the presence of the Gam protein. The Gam protein is supplied in trans form as a fusion protein with reverse transcriptase (N-terminal fusion; Gam-RT(5M)) and / or a fusion protein with a CRISPR-Cas effector polypeptide (e.g., Gam-LbCas12a H759A). [Figure 26] Figure 26 shows the percentage of REDRAW precision edits using primer-binding sites (PBS) and reverse transcriptase templates (RTT) of different lengths. The upper and lower panels show results using two different spacers (upper panel: pwsp143(GCTCAGCAGGCACCTGCCTCAGC)(SEQ ID NO: 136), lower panel: pwsp139(CTGATGGTCCATGTCTGTTACTC)(SEQ ID NO: 137)). [Figure 27] Figure 27 shows the percentage of editing at different editing positions in two different reverse transcriptase templates (RTTs). The editing region is located at positions ranging from position -1 to position 19 in each RTT (numbering is relative to the numbering of the protospacer-adjacent motif of the target nucleic acid) (editing region is in bold). RTT in the upper panel: TTTGGCTCACTCCTGCTCGGTGAATTT Sequence ID 187; RTT in the lower panel: TTTCGCGCTTGTTCCAATCAGTACGCA Sequence ID 188. [Figure 28]Figure 28 shows the percentage of REDRAW precision editing using two forms of Cas9, nuclease (Cas9) and nickase (nCas9 (D10A variant)). Both Cas9 and nCas9 were tested using tagRNAs (denoted as 3' extension or 5' extension) with an extension attached to either the 3' or 5' end of the guide RNA. The RTT and PBS lengths of the tagRNA extensions were varied, and the spacers targeted four different sites (pwsp10:GAGTCCGAGCAGAAGAAGAA (SEQ ID NO: 140); pwsp621:GCATTTTCAGGAGGAAGCGA (SEQ ID NO: 141); pwsp15:GTCATCTTAGTCATTACCTG (SEQ ID NO: 142); pwsp11:GGAATCCCTTCTGCAGCACC (SEQ ID NO: 143)). [Figure 29] Figure 29 shows the percentage of REDRAW precision editing using BhCas12b. BhCas12b was tested with tagRNAs that had extensions attached to the 3' or 5' end (denoted as 3' or 5') of the guide RNA. The RTT and PBS lengths of the tagRNA extensions were varied, and the spacers targeted three different sites (PWsp1099:ACGTACTGATGTTAACAGCTGA (SEQ ID NO: 144); PWsp1098:GGTCAGCTGTTAACATCAGTAC (SEQ ID NO: 145); PWsp1094:TCCAGCCCGCTGGCCCTGTAAA) (SEQ ID NO: 146). [Figure 30] Figure 30 shows the percentage of REDRAW precision edits using EnAsCpf1(H800A) (SEQ ID NO: 149). The left panel shows edits without RT(5M), the center panel shows edits using EnAsCpf1(H800A)(EnAsCpf1(H800A)-RT(5M)) with RT(5M) fused to the C-terminus, and the right panel shows edits using EnAsCpf1(H800A)(RT(5M)-EnAsCpf1(H800A)) with RT(5M) fused to the N-terminus. In this example, a single site was targeted with a spacer having the sequence CCTCACTCCTGCTCGGTGAATTT (SEQ ID NO: 171). [Figure 31] Figure 31 shows the results of editing the URA3-1 target gene in yeast using the method of the present invention (REDRAW). The upper panel shows the editing results using LbCas12a having reverse transcriptase (RT) fused to the C-terminus (colony formation associated with the repair of adenine nutritional requirements by editing). The lower panel shows the editing results using LbCas12a with RT fused to the N-terminus (colony formation associated with the repair of adenine nutritional requirements by editing). The extended guides used for editing shown in Figure 31 either do not have a pseudoknot or contain a pseudoknot at their 3' end. The pseudoknot is referred to as either a decoy hairpin (SEQ ID NO: 95; SEQ ID NO: 203), tEvoPreQ1 (SEQ ID NO: 158), or EvoPreQ1 (SEQ ID NO: 191). The extended guides further include an RTT having a length of 47, 55, or 63 nucleotides, and a PBS having a length of 48 nucleotides. [Figure 32] Figure 32 shows the results of editing ADE2 target genes in yeast using the method of the present invention (REDRAW). The upper panel shows the editing results using LbCas12a with RT fused to the C-terminus (colony formation associated with the repair of uracil nutritional requirements by editing). The lower panel shows the editing results using LbCas12a with RT fused to the N-terminus (colony formation associated with the repair of uracil nutritional requirements by editing). The extension guides used for editing shown in Figure 32 either do not have a pseudoknot or contain a pseudoknot at their 3' end. The pseudoknots used are referred to as decoy hairpin (SEQ ID NO: 95, SEQ ID NO: 203), tEvoPreQ1 (SEQ ID NO: 158), or EvoPreQ1 (SEQ ID NO: 191). The extension guide further comprises an RTT having a length of 40, 50, or 72 nucleotides and a PBS having a length of 48 nucleotides. Generally, the extension guide nucleic acid contains the RTT, PBS, and a 3' pseudoknot, if present, in a 5'-3' orientation. In the first row of data for the decoy hairpin, tagRNA with a 40-bp RTT and decoy hairpin could not be synthesized in either the upper or lower panel, and therefore the conditions for this were not tested. [Figure 33] Figure 33 shows the results of the precision editing rate when using ssRNA-binding proteins, defensin (SEQ ID NO: 152), and ORF5 (SEQ ID NO: 153), respectively, fused to the N-terminus of an RT-LbCas12 fusion protein (e.g., RT-LbCas12a), compared to the same RT-Cas12a fusion protein without the ssRNA-binding protein fused to its N-terminus. [Figure 34] Figure 34 shows the results of the precision editing rate when using LbCas12a(H759A) fused to a reverse transcriptase (RT) domain with different mutations at its N-terminus. The RTs included RT(L139P, D200N, W388R, E607K), RT(L139P, D200N, T306K, W313F, W388R, E607K), RT(5M, F155Y, H638G), RT(5M, Q221R, V223M), and RT(5M, D524N). [Figure 35] Figure 35 shows the results of the precision editing using four different tagRNAs, each containing structured RNA at its 3' end. The nucleic acid sequences of the structured RNAs are provided in Table 16. [Figure 36] Figure 36 shows the results of the precision editing ratio using chromatin-modifying peptides fused to the construct of the present invention in various fusion orientations. The chromatin-modifying peptides tested included HN1, HB1, H1G, and CHD1. [Figure 37] Figure 37 shows the results for the percentage of precision editing of fusions using the MS2 / MCP system. LbCas12a H759A with RT(5M) was transiently expressed either without MCP (trans control) or with MCP-RT(5M) (fusion construct). Two tagRNAs, tagRNA5 and tagRNA6, were tested. The different tagRNA versions tested contained tagRNAs modified with an MS2 sequence at the 3' end. [Sequence Listing Free Text]
[0014] Sequence IDs 1-20 and 148-150 are exemplary Cas12a amino acid sequences. Sequence IDs 21 and 22 are exemplary regulatory sequences that encode a promoter and an intron. Sequence IDs 23-25 provide exemplary peptide tags and affinity polypeptides. Sequence IDs 26-36 provide exemplary RNA recruiting motifs and their corresponding affinity polypeptides. Sequence IDs 37-52 provide exemplary single-stranded RNA-binding domains (RBDs). Sequence IDs 53, 97, and 172 provide exemplary reverse transcriptase polypeptide sequences: Moloney mouse leukemia virus (M-MuLV) 5(M), 5(M) adjacent to NLS, and M-MuLV, respectively. Sequence IDs 54-56 provide examples of protospacer-adjacent motif positions in V-type CRISPR-Cas12a nucleases. Sequence IDs 57 and 58 provide exemplary constructs of the present invention. Sequence IDs 59 and 60 provide exemplary CRISPR RNA and exemplary protospacers. Sequence IDs 61 and 62 provide exemplary introns. Sequence codes 63-86 and 154-157 provide exemplary REDRAW editor constructors. Sequence ID 87 provides an example of a tag RNA having an 11-base pair (bp) primer-binding sequence and a 96-bp reverse transcriptase template. Sequence IDs 88-91 provide exemplary plasmid sequences. Sequence IDs 92-94 provide the tagRNA sequences associated with the editorial department, as shown in Figures 9-11. Sequence IDs 95, 158, 191, and 203 provide exemplary pseudoknot sequences. Sequence ID 96 provides an exemplary LbCas12a with the H759A mutation and flanked by NLS on both sides. Sequence IDs 98-101 provide exemplary 5'-3' exonuclease polypeptides. Sequence IDs 102 and 103 provide exemplary DMNT1 target sites and target spacers. Sequence IDs 104 and 105 provide exemplary FANCF1 target sites and target spacers. Sequence IDs 106 and 107 provide exemplary Cas9 polypeptides. Sequence IDs 108-122 provide exemplary Cas9 polynucleotides. Sequence IDs 123-128 provide exemplary single-stranded DNA-binding proteins. Sequence IDs 129-135 provide exemplary 5'-3' exonucleases. Sequence numbers 136, 137, 140-146, 159-161, and 171 are exemplary spacers. Sequence IDs 138, 139, and 164-169 provide exemplary reverse transcriptase templates. Sequence ID 140 provides an exemplary Gam protein. Sequence ID 151 provides an exemplary Cas12b polypeptide. Sequence IDs 152 and 153 provide exemplary single-stranded RNA-binding proteins, defensins, and ORF5, respectively. Sequence IDs 162 and 163 provide exemplary primer-binding site (PBS) sequences. Sequence ID 170 provides an exemplary LbCas12a crRNA scaffold. Sequence IDs 173-186 provide exemplary tagRNAs (not tagRNA1, tagRNA2, tagRNA3, tagRNA4, tagRNA5, tagRNA6, tagRNA7, tagRNA8, tagRNA9, tagRNA10, tagRNA11, tagRNA12, tagRNA13, and tagRNA14). Sequence IDs 187 and 188 are reverse transcriptase templates shown in Figure 27. Sequence IDs 95, 189-198, and 203 are exemplary RNA structures. Sequence IDs 199-202 are exemplary chromatin-regulating peptides. Sequence numbers 204-215 are the sequences shown in Figures 8, 9, 10, and 11. [Modes for carrying out the invention]
[0015] Next, the present invention will be described hereafter with reference to the accompanying drawings and examples illustrating embodiments of the invention. This description is not intended to be a detailed catalog of all possible ways in which the invention can be carried out, nor is it intended to be a list of all possible features that may be added to the invention. For example, features described specifically in relation to one embodiment may be incorporated into other embodiments, and features described specifically in relation to a particular embodiment may be omitted from that embodiment. Thus, the present invention is intended to exclude or omit any features or combinations of features shown herein in some embodiments of the invention. Furthermore, numerous variations and additions to the various embodiments suggested herein that do not depart from the invention will be apparent to those skilled in the art in consideration of this disclosure. Therefore, the following description is intended to show some specific embodiments of the invention and is not intended to exhaustively specify all sequences, combinations thereof, and variations.
[0016] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the present invention pertains. The technical terms used herein in describing the present invention are for the purpose of illustrating only specific embodiments and are not intended to be limitations of the invention.
[0017] All publications, patent applications, patents, and other references cited herein, in whole, with respect to the teachings relating to the sentences and / or paragraphs in which they are referenced, constitute part of this specification by reference.
[0018] Unless otherwise indicated by the context, it is specifically intended that the various features of the present invention described herein may be used in any combination. Furthermore, it is also intended that in some embodiments of the present invention, any feature or combination of features shown herein may be excluded or omitted. It is specifically intended that A, B, or C, or any combination thereof, may be omitted or discarded individually or in any combination, in order to indicate that the specification states that a composition includes components A, B, and C.
[0019] The singular forms "a," "an," and "the" used in the description of this invention and the appended claims are intended to similarly include the plural form unless the context clearly indicates otherwise.
[0020] Furthermore, as used herein, “and / or” means and encompasses all possible combinations of one or more of the items described relating to each other, and, when interpreted alternatively (“or”), the absence of any combination.
[0021] When referring to measurable values, such as quantity or concentration, the term “about” as used herein is intended to include variations of ±10%, ±5%, ±1%, ±0.5%, or ±0.1% of the specified value, as well as the specified value itself. For example, if X is a measurable value, “about X” is intended to include X, as well as variations of X of ±10%, ±5%, ±1%, ±0.5%, or ±0.1%. The ranges provided herein for measurable values may include any other ranges and / or individual values within them.
[0022] In this specification, phrases such as "between X and Y" and "about X and Y" should be interpreted as including X and Y. In this specification, phrases such as "about X and Y" mean "about X and about Y," and phrases such as "about X to Y" mean "about X to about Y."
[0023] The descriptions of value ranges in this specification are intended merely as abbreviations for referring individually to each individual value within that range, unless otherwise specifically stated herein, and each individual value is incorporated into the specification as if it were individually stated herein. For example, if the range 10 to 15 is disclosed, then 11, 12, 13, and 14 are also disclosed.
[0024] As used herein, the terms “comprise,” “comprises,” and “comprising” specify the presence of an expressly defined feature, integer, process, operation, element, and / or component, but do not exclude the presence or addition of one or more other features, integers, processes, operations, elements, components, and / or groups thereof.
[0025] As used herein, the transitional phrase “essentially from” should be interpreted as encompassing the specified materials or processes enumerated in the claims, and those that do not materially affect the essential and novel features of the claimed invention. Therefore, as used in the claims of this invention, the term “essentially from” is not intended to be interpreted as equivalent to “include.”
[0026] As used herein, the terms “increase,” “increasing,” “enhance,” “enhancing,” “improve,” and “improving” (and their grammatical variations) describe an increase of at least about 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500%, or more compared to a control.
[0027] As used herein, the terms “reduce,” “reduce,” “reduce,” “reduce,” “decrease,” and “lower” (and their grammatical variations thereof) describe, for example, a reduction of at least about 5%, 10%, 15%, 20%, 25%, 35%, 50%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% compared to a control. In certain embodiments, the reduction may not result in or is essentially unable to result in any detectable activity or amount (i.e., an insignificant amount, e.g., less than about 10% or 5%).
[0028] A "heterogeneous" or "recombinant" nucleotide sequence is a nucleotide sequence that is not naturally associated with the host cell into which it is introduced, and may include multiple copies of a naturally occurring nucleotide sequence that are not naturally occurring.
[0029] "Natural" or "wild-type" nucleic acids, nucleotide sequences, polypeptides, or amino acid sequences refer to nucleic acids, nucleotide sequences, polypeptides, or amino acid sequences that are naturally occurring or endogenous. Therefore, for example, "wild-type mRNA" is mRNA that is naturally occurring or endogenous to a reference organism. A "homologous" nucleic acid sequence is a nucleotide sequence that is naturally associated with the host cell into which it is introduced.
[0030] As used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleotide sequence,” and “polynucleotide” refer to RNA or DNA that are linear or branched, single-stranded or double-stranded, or hybrids thereof. The terms also encompass RNA / DNA hybrids. Furthermore, when dsRNA is synthetically produced, less common bases, such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine, and others, can be used for antisense, dsRNA, and ribozyme pairing. For example, polynucleotides containing C-5 propine analogs of uridine and cytidine have been shown to bind to RNA with high affinity and to be potent antisense inhibitors of gene expression. Other modifications, such as phosphodiester backbone modifications or modifications to the 2'-hydroxyl group within the ribose sugar group of RNA, are also possible.
[0031] As used herein, the term "nucleotide sequence" refers to a heteropolymer or sequence of nucleotides from the 5' end to the 3' end of a nucleic acid molecule, including DNA molecules or RNA molecules such as cDNA, DNA fragments or portions, genomic DNA, synthetic (e.g., chemically synthesized) DNA, plasmid DNA, mRNA, and antisense RNA (all of which may be single-stranded or double-stranded). The terms "nucleotide sequence," "nucleic acid," "nucleic acid molecule," "nucleic acid structure," "oligonucleotide," and "polynucleotide" are used interchangeably herein to refer to a heteropolymer of nucleotides. The nucleic acid molecules and / or nucleotide sequences provided herein are shown from left to right in a 5' to 3' orientation and are represented using standard codes for indicating nucleotide properties as shown in the US Sequencing Rules, 37 CFR §§1.821-1.825, and the World Intellectual Property Organization (WIPO) standard ST.25. As used herein, the "5' region" may mean the region of a polynucleotide closest to the 5' end. Therefore, for example, elements within the 5' region of a polynucleotide can be positioned anywhere from the first nucleotide located at the 5' end of the polynucleotide to nucleotides located in the middle of the polynucleotide. As used herein, the "3' region" may mean the region of the polynucleotide closest to the 3' end of the polynucleotide. Therefore, for example, elements within the 3' region of a polynucleotide can be positioned anywhere from the first nucleotide located at the 3' end of the polynucleotide to nucleotides located in the middle of the polynucleotide.
[0032] As used herein, the term “gene” refers to a nucleic acid molecule that can be used to produce mRNA, antisense RNA, miRNA, and anti-microRNA antisense oligodeoxyribonucleotides (AMOs), etc. Genes may or may not be used to produce functional proteins or gene products. Genes may include both coding and non-coding regions (e.g., introns, regulatory elements, promoters, enhancers, termination sequences, and / or 5' and 3' untranslated regions). Genes may be “isolated,” meaning nucleic acids that are substantially or essentially free from the components normally found in association with nucleic acids in their native state. Such components include other cellular material, culture media derived from recombinant products, and / or various chemicals used to chemically synthesize nucleic acids.
[0033] The term "mutation" refers to point mutations (e.g., missense or nonsense, or the insertion or deletion of a single base pair resulting in a frameshift), insertions, deletions, and / or truncations. When a mutation is the substitution of one residue in an amino acid sequence with another, or the deletion or insertion of one or more residues in a sequence, the mutation is typically described by identifying the position of the residue in the sequence following the original residue, and then identifying the newly substituted residue.
[0034] As used herein, the terms “complementary” or “complementarity” refer to the innate bonding of polynucleotides by base pairing under acceptable salt and temperature conditions. For example, the sequence “AGT” (5' to 3') bonds to the complementary sequence “TCA” (3' to 5'). Complementarity between two single-stranded molecules may be “partial,” where only a portion of the nucleotides are bonded, or it may be complete, if total complementarity exists between the single-stranded molecules. The degree of complementarity between nucleic acid strands has a significant impact on the efficiency and strength of hybridization between nucleic acid strands.
[0035] As used herein, "complementary" may mean 100% complementarity with the comparator nucleotide sequence, or it may mean less than 100% complementarity (e.g., approximately 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%).
[0036] A “part” or “fragment” of a nucleotide sequence in the present invention is reduced in length compared to a reference nucleic acid or nucleotide sequence (for example, by reducing the length by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides) and is identical or nearly identical to the reference nucleic acid or nucleotide sequence (for example, 70%, 71%). It is understood that this means a nucleotide sequence that comprises, and / or comprises a nucleotide sequence containing, or essentially derived from, a nucleotide sequence of consecutive nucleotides (identical to 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%). Such nucleic acid fragments or portions according to the present invention may, where appropriate, be contained within a larger polynucleotide in which it is a component. As an example, the repeat sequence of the guide nucleic acid of the present invention may include a portion of the wild-type V CRISPR-Cas repeat sequence (e.g., wild-type CRISPR-Cas repeats, e.g., repeats derived from the CRISPR-Cas system such as Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b, and / or Cas14c). In some embodiments, the repeat sequence of the guide nucleic acid of the present invention may include a portion of the wild-type CRISPR-Cas9 repeat sequence.
[0037] Different nucleic acids or proteins that exhibit homology are referred to herein as “homologous.” The term “homologous” includes homologous sequences from the same and other species, as well as orthologous sequences from the same and other species. “Homologous” refers to the level of similarity between two or more nucleic acids and / or amino acid sequences, expressed as a percentage of positional identity (i.e., sequence similarity or identity). Homology also refers to the concept of similar functional properties between different nucleic acids or proteins. Thus, the compositions and methods of the present invention further include homologous to the nucleotide and polypeptide sequences of the present invention. As used herein, “ortholog” refers to homologous nucleotide and / or amino acid sequences in different species that arose from a common ancestral gene during speciation. Homogenetics of the nucleotide sequence of the present invention have substantial sequence identity with respect to the nucleotide sequence of the present invention (for example, at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%).
[0038] As used herein, “sequence identity” refers to the degree to which two optimally aligned polynucleotide or polypeptide sequences remain invariant throughout the entire alignment window of their constituent elements, such as nucleotides or amino acids. "Identity" can be easily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology (Lesk, AM, ed.) Oxford University Press, New York (1988), Biocomputing: Informatics and Genome Projects (Smith, DW, ed.) Academic Press, New York (1993), Computer Analysis of Sequence Data, Part I (Griffin, AM, and Griffin, HG, eds.) Humana Press, New Jersey (1994), Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987), and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).
[0039] As used herein, the terms “sequence identity percentage” or “identity percentage” refer to the percentage of identical nucleotides in the linear polynucleotide sequence of a reference ("query") polynucleotide molecule (or its complementary chain) compared to a test ("subject") polynucleotide molecule (or its complementary chain), assuming the two sequences are optimally aligned. In some embodiments, “identity percentage” may refer to the percentage of identical amino acids in the amino acid sequence compared to the reference polypeptide.
[0040] As used herein, the phrases “substantially identical” or “substantially identical” in the context of two nucleic acid molecules, nucleotide sequences, or protein sequences mean two or more sequences or subsequences whose nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence using one of the following sequence comparison algorithms or by visual inspection, is at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or greater. In some embodiments of the present invention, substantial identity exists over nucleotide lengths of approximately 10 to approximately 20 nucleotides, approximately 10 to approximately 25 nucleotides, approximately 10 to approximately 30 nucleotides, approximately 15 to approximately 25 nucleotides, approximately 30 to approximately 40 nucleotides, approximately 50 to approximately 60 nucleotides, approximately 70 to approximately 80 nucleotides, approximately 90 to approximately 100 nucleotides, or more, and over all ranges therein, up to the full length of the sequence, of the continuous nucleotide region of the nucleotide sequence of the present invention. In some embodiments, nucleotide sequences may be substantially identical over at least approximately 20 nucleotides (e.g., approximately 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleotides). In some embodiments, substantially identical nucleotides or protein sequences perform substantially the same function as the nucleotide (or encoded protein sequence) that is substantially identical.
[0041] In sequence comparison, typically, one sequence functions as the reference sequence compared to the test sequence. When using a sequence comparison algorithm, the test sequence and reference sequence are input into the computer, and if necessary, sub-sequence coordinates and sequence algorithm program parameters are specified. Subsequently, the sequence comparison algorithm calculates the sequence identity percentage for the test sequence compared to the reference sequence based on the specified program parameters.
[0042] The optimal alignment of sequences for aligning the comparison window is well known to those skilled in the art and may be performed by tools, such as Smith and Waterman's local homology algorithm, Needleman and Wunsch's homology alignment algorithm, Pearson and Lipman's similarity search method, and possibly by computer implementations of these algorithms, such as GAP, BESTFIT, FASTA, and TFASTA, available as part of the GCG® Wisconsin Package® (Accelrys Inc., San Diego, CA). The “identity fraction” for the aligned segments of the test sequence and reference sequence is the total number of components in the reference sequence segment, e.g., the number of identical components shared by the two aligned sequences, divided by the entire reference sequence or a defined smaller portion of the reference sequence. The sequence identity percentage is expressed as the identity fraction multiplied by 100. The comparison of one or more polynucleotide sequences may be for the full-length polynucleotide sequence or a portion thereof, or for longer polynucleotide sequences. Furthermore, for the purposes of the present invention, the "identity percentage" may be determined using BLASTX version 2.0 for translated nucleotide sequences and BLASTN version 2.0 for polynucleotide sequences.
[0043] Furthermore, two nucleotide sequences may be considered substantially complementary if they hybridize with each other under stringent conditions. In some representative embodiments, two nucleotide sequences considered substantially complementary hybridize with each other under highly stringent conditions.
[0044] In the context of nucleic acid hybridization experiments such as Southern and Northern hybridization, "stringent hybridization conditions" and "stringent hybridization washing conditions" are sequence-dependent and vary under various environmental parameters. A comprehensive guide to nucleic acid hybridization can be found in Tijssen Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes part I chapter 2, “Overview of principles of hybridization and the strategy of nucleic acid probe assays,” Elsevier, New York (1993). Typically, highly stringent hybridization and washing conditions involve defining the thermal melting point (T) for a particular sequence at defined ionic strength and pH. m It is selected to be approximately 5°C lower than ).
[0045] T m This is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matching probe. mVery stringent conditions are selected to be equivalent to the above. An example of stringent hybridization conditions for hybridizing complementary nucleotide sequences with more than 100 complementary residues on the filter in Southern or Northern blotting is 50% formamide with 1 mg heparin at 42°C, with hybridization performed overnight. An example of highly stringent washing conditions is 0.1 5M NaCl at 72°C for about 15 minutes. An example of stringent washing conditions is 0.2×SSC washing at 65°C for 15 minutes (see Sambrook below for an explanation of SSC buffer). Often, high-stringency washing follows low-stringency washing to remove background probe signals. For example, an example of moderate stringency washing for double helixes with more than 100 nucleotides is 1×SSC at 45°C for 15 minutes. For example, a low-stringency wash for double hemispheres of more than 100 nucleotides is 4-6 × SSC at 40°C for 15 minutes. For short probes (e.g., about 10-50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.0 M Na ions, typically about 0.01-1.0 M Na ions (or other salts) at pH 7.0-8.3, and a temperature of at least about 30°C. Stringent conditions can also be achieved by adding destabilizers such as formamide. Generally, a signal-to-noise ratio of 2 × (or higher) than observed for unrelated probes in a particular hybridization assay indicates the detection of specific hybridization. Nucleotide sequences that do not hybridize to each other under stringent conditions are also substantially identical if the encoding proteins are substantially identical. This can occur, for example, when copies of nucleotide sequences occur using the maximum codon degeneracy acceptable by the genetic code.
[0046] The polynucleotides and / or recombinant nucleic acid structures of the present invention may be codon-optimized for expression. In some embodiments, the polynucleotides, nucleic acid structures, expression cassettes, and / or vectors of the present invention (including / encoding, for example, CRISPR-Cas effector proteins (e.g., type V CRISPR-Cas effector proteins), reverse transcriptases, flap endonucleases, 5'-3' exonucleases, etc.) are codon-optimized for expression in organisms (e.g., certain species), possibly animals, plants, fungi, archaea, or bacteria. In some embodiments, codon-optimized nucleic acid structures, polynucleotides, expression cassettes and / or vectors of the present invention have approximately 70% to approximately 99.9% or more identity (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%) identity with non-codon-optimized nucleic acid structures, polynucleotides, expression cassettes and / or vectors.
[0047] In any of the embodiments described herein, the polynucleotide or nucleic acid structure of the present invention may be operably associated with various promoters and / or other regulatory elements for expression in plants and / or plant cells. Thus, in some embodiments, the polynucleotide or nucleic acid structure of the present invention may further include one or more promoters, introns, enhancers, and / or terminators operably linked to one or more nucleotide sequences. In some embodiments, a promoter may be operably bound to an intron (e.g., a Ubi1 promoter and an intron). In some embodiments, a promoter bound to an intron may be referred to as a “promoter region” (e.g., a Ubi1 promoter and an intron).
[0048] As used herein with respect to polynucleotides, “operably linked” or “operably connected” means that the elements being referred to are functionally related to each other and generally physically related as well. Thus, as used herein, the terms “operably linked” or “operably related” refer to nucleotide sequences on a single nucleic acid molecule that are functionally related. Therefore, a first nucleotide sequence operably linked to a second nucleotide sequence means a situation in which the first nucleotide sequence is positioned to be functionally related to the second nucleotide sequence. For example, a promoter is operably related to a nucleotide sequence if the promoter results in the transcription or expression of the nucleotide sequence. Those skilled in the art will understand that a control sequence (e.g., a promoter) does not need to be contiguous with an operably related nucleotide sequence insofar as it functions to guide the expression of that sequence. Thus, for example, an intervening nucleic acid sequence that is transcribed but not translated may exist between a promoter and a nucleotide sequence, and the promoter can still be considered “operably linked” to the nucleotide sequence.
[0049] In this specification, the term "linked" with respect to polypeptides refers to the attachment of one polypeptide to another. Polypeptides may be linked to another polypeptide directly (e.g., via a peptide bond) at the N-terminus or C-terminus, or via a linker.
[0050] The term "linker" is recognized in the art and refers to a chemical group or molecule that links two molecules or parts, for example, two domains of a fusion protein, such as a DNA-binding polypeptide or domain and a peptide tag, and / or an affinity polypeptide that binds to a reverse transcriptase and a peptide tag; or an affinity polypeptide that binds to a DNA endonuclease polypeptide or domain and a peptide tag, and / or a reverse transcriptase and a peptide tag. A linker may consist of a single linking molecule or may include multiple linking molecules. In some embodiments, the linker may be an organic molecule, a group, a polymer, or a chemical part such as a divalent organic moiety. In some embodiments, the linker may be an amino acid or a peptide. In some embodiments, the linker is a peptide.
[0051] In some embodiments, peptide linkers useful in the present invention are amino acids with a length of about 2 to about 100 or more, for example, with a length of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 5 8, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids (for example, approximately 2 to approximately 40, approximately 2 to approximately 50, approximately 2 to approximately 60, approximately 4 to approximately 40, approximately 4 to approximately 50, approximately 4 to approximately 60, approximately 5 to approximately 40, approximately 5 to approximately 50, approximately 5 to approximately 60, approximately 9 to approximately 4 0, approximately 9 to approximately 50, approximately 9 to approximately 60, approximately 10 to approximately 40, approximately 10 to approximately 50, approximately 10 to approximately 60, or lengths of approximately 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 to approximately 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 5 The amino acids may be 9, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100 or more (for example, amino acids with a length of approximately 105, 110, 115, 120, 130, 140, 150 or more). In some embodiments, the peptide linker may be a GS linker.
[0052] As used herein, the terms “linked” or “fused” with respect to polynucleotides refer to the attachment of one polynucleotide to another. In some embodiments, two or more polynucleotide molecules may be linked by a linker, which may be an organic molecule, a group, a polymer, or a chemical moiety such as a divalent organic moiety. A polynucleotide may be linked or fused to another polynucleotide (at its 5' or 3' end) via a covalent or non-covalent bond or a bond including, for example, a Watson-Crick base pairing, or through one or more linked nucleotides. In some embodiments, a polynucleotide motif of a particular structure may be inserted into another polynucleotide sequence (e.g., extension of a hairpin structure in guide RNA). In some embodiments, the linked nucleotides may be naturally occurring nucleotides. In some embodiments, the linked nucleotides may be nucleotides that do not exist in nature.
[0053] A “promoter” is a nucleotide sequence that controls or regulates the transcription of a nucleotide sequence (e.g., a coding sequence) that is operably associated with the promoter. The coding sequence controlled or regulated by the promoter may encode a polypeptide and / or functional RNA. Typically, a “promoter” refers to a nucleotide sequence that contains an RNA polymerase II binding site and directs the initiation of transcription. Generally, promoters are found 5' or upstream of the start of the coding region of the corresponding coding sequence. Promoters may also include other elements that act as regulators of gene expression, such as the promoter region. This includes TATA box consensus sequences and often CAAT box consensus sequences (Breathnach and Chambon, (1981) Annu. Rev. Biochem. 50:349). In plants, the CAAT box may be replaced by the AGGA box (Messing et al., (1983) in Genetic Engineering of Plants, T. Kosuge, C. Meredith and A. Hollaender (eds.), Plenum Press, pp. 211-227). In some embodiments, the promoter region may contain at least one intron (see, e.g., SEQ ID NO: 21, SEQ ID NO: 22).
[0054] Promoter useful in the present invention may include, for example, constitutive, inducible, temporally regulated, developmentally regulated, chemically regulated, tissue-preferential, and / or tissue-specific promoters for use in the preparation of recombinant nucleic acid molecules, such as "synthetic nucleic acid structures" or "protein-RNA complexes." Various types of these promoters are known in the art.
[0055] The choice of promoter may vary depending on the temporal and spatial requirements of expression, or on the host cell to be transformed. Promoters for a wide variety of organisms are well known in this technique. Based on the extensive knowledge available in this technique, a promoter suitable for a specific host organism of interest can be selected. For example, much is known about the upstream promoters of highly constitutively expressed genes in model organisms, and such knowledge is readily accessible and applicable in other systems as needed.
[0056] In some embodiments, functional promoters within plants may be used in conjunction with the constructs of the present invention. Non-limiting examples of promoters useful for driving expression in plants include the promoter for RubisCo small subunit gene 1 (PrbcS1), the promoter for actin gene (Pactin), the promoter for nitrate reductase gene (Pnr), and the promoter for duplicate carbonic anhydrase gene 1 (Pdca1) (see Walker et al. Plant Cell Rep. 23:727-735 (2005); Li et al. Gene 403:132-142 (2007); Li et al. Mol Biol. Rep. 37:1143-1154 (2010)). PrbcS1 and Pactin are constitutive promoters, while Pnr and Pdca1 are inductive promoters. Pnr is induced by nitrates and inhibited by ammonium (Li et al. Gene 403:132-142 (2007)), and Pdca1 is induced by salts (Li et al. Mol Biol. Rep. 37:1143-1154 (2010)). In some embodiments, the promoter useful in the present invention is the RNA polymerase II (Pol II) promoter. In some embodiments, the U6 promoter or 7SL promoter derived from zea mays may be useful in the constructs of the present invention. In some embodiments, the U6c promoter and / or 7SL promoter derived from zea may help drive the expression of guide nucleic acids. In some embodiments, the U6c promoter, U6i promoter and / or 7SL promoter derived from soybean may be useful in the constructs of the present invention. In some embodiments, the U6c promoter, U6i promoter and / or 7SL promoter derived from soybean may help drive the expression of guide nucleic acids.
[0057] Examples of constitutive promoters useful for plants include the cestrum virus promoter (cmp) (US Patent No. 7,166,770), the rice actin 1 promoter (Wang et al. (1992) Mol. Cell. Biol. 12:3399-3406; and US Patent No. 5,641,876), the CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812), the CaMV 19S promoter (Lawton et al. (1987) Plant Mol. Biol. 9:315-324), the nos promoter (Ebert et al. (1987) Proc. Natl. Acad. Sci. USA 84:5745-5749), and the Adh promoter (Walker et al. (1987) Proc. Natl. Acad. Sci. USA This includes, but is not limited to, the ubiquitin promoter (84:6624-6629), the sucrose synthase promoter (Yang & Russell (1990) Proc. Natl. Acad. Sci. USA 87:4144-4148), and the ubiquitin promoter. Constitutive promoters derived from ubiquitin accumulate in many cell types. Ubiquitin promoters have been cloned from several plant species for use in transgenic plants, such as sunflower (Binet et al., 1991. Plant Science 79:87-94), maize (Christensen et al., 1989. Plant Molec. Biol. 12:619-632), and Arabidopsis thaliana (Norris et al., 1993. Plant Molec. Biol. 21:895-906). The maize ubiquitin promoter (UbiP) has been developed in transgenic monocotyledonous plant systems, and its sequence and vector constructed for monocotyledonous plant transformation are disclosed in Japanese Patent Publication No. EP0342926. The ubiquitin promoter is suitable for the expression of the nucleotide sequence of the present invention in transgenic plants, particularly monocotyledonous plants.Furthermore, the promoter expression cassette described by McElroy et al. (Mol.Gen.Genet.231:150-160(1991)) can be readily modified for the expression of the nucleotide sequence of the present invention and is particularly suitable for use in monocotyledonous plant hosts.
[0058] In some embodiments, tissue-specific / tissue-preferential promoters can be used for the expression of heterologous polynucleotides in plant cells. Tissue-specific or preferential expression patterns include, but are not limited to, leaf-specific or preferential, root-specific or preferential, stem-specific or preferential, flower-specific or preferential, or pollen-specific or preferential. Promoter suitable for expression in leaf tissues includes many that control genes involved in photosynthesis, and many of these have been cloned in both monocots and dicots. In one embodiment, a useful promoter in the present invention is the maize PEPC promoter derived from the phosphoenolcarboxylase gene (Hudspeth & Grula, Plant Molec. Biol. 12:579-589 (1989)). Non-limiting examples of tissue-specific promoters include those relating to genes encoding seed storage proteins (such as β-conglycinin, cluciferin, napine, and phaseolin), zein or lipid proteins (such as oleosin), or proteins involved in fatty acid biosynthesis (including acyl carrier proteins, stearoyl-ACP desaturase, and fatty acid desaturase (fad 2-1)), as well as other nucleic acids expressed during embryonic development (such as Bce4, see, for example, Kridl et al. (1991) Seed Sci. Res. 1:209-219 and European Patent No. 255378). Tissue-specific or tissue-selective promoters useful for the expression of the nucleotide sequences of the present invention in plants, particularly maize, include, but are not limited to, those that direct expression in roots, pith, leaves, or pollen. Such promoters are disclosed, for example, in WO93 / 07278, which in whole forms part of this specification by reference.Other non-limiting examples of tissue-specific or tissue-preferential promoters useful in the present invention include the cotton rubisco promoter disclosed in U.S. Patent No. 6,040,504; the riceseed synthase promoter disclosed in U.S. Patent No. 5,604,121; the root-specific promoter described by de Framond (FEBS 290:103-106 (1991); Ciba-Geigy EP0452269); the stem-specific promoter described in U.S. Patent No. 5,625,136 (Ciba-Geigy) that drives the expression of the maize trpA gene; the Cestrum yellow leaf curl virus promoter disclosed in WO01 / 73087; and pollen-specific or preferential promoters, including rice-derived ProOsLPS10 and ProOsLPS11 (Nguyen et al. Plant Biotechnol. Reports). This includes, but is not limited to, the following: 9(5):297-306(2015)), ZmSTK2_USP derived from maize (Wang et al. Genome 60(6):485-495(2017)), LAT52 and LAT59 derived from tomato (Twell et al. Development 109(3):705-713(1990)), Zm13 (US Patent No. 10,421,972), the PLA2-δ promoter derived from Arabidopsis thaliana (US Patent No. 7,141,424), and / or the ZmC5 promoter derived from maize (International PCT Publication No. WO1999 / 042587).
[0059] Examples of the addition of plant tissue-specific / tissue-preferential promoters include the root hair-specific cis-element (RHE) (Kim et al. The Plant Cell 18:2958-2970 (2006)), the root-specific promoter RCc3 (Jeong et al. Plant Physiol. 153:185-197 (2010)) and RB7 (US Patent No. 5459252), the lectin promoter (Lindstrom et al. (1990) Der. Genet. 11:160-167; and Vodkin (1983) Prog. Clin. Biol. Res. 138:87-98), the maize alcohol dehydrogenase 1 promoter (Dennis et al. (1984) Nucleic Acids Res. 12:3983-4000), and the S-adenosyl-L-methionine synthetase (SAMS) (Vander Mijnsbrugge et al. al. (1996) Plant and Cell Physiology, 37(8):1108-1115), maize light harvesting complex promoter (Bansal et al. (1992) Proc. Natl. Acad. Sci. USA 89:3654-3658), maize heat shock protein promoter (O'Dell et al. (1985) EMBO J.5:451-458; and Rochester et al. (1986) EMBO J.5:451-458), pea small subunit RuBP carboxylase promoter (Cashmore, “Nuclear genes encoding the small subunit of ribulose-l,5-bisphosphate carboxylase” pp.29-39 In: Genetic Engineering of Plants (Hollaender ed., Plenum Press 1983; and Poulsen et al.) al. (1986) Mol. Gen. Genet. 205:193-200), Ti plasmid mannopine synthase promoter (Langridge et al. (1989) Proc. Natl. Acad. Sci. USA 86:3219-3223), Ti plasmid noparin synthase promoter (Langridge et al.(1989), previously mentioned), petunia chalcone isomerase promoter (van Tunen et al. (1988) EMBO J.7:1257-1263), mame glycine-rich protein 1 promoter (Keller et al. (1989) Genes Dev.3:1639-1646), cleaved CaMV 35S promoter (O'Dell et al. (1985) Nature 313:810-812), potato patatin promoter (Wenzler et al. (1989) Plant Mol. Biol.13:347-354), root cell promoter (Yamamoto et al. (1990) Nucleic Acids Res.18:7449), maize zein promoter (Kriz et al. (1987) Mol.Gen.Genet.207:90-98; Langridge et al. al. (1983) Cell 34:1015-1022; Reina et al. (1990) Nucleic Acids Res. 18:6425; Reina et al. (1990) Nucleic Acids Res. 18:7449; and Wandelt et al. (1989) Nucleic Acids Res. 17:2354, globulin-1 promoter (Belanger et al. (1991) Genetics 129:863-872), α-tubulin cab promoter (Sullivan et al. (1989) Mol.Gen.Genet. 215:431-440), PEPCase promoter (Hudspeth & Grula (1989) Plant Mol.Biol. 12:579-589), R gene complex-related promoter (Chandler et al. (1989) Plant This includes, but is not limited to, the Cell 1:1175-1183 and the chalcone synthase promoter (Franken et al. (1991) EMBO J.10:2605-2612).
[0060] Useful for seed-specific expression are the pea vicillin promoter (Czako et al. (1992) Mol. Gen. Genet. 235:33-40; and the seed-specific promoter disclosed in U.S. Patent No. 5,625,136). Useful promoters for expression in mature leaves are those that switch at the onset of senescence, such as the SAG promoter derived from Arabidopsis thaliana (Gan et al. (1995) Science 270:1986-1988).
[0061] Furthermore, promoters that function in chloroplasts can be used. Non-limiting examples of such promoters include the 5'UTR of the bacteriophage T3 gene 9 and other promoters disclosed in U.S. Patent No. 7,579,516. Other promoters useful in the present invention include, but are not limited to, the S-E9 small subunit RuBP carboxylase promoter and the Knitz trypsin inhibitor gene promoter (Kti3).
[0062] Additional modulogenic elements useful in the present invention include, but are not limited to, introns, enhancers, stop sequences, and / or 5' and 3' untranslated regions.
[0063] Introns useful in the present invention may be introns identified within a plant, isolated from the plant, and then inserted into an expression cassette used for plant transformation. As will be understood by those skilled in the art, introns may contain sequences necessary for self-excision and are incorporated into the nucleic acid structure / expression cassette in frame. Introns may be used as spacers to separate multiple protein-coding sequences within a single nucleic acid structure, or within a single protein-coding sequence, for example, to stabilize mRNA. When used within a protein-coding sequence, they are inserted "in frame," including the excision site. Introns may be conjugated with a promoter to improve or modify expression. As an example, promoter / intron combinations useful in the present invention include, but are not limited to, combinations of the maize Ubi1 promoter and introns.
[0064] Non-limiting examples of introns useful in the present invention include introns derived from the ADHI gene (e.g., Adh1-S introns 1, 2, and 6), the ubiquitin gene (Ubi1), the RuBisCO small subunit (rbcS) gene, the RuBisCO large subunit (rbcL) gene, the actin gene (e.g., the actin-1 intron), the pyruvate dehydrogenase kinase gene (pdk), the nitrate reductase gene (nr), the duplicate carbonic anhydrase gene 1 (Tdca1), the psbA gene, the atpA gene, or any combination thereof. Examples of intron sequences may include, but are not limited to, SEQ ID NOs. 61 and SEQ ID NOs. 62.
[0065] In some embodiments, the polynucleotide and / or nucleic acid structures of the present invention may be an “expression cassette” or may be contained within an expression cassette. As used herein, “expression cassette” means a recombinant nucleic acid molecule comprising, for example, the nucleic acid structures of the present invention (e.g., a CRISPR-Cas effector protein, a reverse transcriptase polypeptide or domain, a flap endonuclease polypeptide or domain (e.g., FEN)), and / or a 5'-3' exonuclease), wherein the nucleic acid structures are operably bound to one or more regulatory sequences (e.g., a promoter, a terminator, etc.). Accordingly, some embodiments of the present invention provide, for example, an expression cassette designed to express the nucleic acid structures of the present invention (e.g., nucleic acid structures of the present invention encoding a CRISPR-Cas effector protein or domain, a reverse transcriptase polypeptide or domain, a flap endonuclease polypeptide or domain, and / or a 5'-3' exonuclease polypeptide or domain). If the expression cassette of the present invention contains two or more polynucleotides, the polynucleotides may be operably ligated to a single promoter that drives the expression of all polynucleotides, or they may be operably ligated to one or more separate promoters (for example, three polynucleotides may be driven by one, two or three promoters in any combination). If two or more separate promoters are used, the promoters may be the same promoter, or they may be different promoters. Thus, the polynucleotides encoding the CRISPR-Cas effector protein or domain, the polynucleotides encoding the reverse transcriptase polypeptide or domain, the polynucleotides encoding the flap endonuclease polypeptide or domain, and / or the polynucleotides encoding the 5'-3' exonuclease polypeptide or domain contained in the expression cassette may each be operably ligated to a separate promoter, or they may be operably ligated to two or more promoters in any combination.
[0066] The expression cassette comprising the nucleic acid structure of the present invention may be a chimeric, meaning that at least one of its components is heterogeneous with respect to at least one of the other components (for example, a promoter derived from a host organism, operably linked to a polynucleotide of interest to be expressed in the host organism, where the polynucleotide of interest is derived from an organism other than the host or is not typically found in association with the promoter). The expression cassette may also be obtained in a naturally occurring but recombinant form useful for heterologous expression.
[0067] Expression cassettes may, in some cases, include transcription and / or translation termination regions (i.e., termination regions) and / or enhancer regions that are functional in selected host cells. Various transcription terminators and enhancers are known in the art and are available for use in expression cassettes. Transcription terminators are responsible for transcription termination and precise mRNA polyadenylation. The termination region and / or enhancer region may be specific to the transcription initiation region, for example, to the gene encoding the CRISPR-Cas effector protein, the gene encoding the reverse transcriptase, the gene encoding the flap endonuclease, and / or the gene encoding the 5'-3' exonuclease may be specific to the host cell or specific to another source (e.g., exogenous or heterologous to the host cell or any combination thereof, for the promoter, to the gene encoding the CRISPR-Cas effector protein, the gene encoding the reverse transcriptase, the gene encoding the flap endonuclease, and / or the gene encoding the 5'-3' exonuclease).
[0068] Furthermore, the expression cassette of the present invention may include a polynucleotide encoding a selection marker, which can be used to select transformed host cells. As used herein, “selection marker” means a polynucleotide sequence that, when expressed, gives host cells expressing the marker a distinctive phenotype, so that such transformed cells can be distinguished from cells that do not have the marker. Such a polynucleotide sequence may encode a selection marker or a screening marker, depending on whether the marker confers a trait that can be selected by chemical means, for example by using a selector (e.g., an antibiotic), or whether the marker is a trait that can be identified simply through observation or testing, for example by screening (e.g., fluorescence). Many examples of suitable selection markers are known in the art and can be used in the expression cassettes described herein.
[0069] In addition to expression cassettes, nucleic acid molecules / constructs and polynucleotide sequences described herein may be used in conjunction with vectors. The term “vector” refers to a composition for transmitting, delivering, or introducing nucleic acids into cells. A vector comprises a nucleic acid structure containing the nucleotide sequence to be transmitted, delivered, or introduced. Vectors used for the transformation of host organisms are well known in the art. Non-limiting examples of a common class of vectors include double-stranded or single-stranded linear or cyclic viral vectors, plasmid vectors, phage vectors, phagemide vectors, cosmid vectors, fosmid vectors, bacteriophages, artificial chromosomes, minicircles, or Agrobacterium binary vectors, which may or may not be self-transmitting or mobile. In some embodiments, viral vectors may include, but are not limited to, retrovirus, lentivirus, adenovirus, adeno-associated virus, or herpes simplex virus vectors. Vectors as defined herein can transform prokaryotic or eukaryotic hosts either by integration into the cellular genome or by extrachromosomal presence (e.g., autonomous replication plasmids with origins of replication). In addition, shuttle vectors, meaning DNA vehicles capable of replication naturally or by design within two different host organisms, may be selected from Actinomyces and related species, bacteria, and eukaryotes (e.g., higher-order plant, mammalian, yeast, or fungal cells). In some embodiments, the nucleic acids within the vector are under the control of a promoter or other regulatory element suitable for transcription within the host cell and are operably linked to it. The vector may be a binary functional expression vector that functions in multiple hosts. In the case of genomic DNA, it may contain its own promoter and / or other regulatory elements, and in the case of cDNA, it may be under the control of a promoter and / or other regulatory element suitable for expression within the host cell.Therefore, the nucleic acid structure or polynucleotide and / or expression cassette containing the present invention may be included in the vectors described herein and in vectors known in the art.
[0070] As used herein, “to bring into contact,” “in contact,” “contacted,” and their grammatical variations refer to placing together the components of a desired reaction (e.g., transformation, transcriptional regulation, genome editing, nicking, and / or cleavage) under conditions suitable for carrying out the desired reaction. As an example, a target nucleic acid may be brought into contact with a type II or type V CRISPR-Cas effector protein and a reverse transcriptase, and the target nucleic acid may be modified, under conditions in which a CRISPR-Cas effector protein and reverse transcriptase are expressed, the CRISPR-Cas effector protein binds to the target nucleic acid, and the reverse transcriptase is fused to the CRISPR-Cas effector protein or recruited to the CRISPR-Cas effector protein (e.g., via a peptide tag fused to the CRISPR-Cas effector protein and an affinity tag fused to the reverse transcriptase), so that the reverse transcriptase is positioned near the target nucleic acid. Other protein-protein interactions, as well as other methods utilizing RNA-protein interactions and chemical interactions, may be used to recruit the reverse transcriptase.
[0071] As used herein, “modifying” or “modifying” a target nucleic acid includes editing (e.g., mutation), covalent modification, exchange / substitution of nucleic acid / nucleotide bases, deletion, cleavage, nicking, and / or transcriptional regulation of the target nucleic acid. In some embodiments, modifications may include indels of any size and / or single nucleotide changes (SNPs) of any type.
[0072] In the context of the polynucleotide of interest, “introducing,” “introducing,” and “introduced” (and their grammatical variations) mean presenting the nucleotide sequence of interest (e.g., polynucleotide, nucleic acid structure, and / or guide nucleic acid) to a host organism or the cells of said organism (e.g., host cells, e.g., plant cells) so that the nucleotide sequence gains access to the inside of the cell.
[0073] The terms “transformation” or “transfection” can be used interchangeably and, as used herein, refer to the introduction of a different nucleic acid into a cell. Cellular transformation may be stable or transient. Thus, in some embodiments, a host cell or host organism may be stably transformed with the polynucleotide / nucleic acid molecule of the present invention. In some embodiments, a host cell or host organism may be transiently transformed with the nucleic acid structure of the present invention.
[0074] In the context of polynucleotides, "transient transformation" means that polynucleotides are introduced into a cell but are not integrated into the cell's genome.
[0075] In the context of polynucleotides introduced into cells, "stable introduction" or "being stable introduced" means that the introduced polynucleotides are stablely integrated into the cell's genome, and the cell is stablely transformed by the polynucleotides.
[0076] As used herein, “stable transformation” or “stable transformed” means that a nucleic acid molecule is introduced into a cell and integrated into the cell’s genome. Therefore, the integrated nucleic acid molecule can be inherited by subsequent generations, more specifically by multiple successive generations. As used herein, “genome” includes the nuclear genome, mitochondrial genome, and plastid genome, and therefore includes, for example, the integration of nucleic acids into the chloroplast genome or mitochondrial genome. Furthermore, as used herein, stable transformation may refer to a transgene maintained outside the chromosome, for example, as a microchromosome or plasmid.
[0077] Transient transformations can be detected, for example, by enzyme-linked immunosorbent assay (ELISA) or Western blotting, which can detect the presence of peptides or polypeptides encoded by one or more transgenes introduced into an organism. Stable transformations of cells can be detected, for example, by Southern blotting hybridization assays of the cell's genomic DNA with nucleic acid sequences, which specifically hybridize with the nucleotide sequence of the transgene introduced into the organism (e.g., a plant). Stable transformations of cells can also be detected, for example, by Northern blotting hybridization assays of the cell's RNA with nucleic acid sequences, which specifically hybridize with the nucleotide sequence of the transgene introduced into the host organism. Furthermore, stable transformations of cells can be detected, for example, by polymerase chain reaction (PCR) or other amplification reactions well known in the art, which result in amplification of the transgene sequence using specific primer sequences that hybridize with the target sequence of the transgene, and which can be detected according to standard methods. Transformations can also be detected by direct sequencing and / or hybridization protocols well known in the art.
[0078] Therefore, in some embodiments, the nucleotide sequences, polynucleotides, nucleic acid structures, and / or expression cassettes of the present invention can be transiently expressed and / or stably incorporated into the genome of a host organism. Thus, in some embodiments, the nucleic acid structures of the present invention (e.g., one or more expression cassettes encoding DNA-binding polypeptides or domains, endonuclease polypeptides or domains, reverse transcriptase polypeptides or domains, flap endonuclease polypeptides or domains, and / or nucleic acid-modifying polypeptides or domains) can be transiently introduced into a cell together with a guide nucleic acid, so that no DNA is maintained within the cell.
[0079] The nucleic acid structures of the present invention can be introduced into cells by any method known to those skilled in the art. In some embodiments of the present invention, cell transformation includes nuclear transformation. In other embodiments, cell transformation includes plastid transformation (e.g., chloroplast transformation). In further embodiments, the recombinant nucleic acid structures of the present invention can be introduced into cells via conventional breeding techniques.
[0080] The procedures for transforming both eukaryotes and prokaryotes are well-known and routine in this technique and are described throughout the literature (see, for example, Jiang et al. 2013. Nat. Biotechnol. 31:233-239, Ran et al. Nature Protocols 8:2281-2308 (2013)).
[0081] Therefore, nucleotide sequences can be introduced into a host organism or its cells by several methods known in the art. The method of the present invention introduces one or more nucleotide sequences into an organism, but does not depend on a specific method of accessing the interior of at least one cell of the organism. When multiple nucleotide sequences are to be introduced, they can be assembled as part of a single nucleic acid structure or as separate nucleic acid structures, and can be positioned on the same or different nucleic acid structures. Thus, nucleotide sequences can be introduced into cells of interest in a single transformation event and / or in separate transformation events, or, where applicable, nucleotide sequences can be incorporated into plants, for example, as part of a breeding protocol.
[0082] Base editing has been shown to be an efficient method for changing cytosine and adenine residues into thymine and guanine, respectively. While these tools are powerful, they have several limitations, including bystander bases, a small base editing window, and limited PAM (Periodic Amplification).
[0083] Performing precise template-based editing in cells involves several critical steps, each with its own rate limitations and low efficiency, which can significantly hinder the overall ability to perform editing effectively. For example, one step requires inducing the cell to initiate a repair event at the target site. This is typically done by inducing a double-strand break (DSB) or nick using an exogenously provided sequence-specific nuclease or nickase. Another step requires that the homologous template used for repair be locally available. In this step, the template must be near the DSB at a precise time when the DSB can commit to the editing pathway using the template. This step, in particular, is widely considered to be the rate-limiting step in current editing techniques. A further step is to efficiently incorporate the template-derived sequence into the cleaved or nicked target. Prior to this invention, this step was typically provided by the cell's endogenous DNA repair enzymes. This step is inefficient and difficult to manipulate. This invention avoids many of the major obstacles to the efficiency of template-based editing processes by coordinating the functions necessary to perform the steps described above.
[0084] Figure 1 shows the generation of a DNA sequence from reverse transcription of crRNA using the method and construct of the present invention, and its subsequent incorporation into a nick site. The extended crRNA is shown in blue and is bound to the second-chain nickase Cpf1 (Cas12a) (nCpf1, upper left). As will be described in more detail herein, nCpf1 may be covalently bound to reverse transcriptase (RT), for example via a peptide, or RT may be recruited to nCpf1 (for example, via the use of a peptide tag motif / affinity polypeptide that binds to a peptide tag, or by chemical interactions described herein), in which case multiple reverse transcriptase proteins (RT) may be involved. n) may be mobilized. The 3' end of the guide RNA is complementary to the DNA at the nick site (non-bold pairing line, top left). RT then polymerizes the DNA from the 3' end of the DNA nick to produce a DNA sequence complementary to the RNA, with complementary nucleotides (non-bold pairing line, top right) followed by non-complementary nucleotides (bold pairing line, brackets, top right). Upon dissociation, the resulting DNA has an extended ssDNA with a 3' overhang, which is nearly identical in sequence to the original DNA (non-bold pairing line, bottom right), but has some non-native nucleotides (bold pairing line, brackets, bottom right). This flap is in equilibrium with a structure (bottom left) that has a 5' overhang with mismatched nucleotides incorporated into the DNA. This equilibrium is biased towards the favorable perfect pairing on the right, but can be driven in various ways, including, for example, nicking a second strand (e.g., a non-target strand or top strand). The structure on the left can be preferentially cleaved by cell flap endonucleases involved in DNA lagging strand synthesis, which are highly conserved between mammalian and plant cells (the amino acid sequence of human (Homo sapiens) FEN1 is more than 50% identical to both maize and soybean FEN1). In some embodiments, flap endonucleases may be introduced to drive equilibrium toward a 3' flap containing non-native / mismatched nucleotides. In eukaryotic cells, the long 5' flap is often removed by the Dna2 protein, where again, equilibrium is driven toward the product of the 3' flap (desired) (see, e.g., Nucleic Acids Res. 2012 Aug;40(14):6774-86).
[0085] In the process of the present invention, as illustrated in Figure 2, Cpf1 nickase may be targeted to a region outside the RT editing region (lightning bolt) as described herein, in order to reduce mismatch repair and more drive the equilibrium in favor of the formation of a final product having modified nucleotides (bold, in parentheses). The nCpf1:crRNA molecule may be on either side of the editing bubble or on both sides. Nicking the first strand (e.g., the target strand or bottom strand in Figure 2) (dashed line) indicates to the cell that the newly incorporated nucleotides during mismatch repair and replication are correct nucleotides, and therefore favors a final product having new nucleotides.
[0086] Mutants of reverse transcriptase (RT) can significantly affect the temperature sensitivity and processing capacity of editing systems. Natural, rational, and irrationally engineered (i.e., directed evolution) mutants of RT may be useful for optimizing activity and processing capacity profiles at plant-preferred temperatures.
[0087] The fusion of protein domains to RT polypeptides can significantly affect the temperature sensitivity and processing capacity of the editing system. RT enzymes can be improved in terms of temperature sensitivity, processing capacity, and template affinity by fusion with ssRNA-binding domains (RBDs). These RBDs can be sequence-specific, non-specific, or sequence-preferential (see, e.g., SEQ ID NOs. 37–52). Various affinity distributions can be beneficial for editing in different intracellular and in vitro environments. RBDs can be modified in terms of both specificity and binding free energy by increasing or decreasing their size to recognize more or fewer nucleotides. Multiple RBDs result in proteins with affinity distributions that are combinations of the individual RBDs. Adding one or more RBDs to an RT enzyme can result in increased affinity, increased or decreased sequence specificity, and / or enhanced cooperativity.
[0088] The RT polypeptide used in the present invention may be fused with a single-stranded RNA-binding protein (RBD). RBDs useful in the present invention may be, for example, RBDs obtained from humans, mice, or flies. The single-stranded RNA-binding protein may contain, but is not limited to, any one of SEQ ID NOs. 37-52, and may contain an amino acid sequence.
[0089] After reverse transcriptase incorporates the edit into the genome, sequence redundancy arises between the newly synthesized edited sequence and the original WT sequence intended for substitution. This results in a 5' or 3' flap at the target site, which needs to be repaired by the cell. In equilibrium, two states exist: when the WT sequence is paired with its complement, the binding energy is favorable to the 3' flap because more base pairs are available than when the edited strand is paired with its complement. This is undesirable for efficient editing because processing (removal) of the 3' flap could remove the edited residues, potentially returning the target to the WT sequence. However, cellular flap endonucleases such as FEN1 or Dna2 can efficiently process the 5' flap. Therefore, instead of relying on the function of cell-specific 5'-flap endonucleases, in some embodiments of the present invention, the concentration of flap endonucleases at the target may be increased to further favor the desired equilibrium outcome (removal of the WT sequence in the 5' flap such that the edited sequence is stably incorporated into the target site). This can be achieved by overexpression of 5' flap endonuclease as a free protein in cells. Alternatively, FEN or Dna2 may be actively recruited to the target site by binding to the CRISPR complex via direct protein fusion or by non-covalent recruitment such as a peptide tag-affinity polypeptide pair (e.g., a SunTag antibody / epitope pair) or chemical interactions as described herein.
[0090] The present invention further provides methods for modifying target nucleic acids using the proteins / polypeptides and / or fusion proteins of the present invention, as well as polynucleotides and nucleic acid structures encoding them, and / or expression cassettes and / or vectors containing them. These methods can be carried out in an in vivo system (e.g., intracellular or within a living organism) or in a vitro system (e.g., cell-free). Thus, in some embodiments, a method for modifying target nucleic acids in plant cells is provided, comprising contacting the target nucleic acid with (a) a type V CRISPR-Cas effector protein or a type II CRISPR-Cas effector protein; (b) a reverse transcriptase; and (c) an extended guide nucleic acid (e.g., extended type II or V CRISPR RNA, extended type II or V CRISPR DNA, extended type II or V crRNA, extended type II or V crDNA; e.g., tagRNA, tagDNA), thereby modifying the target nucleic acid. In some embodiments, a type V CRISPR-Cas effector protein or a type II CRISPR-Cas effector protein, a reverse transcriptase, and an extended guide nucleic acid may form a complex that can interact with the target nucleic acid, or may be contained within the complex. In some embodiments, the method of the present invention may further comprise contacting the target nucleic acid with (a) a second type V CRISPR-Cas effector protein or a second type II CRISPR-Cas effector protein; (b) a second reverse transcriptase; and (c) a second extended guide nucleic acid (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA; e.g., tagDNA, tagRNA), where the second extended guide nucleic acid targets a site on the first strand of the target nucleic acid (the spacer is substantially complementary to / bound to a site on the first strand of the target nucleic acid), thereby modifying the target nucleic acid.In some embodiments, the method of the present invention may further comprise contacting a target nucleic acid with (a) a second type V CRISPR-Cas effector protein or a second type II CRISPR-Cas effector protein; (b) a second reverse transcriptase; and (c) a second extended guide nucleic acid (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA; e.g., tagDNA, tagRNA), wherein the second extended guide nucleic acid targets a site on the second strand of the target nucleic acid (the spacer is substantially complementary to / bound to a site on the second strand of the target nucleic acid), thereby modifying the target nucleic acid. In some embodiments, the method of the present invention involves contacting a target nucleic acid at a temperature of about 20°C to 42°C (e.g., about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42°C, and any value or range therein). In some embodiments, the target nucleic acid may be contacted with additional polypeptides and / or nucleic acid structures encoding them in order to improve mismatch repair.In some embodiments, the method of the present invention may further comprise contacting a target nucleic acid with (a) a CRISPR-Cas effector protein; and (b) a guide nucleic acid, wherein (i) the CRISPR-Cas effector protein is a nickase (e.g., nCas9, nCas12a) and is nicked by a type II or type V CRISPR-Cas effector protein, approximately in either the 5' or 3' direction from a site on the second strand nicked by the type II or V CRISPR-Cas effector protein. 10 to approximately 125 base pairs (for example, approximately 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 7 3, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124 or 125 base pairs, or any range or value within that range. (ii) Nicking a site on the first strand of the target nucleic acid located at (ii) or (ii) a CRISPR-Cas effector protein is a nickase (e.g., nCas9, nCas12a) that nicknames a site on the second strand of the target nucleic acid located about 10 to about 125 base pairs (either 5' or 3') from the site on the first strand nicknamed by the type II or V CRISPR-Cas effector protein, thereby improving mismatch repair. In some embodiments, nicknamening the second strand (non-target strand) of the target nucleic acid involves contacting the target nucleic acid with a crRNA containing a mismatch spacer (e.g., about 1, 2, 3, or 4 mismatches; e.g., about 80–96% complementary to the second strand (non-target strand)).In this configuration, nicking does not alter the equilibrium, but because the 5' flap is preferentially processed within the cell, it actually promotes the formation of mismatch product species. Nicking of the non-target chain improves the resolution of the next steps involving mismatch repair.
[0091] Therefore, in some embodiments, at least two RNAs may be utilized in the method of the present invention: a tagRNA that guides the CRISPR-Cas effector protein to the correct location and performs a double-strand break using a complete RNA:DNA match, and a second RNA (crRNA) that anneals to DNA in close proximity on the same strand. This second RNA (crRNA) has a spacer sequence containing several mismatches (not perfectly complementary, e.g., about 1, 2, 3, or 4 mismatches, e.g., about 80% to about 96% complementarity (80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96%)). This results in a CRISPR-Cas effector protein nicking the non-target strand. While not intended to limit to any particular theory, it is thought that after nicking, there is a cellular nuclease that chews back a portion of the non-target strand. Without a non-target strand, there is no blueprint for "repairing" the editing performed using the method of the present invention (REDRAW), resulting in improved editing efficiency. In this configuration, only one fusion enzyme is used, but it can bind to two different RNAs (tagRNA and crRNA).
[0092] In some embodiments, the expansion guide nucleic acid comprises (i) a type V CRISPR nucleic acid or a type II CRISPR nucleic acid (type II or V CRISPR RNA, type II or V CRISPR DNA, type II or V crRNA, type II or V crDNA), and / or a CRISPR nucleic acid and a tracr nucleic acid (e.g., type II or V tracrRNA, type II or V tracrDNA); and (ii) an expansion portion comprising a primer binding site and a reverse transcriptase template (RT template). In some embodiments, the expansion portion may be fused to either the 5' or 3' end of the CRISPR nucleic acid (e.g., 5' to 3' orientation: repeat-spacer-expansion portion, or expansion portion-repeat-spacer), and / or to the 5' or 3' end of the tracr nucleic acid. In some embodiments, the extended portion of the extended guide nucleic acid includes an RT template (RTT) and a primer binding site (PBS) oriented from 5' to 3' (e.g., 5'-crRNA-spacer-RTT(edited-coded)-PBS-3'), or depending on the position of the extended portion of the guide relative to the CRISPR RNA, it includes PBS and RTT oriented from 5' to 3' (e.g., 5'-crRNA-spacer-PBS-RTT(edited-coded)-3'). In some embodiments, the target nucleic acid is double-stranded, comprising a first and second strand, and the primer binding site binds to the second strand (non-target, top strand) of the target nucleic acid. In some embodiments, the target nucleic acid is double-stranded, comprising a first and second strand, and the primer binding site binds to the first strand of the target nucleic acid (e.g., the target strand, the same strand from which the CRISPR-Cas effector protein is recruited, the bottom strand). In some embodiments, the target nucleic acid is double-stranded, comprising a first and a second strand, and the primer binding site binds to the second strand of the target nucleic acid (the non-target strand, the strand opposite to the one from which the CRISPR-Cas effector protein is recruited).Therefore, in some embodiments, the editing reverse transcriptase (RT) is attached to the target strand (the strand to which the CRISPR RNA spacer is complementary and the CRISPR-Cas effector protein is recruited), and in some embodiments, the editing reverse transcriptase (RT) is attached to the non-target strand (the strand to which the CRISPR RNA spacer is complementary and the CRISPR-Cas effector protein is recruited).
[0093] The RT template encodes modifications (edits) that are incorporated into the target nucleic acid. The edited modifications can be located at any position within the RT template (relative to the position of the protospacer adjacent motif (PAM) in the target nucleic acid). For example, Figure 27 shows an RT template having edits located at positions -1 to 19 (-1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 27, 18, or 19) relative to the position of the protospacer adjacent motif (PAM) (TTTG) in the target nucleic acid. In all cases, precise editing was observed. In some embodiments, the RT template may include edits located at nucleotide positions -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 27, 18, or 19. In some embodiments, the RT template may include edits located at nucleotide positions 4 through 17 of the RT template relative to the protospacer adjacent motif (PAM) of the target nucleic acid (e.g., positions 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17). In some embodiments, the RT template may include edits located at nucleotide positions 10 through 17 of the RT template relative to the protospacer adjacent motif (PAM) of the target nucleic acid (e.g., positions 10, 11, 12, 13, 14, 15, 16, or 17). In some embodiments, the RT template may include edits located at nucleotide positions 12 through 15 of the RT template relative to the protospacer adjacent motif (PAM) of the target nucleic acid (e.g., positions 12, 13, 14, or 15).
[0094] In some embodiments, a method is provided for modifying a target nucleic acid having a first and second strand, the method comprising contacting the target nucleic acid with (a) a type V CRISPR-Cas effector protein or a type II CRISPR-Cas effector protein; (b) a reverse transcriptase; and (c) an extended guide nucleic acid (e.g., extended type II or V CRISPR RNA, extended type II or V CRISPR DNA, extended type II or V crRNA, extended type II or V crDNA), wherein the extended guide nucleic acid is (i) a type II or V CRISPR nucleic acid (type II or V CRISPR RNA, type II or V CRISPR The complex comprises (ii) DNA, type II or V crRNA, type II or V crDNA) and / or CRISPR nucleic acids and tracr nucleic acids (e.g., type II or V tracrRNA, type II or V tracrDNA); and (ii) an extended portion comprising a primer binding site and a reverse transcriptase template (RT template), wherein the type II or V CRISPR nucleic acid comprises a spacer that binds to a first strand (e.g., a target strand) (i.e., complementary to a portion of the consecutive nucleotides of the first strand of the target nucleic acid), and the primer binding site binds to the first strand (target strand) and thereby modifies the target nucleic acid. In some embodiments, the type II CRISPR-Cas effector protein may be a Cas9 polypeptide, possibly spCas9. In some embodiments, the type V CRISPR-Cas effector protein may be a Cas12a polypeptide or a cas12b polypeptide. In some embodiments, the type II or V CRISPR-Cas effector protein, reverse transcriptase, and extended guide nucleic acid may form a complex or be contained within a complex. In some embodiments, contact may further include contacting the target nucleic acid with a 5'-3' exonuclease.
[0095] In some embodiments, the target nucleic acid may be further contacted with a 5' flap endonuclease (FEN), optionally with FEN1 and / or Dna2 polypeptides, thereby improving mismatch repair by removing the 5' flap without the edited region that is incorporated into the target nucleic acid. In some embodiments, FEN and / or Dna2 may be overexpressed in the presence of the target nucleic acid. In some embodiments, the FEN may be a fusion protein containing a V-type CRISPR-Cas effector protein or a domain fused to an FEN domain, thereby recruiting the FEN to the target nucleic acid.
[0096] In some embodiments, Dna2 may be a fusion protein containing a Dna2 domain fused to a V-type CRISPR-Cas effector protein or domain, thereby recruiting Dna2 to the target nucleic acid.
[0097] In some embodiments, the type II or type V CRISPR-Cas effector protein may be a type II or type V CRISPR-Cas fusion protein comprising a type V CRISPR-Cas effector protein domain fused (linked) to a peptide tag (e.g., an epitope or a multimerized epitope), and the FEN may be an FEN fusion protein comprising an FEN domain fused to an affinity polypeptide bound to the peptide tag, thereby recruiting the FEN to the type II or type V CRISPR-Cas effector protein domain and the target nucleic acid. In some embodiments, the type II or type V CRISPR-Cas effector protein may be a type II or type V CRISPR-Cas fusion protein containing a type II or type V CRISPR-Cas effector protein domain fused (linked) to a peptide tag (e.g., an epitope or a multimerized epitope), and Dna2 may be a Dna2 fusion protein containing a Dna2 domain fused to an affinity polypeptide that binds to the peptide tag, thereby recruiting Dna2 to the type II or type V CRISPR-Cas effector protein domain and the target nucleic acid. In some embodiments, the type V CRISPR-Cas effector protein may be a type II or type V CRISPR-Cas fusion protein containing a type II or type V CRISPR-Cas effector protein domain fused (linked) to a peptide tag (e.g., an epitope or a multimerized epitope), and the FEN may be an FEN fusion protein containing an FEN domain fused to an affinity polypeptide that binds to the peptide tag, thereby recruiting the FEN to the type II or type V CRISPR-Cas effector protein domain and the target nucleic acid.In some embodiments, the type II or V CRISPR-Cas effector protein may be a type II or V CRISPR-Cas fusion protein containing a type II or V CRISPR-Cas effector protein domain fused (linked) to a peptide tag (e.g., an epitope or a multimerized epitope), and Dna2 may be a Dna2 fusion protein containing a Dna2 domain fused to an affinity polypeptide that binds to the peptide tag, thereby recruiting Dna2 to the type II or V CRISPR-Cas effector protein domain and the target nucleic acid. In some embodiments, the target nucleic acid may be contacted with two or more FEN fusion proteins and / or Dna2 fusion proteins.
[0098] In some embodiments, the method of the present invention may further involve contacting a target nucleic acid with a 5'-3' exonuclease, thereby improving mismatch repair by removing a 5' flap that does not contain the edited portion (unedited strand) incorporated into the target nucleic acid. In some embodiments, the 5'-3' exonuclease may be fused to a type II or type V CRISPR-Cas effector protein, and optionally to a type II or type V CRISPR-Cas fusion protein. In some embodiments, the 5'-3' exonuclease may be a fusion protein comprising a 5'-3' exonuclease fused to a peptide tag, and the type II or type V CRISPR-Cas effector protein may be a fusion protein comprising a type II or type V CRISPR-Cas effector protein domain fused to an affinity polypeptide capable of binding to the peptide tag, thereby improving mismatch repair. In some embodiments, the 5'-3' exonuclease may be a fusion protein comprising a 5'-3' exonuclease fused with an affinity polypeptide capable of binding to a peptide tag, and the type II or V CRISPR-Cas effector protein may be a fusion protein comprising a type II or V CRISPR-Cas effector protein domain fused to a peptide tag. In some embodiments, the 5'-3' exonuclease may be a fusion protein comprising a 5'-3' exonuclease fused with an affinity polypeptide capable of binding to an RNA recruitment motif, and an extended guide nucleic acid is linked to the RNA recruitment motif, thereby recruiting the 5'-3' exonuclease to the target nucleic acid via an interaction between the affinity polypeptide and the RNA recruitment motif. The 5'-3' exonuclease may be a known or subsequently discovered 5'-3' exonuclease functioning in the organism, cell, or in vitro system of interest.In some embodiments, the 5'-3' exonuclease may include, but is not limited to, RecE exonuclease (RecE, e.g., SEQ ID NO: 129), RecJ exonuclease (RecJ, e.g., SEQ ID NO: 130), T5 exonuclease (T5_Exo, e.g., SEQ ID NO: 131), and / or T7 exonuclease (T7_Exo, e.g., SEQ ID NO: 132), lambda exonuclease (Lambda_Exo, e.g., SEQ ID NO: 133), Escherichia coli exonuclease sbcB (SEQ ID NO: 134), and / or human exonuclease (Exo, e.g., SEQ ID NO: 135). In some embodiments, for example, a RecE exonuclease C-terminal fragment with nuclear localization sequences (NLS) flanked on both sides by Escherichia coli (K12 strain) may be used (SEQ ID NO: 98). In some embodiments, for example, a RecJ exonuclease flanked by nuclear localization sequences (NLS) from Escherichia coli (K12 strain) may be used (SEQ ID NO: 99). In some embodiments, a T5 exonuclease flanked by nuclear localization sequences (NLS) may be used (SEQ ID NO: 100). In some embodiments, for example, a T7 exonuclease flanked by nuclear localization sequences (NLS) from Escherichia phage 7 may be used (SEQ ID NO: 101). In some embodiments, the 5'-3' exonuclease includes, but is not limited to, RecE (e.g., SEQ ID NO: 129), RecJ (e.g., SEQ ID NO: 130), T5_Exo (e.g., SEQ ID NO: 131), T7_Exo (e.g., SEQ ID NO: 132), sbcB (SEQ ID NO: 134), and / or Exo (SEQ ID NO: 135).
[0099] In some embodiments, the methods of the present invention may further include reducing double-strand breaks. In some embodiments, the reduction of double-strand breaks may be carried out by introducing a chemical inhibitor of non-homologous end joining (NHEJ) into a region of the target nucleic acid, or by introducing siRNA targeting a CRISPR-guided nucleic acid or an NHEJ protein to transiently knock down the expression of the NHEJ protein. In some embodiments, the NHEJ inhibitor may be fused to the reverse transcriptase (RT) or CRISPR-Cas effector protein of the present invention, and possibly to the N-terminus of the RT or CRISPR-Cas effector protein. In some embodiments, the NHEJ inhibitor includes, but is not limited to, the Escherichia phage Mu Gam (SEQ ID NO: 147).
[0100] In some embodiments, the type II or type V CRISPR-Cas effector protein may be a fusion protein, and / or the reverse transcriptase may be a fusion protein, where the type II or type V CRISPR-Cas fusion protein, the reverse transcriptase fusion protein, and / or the extended guide nucleic acid may be fused with one or more components, which allows the reverse transcriptase to be recruited to the type II or type V CRISPR-Cas effector protein. In some embodiments, one or more components are recruited via protein-protein interactions, protein-RNA interactions, and / or chemical interactions.
[0101] Therefore, in some embodiments, the type V CRISPR-Cas effector protein may be a type V CRISPR-Cas effector fusion protein comprising a type V CRISPR-Cas effector protein domain fused (linked) to a peptide tag (e.g., an epitope or a multimerizing epitope), and the reverse transcriptase may be a reverse transcriptase fusion protein comprising a reverse transcriptase domain fused (linked) to an affinity polypeptide that binds to the peptide tag, where the type V CRISPR-Cas effector protein interacts with a guide nucleic acid, which binds to a target nucleic acid, thereby recruiting the reverse transcriptase to the type V CRISPR-Cas effector protein and the target nucleic acid. In some embodiments, the type II CRISPR-Cas effector protein is a type II CRISPR-Cas fusion protein comprising a type II CRISPR-Cas effector protein domain fused (linked) to a peptide tag (e.g., an epitope or a polymerized epitope), FEN is an FEN fusion protein comprising an FEN domain fused to an affinity polypeptide that binds to the peptide tag, and / or the type II CRISPR-Cas effector protein is a type II CRISPR-Cas fusion protein comprising a type II CRISPR-Cas effector protein domain fused to a peptide tag, and the Dna2 polypeptide is a Dna2 fusion protein comprising a Dna2 domain fused to an affinity polypeptide that binds to the peptide tag, and in some cases, the target nucleic acid is brought into contact with two or more FEN fusion proteins and / or two or more Dna2 fusion proteins, thereby recruiting FEN and / or Dna2 to the type II CRISPR-Cas effector protein domain and the target nucleic acid. In some embodiments, two or more reverse transcriptase fusion proteins may be recruited to a type II or type V CRISPR-Cas effector protein, thereby bringing the target nucleic acid into contact with the two or more reverse transcriptase fusion proteins.
[0102] Peptide tags may include, but are not limited to, GCN4 peptide tags (e.g., Sun-Tag), c-Myc affinity tags, HA affinity tags, His affinity tags, S affinity tags, methionine-His affinity tags, RGD-His affinity tags, FLAG octapeptides, strep tags or strep tag II, V5 tags, and / or VSV-G epitopes. Any epitope that can be linked to a polypeptide and for which there is a corresponding affinity polypeptide that can be linked to another polypeptide may be used in the present invention. In some embodiments, peptide tags may include one or more copies of a peptide tag (e.g., epitopes, polymerized epitopes (e.g., tandem repeats)) (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more peptide tags). In some embodiments, the affinity polypeptide that binds to the peptide tag may be an antibody. In some embodiments, the antibody may be an scFv antibody. In some embodiments, the affinity polypeptide that binds to the peptide tag may include, but are not limited to, aphibodies, antikalin, monobodies, and / or DARPins, synthetic compounds (e.g., those evolved for affinity interactions) (see, e.g., Sha et al., Protein Sci. 26(5):910-924 (2017)); Gilbreth (Curr Opin Struc Biol 22(4):413-420 (2013)), U.S. Patent No. 9,982,053. Each of these, with respect to teachings relating to aphibodies, antikalin, monobodies, and / or DARPins, is incorporated herein by reference in whole). Exemplary peptide tag sequences and their affinity polypeptides include, but are not limited to, the amino acid sequences of SEQ ID NOs. 23-25.
[0103] In some embodiments, the extended guide nucleic acid may be linked to an RNA recruitment motif, and the reverse transcriptase may be a reverse transcriptase fusion protein, which may include a reverse transcriptase domain fused to an affinity polypeptide that binds to the RNA recruitment motif, where the extended guide binds to the target nucleic acid, and the RNA recruitment motif binds to the affinity polypeptide, thereby recruiting the reverse transcriptase fusion protein to the extended guide and bringing the target nucleic acid into contact with the reverse transcriptase domain. In some embodiments, two or more reverse transcriptase fusion proteins may be recruited to the extended guide nucleic acid, thereby bringing the target nucleic acid into contact with two or more reverse transcriptase fusion proteins. Exemplary RNA recruitment motifs and their affinity polypeptides include, but are not limited to, the sequences of SEQ ID NOs: 26-36.
[0104] In some embodiments, the RNA recruitment motif may be located at the 3' end of the expansion portion of the expansion guide nucleic acid (e.g., 5'-3', repeat-spacer-expansion portion (RT template-primer binding site)-RNA recruitment motif). In some embodiments, the RNA recruitment motif may be embedded in the expansion portion.
[0105] In some embodiments of the present invention, the extended guide RNA and / or guide RNA may be ligated to one or more RNA recruitment motifs (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more motifs, e.g., at least 10 to about 25 motifs), and optionally the two or more RNA recruitment motifs may be the same RNA recruitment motif or different RNA recruitment motifs. In some embodiments, the RNA recruitment motif and the corresponding affinity polypeptide may include, but are not limited to, a telomerase Ku-binding motif (e.g., Ku-binding hairpin) and the corresponding affinity polypeptide Ku (e.g., Ku heterodimer), a telomerase Sm7-binding motif and the corresponding affinity polypeptide Sm7, an MS2 phage operator stem-loop and the corresponding affinity polypeptide MS2 coat protein (MCP), a PP7 phage operator stem-loop and the corresponding affinity polypeptide PP7 coat protein (PCP), an SfMu phage Com stem-loop and the corresponding affinity polypeptide Com RNA-binding protein, a PUF-binding site (PBS) and the affinity polypeptide Pumilio / fem-3 mRNA-binding factor (PUF), and / or an aptamer ligand as a synthetic RNA-aptamer and the corresponding affinity polypeptide. In some embodiments, the RNA recruitment motif and the corresponding affinity polypeptide may also be an MS2 phage operator stem-loop and the affinity polypeptide MS2 coat protein (MCP). In some embodiments, the RNA recruitment motif and the corresponding affinity polypeptide may be a PUF binding site (PBS) and an affinity polypeptide Pumilio / fem-3 mRNA binding factor (PUF).
[0106] In some embodiments, components for recruiting polypeptides and nucleic acids may include, but are not limited to, rapamycin-inducible dimerization of FRB-FKBP; biotin-streptavidin; SNAP tags; Halo tags; CLIP tags; compound-induced DmrA-DmrC heterodimers; and bifunctional ligands (e.g., fusion of two protein-binding chemicals, e.g., dihydrofolate reductase (DHFR)), which may function through chemical interactions.
[0107] In some embodiments of the present invention, the CRISPR-Cas effector proteins (e.g., CRISPR-Cas effector protein, first CRISPR-Cas effector protein, second CRISPR-Cas effector protein, third CRISPR-Cas effector protein, and / or fourth CRISPR-Cas effector protein) may be derived from the type I CRISPR-Cas system, type II CRISPR-Cas system, type III CRISPR-Cas system, type IV CRISPR-Cas system, and / or type V CRISPR-Cas system. In some embodiments, the CRISPR-Cas nuclease is derived from the type II CRISPR-Cas system or the type V CRISPR-Cas system.
[0108] In some embodiments of the present invention, the CRISPR-Cas effector protein is Cas9, C2c1, C2c3, Cas12a (also called Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Casl, CaslB, Cas2, Cas3, Cas3', Cas3'', Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csx12), Cas10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, It may also be Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, Csx10, Csx16, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4(dinG), and / or Csf5 nucleases, and in some cases CRISPR-Cas nucleases These may be Cas9, Cas12a (Cpf1), Cas12b, Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b, and / or Cas14c nucleases.
[0109] In some embodiments, the CRISPR-Cas effector protein may be a protein that functions as a nickase (e.g., Cas9 nickase or Cas12a nickase). In some embodiments, the CRISPR-Cas effector protein useful in the present invention may contain mutations in its nuclease active site (e.g., RuvC, HNH, e.g., the RuvC site of the Cas12a nuclease domain, e.g., the RuvC site and / or HNH site of the Cas9 nuclease domain). A CRISPR-Cas effector protein having a mutation in its nuclease active site and therefore lacking nuclease activity is generally called "dead" or "inactivated," e.g., dCas. In some embodiments, a CRISPR-Cas nuclease domain or polypeptide having a mutation in its nuclease active site may have impaired or reduced activity compared to the same CRISPR-Cas nuclease without the mutation. In some embodiments, the CRISPR-Cas effector protein useful in the present invention may be a double-chain nuclease. In some embodiments, the CRISPR-Cas effector protein having double-chain nuclease activity may be a type II or type V CRISPR-Cas effector protein. In some embodiments, the type V CRISPR-Cas effector protein having double-chain nuclease activity is a Cas12a polypeptide. In some embodiments, the type II CRISPR-Cas effector protein having double-chain nuclease activity is a Cas9 polypeptide.
[0110] In some embodiments, the CRISPR-Cas effector protein may be a type V CRISPR-Cas effector protein. In some embodiments, the type V CRISPR-Cas effector protein may include effector proteins and / or domains of Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b, and / or Cas14c.
[0111] In some embodiments, Cas12a(Cpf1) may include, but is not limited to, LbCas12a, Lb2Cas12a, Lb3Cas12a, AsCas12a, BpCas12a, CMtCas12a, EeCas12a, FnCas12a, LiCas12a, MbCas12a, PbCas12a, PcCas12a, PdCas12a, PeCas12a, PmCas12a, SsCas12a, and enAsCas12a, and in some cases Cas12a may include one or more mutations described herein. In some embodiments, Cas12b(C2c1) may include, but is not limited to, BhCas12b, and in some cases Cas12b may include one or more mutations described herein.
[0112] In some embodiments, the V-type CRISPR-Cas effector protein may include, but is not limited to, a V-type CRISPR-Cas effector protein derived from the genus Acidaminococcus (AsCas12a), a bacterium of the family Lachnospiraceae (e.g., LbCas12a), or Butyrivibrio hungatei (BhCas12b), or a modified V-type CRISPR-Cas effector protein thereof. In some embodiments, the V-type CRISPR-Cas effector protein derived from the genus Acidaminococcus may include a sequence having at least 80% identity with SEQ ID NO: 2. In some embodiments, the V-type CRISPR-Cas effector protein derived from a bacterium of the family Lachnospiraceae may include an amino acid sequence having at least 80% identity with any one of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. In some embodiments, the V-type CRISPR-Cas effector protein derived from Butyrivibrio hyungati may contain a sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 151. In some embodiments, the modified V-type CRISPR-Cas effector protein derived from the genus Acidaminococcus may contain an amino acid sequence having at least 80% identity with any one of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 149, or SEQ ID NO: 150. In some embodiments, the modified V-type CRISPR-Cas effector protein derived from bacteria of the family Lacnospiraceae may contain a sequence having at least 80% identity with SEQ ID NO: 148.
[0113] In some embodiments, the type II CRISPR-Cas effector protein may include, but is not limited to, the Cas9 effector protein, which may be derived from Streptococcus, and possibly from Streptococcus pyogenes. In some embodiments, the Cas9 effector protein may be a modified Cas9 effector protein. In some embodiments, the Cas9 effector protein may include a polypeptide sequence having at least 80% identity with either SEQ ID NO: 106 or SEQ ID NO: 107. In some embodiments, the Cas9 effector protein may be encoded by a polynucleotide sequence having at least 80% identity with any one of SEQ ID NOs: 108-122.
[0114] In some embodiments, the V-type CRISPR-Cas system may include effector proteins that utilize only the V-type CRISPR nucleic acid. In some embodiments, the V-type CRISPR-Cas system may include effector proteins that utilize both the CRISPR nucleic acid and the transactivated CRISPR(tracr) nucleic acid, similar to the II-type CRISPR-Cas system. Therefore, in some embodiments, the V-type CRISPR-Cas effector proteins useful in the present invention may function with only the corresponding CRISPR nucleic acid (e.g., Cas12a, Cas12i, Cas12h, Cas14b, Cas14c, C2c10, C2c9, C2c8, C2c4). In some embodiments, the V-type CRISPR-Cas effector proteins useful in the present invention may function with both the corresponding CRISPR nucleic acid and the tracr nucleic acid (e.g., Cas12b, Cas12c, Cas12e, Cas12g, Cas14a).
[0115] The CRISPR nucleic acid useful in the present invention may include at least one repeat sequence and at least one spacer sequence that can interact with a corresponding V-type CRISPR-Cas effector protein, wherein at least one spacer sequence can bind to a target nucleic acid (e.g., a first or second strand of the target nucleic acid). In some embodiments, the repeat sequence of the CRISPR nucleic acid may be located at the 5' of the spacer sequence. In some embodiments, the CRISPR nucleic acid may include more than one repeat sequence, the repeat sequence being ligated to both the 5' and 3' ends of the spacer. In some embodiments, the CRISPR nucleic acid useful in the present invention may include two or more repeat sequences and one or more spacer sequences, wherein each spacer sequence is ligated to a repeat sequence at its 5' and 3' ends.
[0116] The tracr nucleic acid useful in the present invention may comprise a first portion that is substantially complementary to and hybridizes with the repeat sequence of the corresponding CRISPR nucleic acid, and a second portion that interacts with the corresponding type II or type V CRISPR-Cas effector protein.
[0117] In some embodiments, the V-type CRISPR-Cas effector protein useful for the present invention may function as a double-stranded DNA nuclease. In some embodiments, the V-type CRISPR-Cas effector protein may function as a single-stranded DNA nickase, and the first strand may be nicked. In some embodiments, the V-type CRISPR-Cas effector protein may function as a single-stranded DNA nickase, and the second strand may be nicked. In some embodiments, the V-type CRISPR-Cas effector protein may be a Cas12a effector protein that functions as a nickase, and the first strand (target strand) may be nicked. In some embodiments, the V-type CRISPR-Cas effector protein may be a Cas12a effector protein that functions as a nickase, and the second strand may be nicked. In some embodiments, the V-type CRISPR-Cas effector protein may be a Cas12a effector protein that functions as a nickase through the use of crRNA containing strategic mismatches. Therefore, for example, crRNA may contain spacers (e.g., 80-96% complementary) with 1 to about 4 mismatches (e.g., 1, 2, 3, or 4 mismatches).
[0118] In some embodiments, the Cas12a effector protein may be a Cas12a nickase having an arginine mutation in the LQMRNS motif. The arginine mutation in this motif may be to any amino acid, thereby providing a Cas12a nickase. In some embodiments, the mutation may be to alanine. In some embodiments, the mutation may be to alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. In some embodiments, the mutation may be to alanine. In some embodiments, the mutation does not include a mutation to lysine or histidine. In some embodiments, the Cas12a effector protein may be an LbCas12a nickase containing the R1138 mutation, optionally the R1138A mutation (see SEQ ID NO: 9 in the reference nucleotide sequence), the R1137 mutation, optionally the R1137A mutation (see SEQ ID NO: 1 in the reference nucleotide sequence), or the R1124 mutation, optionally the R1124A mutation (see SEQ ID NO: 7 in the reference nucleotide sequence). In some embodiments, the Cas12a effector protein may be an AsCas12a nickase containing the R1226 mutation, optionally the R1226A mutation (see SEQ ID NO: 2 in the reference nucleotide sequence). In some embodiments, the Cas12a effector protein may be an FnCas12a nickase containing the R1218 mutation, optionally the R1218A mutation (see SEQ ID NO: 6 in the reference nucleotide sequence). In some embodiments, the Cas12a effector protein may be a PdCas12a nickas containing the R1241 mutation, and possibly the R1241A mutation (see SEQ ID NO: 14 of the reference nucleotide sequence).
[0119] In some embodiments, the V-type CRISPR-Cas effector protein useful in the present invention may contain reduced single-strand DNA cleavage activity (ssDNAse activity) (for example, the V-type CRISPR-Cas effector protein may be modified (mutated) to reduce ssDNAse activity (for example, ssDNAse activity about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% lower than that of wild-type or unmodified V-type CRISPR-Cas effector protein)).
[0120] In some embodiments, the V-type CRISPR-Cas effector protein useful in the present invention may contain reduced self-processing RNAse activity (for example, the V-type CRISPR-Cas effector protein may be modified (mutated) to reduce self-processing RNAse activity (for example, about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% lower self-processing RNAse activity than the wild-type or unmodified V-type CRISPR-Cas effector protein)). In some embodiments, the mutation to reduce self-processing RNAse activity may be a histidine mutation at the residue position 759, referring to the nucleotide position numbering of SEQ ID NO: 1 or SEQ ID NO: 9, and may optionally be a histidine-to-alanine mutation (H759A). Exemplary V-type CRISPR-Cas effector proteins having reduced single-strand DNA cleavage activity may include, but are not limited to, LbCas12a(H759A) (SEQ ID NO: 148). In some embodiments, a Cas12a CRISPR-Cas effector protein having the H759A mutation useful in the present invention may contain a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 148. In some embodiments, a Cas12a CRISPR-Cas effector protein having the H759A mutation may be an LbCas12a CRISPR-Cas effector protein, which in some cases contains at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 148.
[0121] In some embodiments, the V-type CRISPR-Cas effector protein or domain useful in the present invention may contain a mutation in its nuclease active site (e.g., RuvC of the dV-type CRISPR-Cas effector protein or domain, e.g., the RuvC site of the Cas12a nuclease domain). A CRISPR-Cas nuclease having a mutation in its nuclease active site and therefore lacking nuclease activity is generally referred to as "inactivated" or "dead," e.g., dCas, dCas12a. In some embodiments, a CRISPR-Cas nuclease domain or polypeptide having a mutation in its nuclease active site may have impaired or reduced activity compared to the same CRISPR-Cas nuclease without the mutation. In some embodiments, an inactivated V-type CRISPR-Cas effector protein may function as a nickase (first-chain nickase and / or second-chain nickase).
[0122] In some embodiments, a V-type CRISPR-Cas effector protein or domain useful in the present invention may include modifications of one or more amino acid residues that reduce the DNA binding affinity of the V-type CRISPR-Cas effector protein. In some embodiments, the modification may be an amino acid substitution. In some embodiments, a positively charged residue that interacts with the DNA backbone may be mutated, and in some cases, a positively charged residue that interacts with the DNA backbone may be mutated to alanine (e.g., substituted with alanine). Substitutions of a positively charged residue with alanine in the Cas12a effector protein may include, but are not limited to, the amino acid substitutions K167A, K272A, and / or K349A, with reference to the amino acid position numbering in SEQ ID NO: 1 or SEQ ID NO: 148. In some embodiments, the V-type CRISPR-Cas effector protein is a Cas12a CRISPR-Cas effector protein containing the amino acid substitutions K167A, K272A, K349A, K167A+K272A, K167A+K349A, K272A+K349A, or K167A+K272A+K349A, with the V-type CRISPR-Cas effector protein being LbCas12a.
[0123] In some embodiments, the V-type CRISPR-Cas effector protein may be a V-type CRISPR-Cas fusion protein, where the V-type CRISPR-Cas fusion protein includes a V-type CRISPR-Cas effector protein domain fused to a reverse transcriptase. In some embodiments, the reverse transcriptase may be fused to the C-terminus of the V-type CRISPR-Cas effector polypeptide. In some embodiments, the reverse transcriptase may be fused to the N-terminus of the V-type CRISPR-Cas effector polypeptide.
[0124] In some embodiments, the V-type CRISPR-Cas effector protein may be a V-type CRISPR-Cas fusion protein, where the V-type CRISPR-Cas fusion protein comprises a V-type CRISPR-Cas effector protein domain fused to a nicking enzyme (e.g., Fok1, BFi1, e.g., engineered Fok1 or BFiI), and in some cases the V-type CRISPR-Cas effector protein domain may be an inactivated V-type CRISPR-Cas domain fused to the nicking enzyme.
[0125] In some embodiments, the type II CRISPR-Cas effector protein may be a type II CRISPR-Cas fusion protein, which includes a type II CRISPR-Cas effector protein domain fused to a reverse transcriptase. In some embodiments, the reverse transcriptase may be fused to the C-terminus of the type II CRISPR-Cas effector polypeptide. In some embodiments, the reverse transcriptase may be fused to the N-terminus of the type II CRISPR-Cas effector polypeptide. In some embodiments, the type II CRISPR-Cas effector protein may be a type II CRISPR-Cas fusion protein, which includes a type II CRISPR-Cas effector protein domain fused to a nicking enzyme (e.g., Fok1, BFi1, e.g., engineered Fok1 or BFiI), and optionally the type II CRISPR-Cas effector protein domain may be an inactivated type II CRISPR-Cas domain fused to a nicking enzyme.
[0126] In some embodiments, the reverse transcriptase useful in the present invention may be wild-type reverse transcriptase. In some embodiments, the reverse transcriptase useful in the present invention may be synthetic reverse transcriptase; see, for example, Heller et al. Nucleic Acids Research, 47(7)3619-3630 (2019). Exemplary reverse transcriptase polypeptides include, but are not limited to, those having substantial identity (e.g., at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% identity) to the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 172.
[0127] In some embodiments, the reverse transcriptase activity may be modified with respect to the gene editing activity (of type V or type II) to provide optimal activity in association with type V or type II CRISPR-Cas effector polypeptides (e.g., activity when conjugated with type V CRISPR-Cas effector polypeptide is increased by approximately 5, 10, 15, 20, 25, 30, 345, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% compared to an unmodified reference reverse transcriptase). Such mutations include those that affect or improve RT initiation, processing capacity, enzyme reaction rate, temperature sensitivity, and / or error rate.
[0128] In some embodiments, the reverse transcriptase useful in the present invention may be modified to improve the transcriptional function of the reverse transcriptase. The transcriptional function of the reverse transcriptase can be improved by increasing the processing capacity of the reverse transcriptase, for example, by increasing the ability of the reverse transcriptase to polymerize more DNA bases during a single binding event to a template (e.g., before it falls off the template) (e.g., by increasing the processing capacity by about 5, 10, 15, 20, 25, 30, 345, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% compared to an unmodified reference reverse transcriptase).
[0129] In some embodiments, the transcriptional function of a reverse transcriptase may be improved by increasing the template affinity of the reverse transcriptase (for example, by increasing the template affinity by about 5, 10, 15, 20, 25, 30, 345, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% compared to an unmodified reference reverse transcriptase).
[0130] In some embodiments, the transcriptional function of the reverse transcriptase may be improved by improving the thermal stability of the reverse transcriptase for improved performance at a desired temperature (e.g., increasing the thermal stability by about 5, 10, 15, 20, 25, 30, 345, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% compared to an unmodified reference reverse transcriptase). In some embodiments, the improved thermal stability is at temperatures from about 20°C to 42°C (e.g., about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42°C, and any value or range therein). In some embodiments, reverse transcriptases with improved thermal stability may include, but are not limited to, the M-MuLV triple mutant D200N+L603W+T330P or the M-MuLV quintuple mutant (5M) D200N+L603W+T330P+T306K+W313F, with reference to the amino acid position numbering of SEQ ID NO: 172 (e.g., SEQ ID NO: 53). See, for example, Baranauskas et al. (Protein Eng. Des. Sel. 25, 657-668 (2012)); Anzalone et al. (Nature 576: 149-157 (2019)). Additional amino acid modifications in reverse transcriptase may include the amino acid substitutions L139P, D200N, W388R, E607K, T306K, W313F, F155Y, H638G, Q221R, V223M and / or D524N, with reference to the amino acid position numbering of SEQ ID NO: 172.
[0131] In some embodiments, the reverse transcriptases useful in the present invention are, with reference to the amino acid position numbering of SEQ ID NO: 172, (1) L139P, D200N, W388R, and E607K, (2) L139P, D200N, T306K, W313F, W388R, and E607K, (3) 5M (T355A / Q357M / K358R / A359G / S360A), F155Y, and H638G, (4) 5M (T355A / Q357M / K358R / A359G / S360A), Q221R, and V223M; or (5) 5M This may include, but is not limited to, combinations of amino acid substitutions of T355A / Q357M / K358R / A359G / S360A) and D524N.
[0132] In some embodiments of the present invention, the reverse transcriptase may be fused to one or more single-stranded RNA-binding domains (RBDs). Useful RBDs in the present invention may include, but are not limited to, SEQ ID NOs: 37-52 (SEQ ID NOs: 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, and / or 52), thereby improving the thermal stability, processing capacity, and template affinity of the reverse transcriptase.
[0133] The polypeptides / proteins / domains of the present invention (e.g., CRISPR-Cas effector proteins, e.g., type II or type V CRISPR-Cas effector proteins), reverse transcriptases, 5' flap endonucleases, and / or 5'-3' exonucleases) may be encoded by one or more polynucleotides and may optionally be operably linked to one or more promoters and / or other regulatory sequences (e.g., terminators, operons, and / or enhancers). In some embodiments, the polynucleotides of the present invention may be contained in one or more expression cassettes and / or vectors. In some embodiments, at least one regulatory sequence may be, for example, a promoter, operon, terminator, or enhancer. In some embodiments, at least one regulatory sequence may be a promoter. In some embodiments, the regulatory sequence may be an intron. In some embodiments, at least one regulatory sequence may be, for example, a promoter operably linked to an intron, or a promoter region containing an intron. In some embodiments, at least one regulatory sequence may be, for example, a ubiquitin promoter and its associated introns (e.g., Medicago truncatula and / or maize and their associated introns) (e.g., ZmUbi1 containing the intron; MtUb2 containing the intron, e.g., SEQ ID NOs. 21 or 22).
[0134] In some embodiments, the present invention provides polynucleotides encoding type II CRISPR-Cas effector proteins or domains or type V CRISPR-Cas effector proteins or domains operably bound to one or more promoter regions containing or bound to introns, polynucleotides encoding CRISPR-Cas effector proteins or domains, polynucleotides encoding reverse transcriptase polypeptides or domains, polynucleotides encoding 5'-3' exonuclease polypeptides or domains, and / or polynucleotides encoding flap endonuclease polypeptides or domains, wherein the promoter region may optionally be a ubiquitin promoter and an intron (e.g., albiflora (Medicago) or maize ubiquitin promoter and intron, e.g., SEQ ID NO: 21 or 22).
[0135] In some embodiments, the polynucleotide encoding the type II or type V CRISPR-Cas effector protein and / or the polynucleotide encoding the reverse transcriptase may be contained in the same or separate expression cassette, and if the polynucleotide encoding the type II or type V CRISPR-Cas effector protein and the polynucleotide encoding the reverse transcriptase are contained in the same expression cassette, the polynucleotide encoding the type II or type V CRISPR-Cas effector protein and the polynucleotide encoding the reverse transcriptase may be operably ligated to a single promoter or to two or more separate promoters in any combination. In some embodiments, the polynucleotide encoding the CRISPR-Cas effector protein may be contained in an expression cassette, where the polynucleotide encoding the CRISPR-Cas effector protein may be operably ligated to a promoter.
[0136] In some embodiments, the extended guide nucleic acid and / or guide nucleic acid may be contained within the expression cassette, and in some cases, the expression cassette is contained within the vector. In some embodiments, the expression cassette and / or vector containing the extended guide nucleic acid may be the same as or different from the expression cassette and / or vector containing the polynucleotide encoding the type II or type V CRISPR-Cas effector protein and / or the polynucleotide encoding the reverse transcriptase. In some embodiments, the expression cassette and / or vector containing the guide nucleic acid may be the same as or different from the expression cassette and / or vector containing the polynucleotide encoding the CRISPR-Cas effector protein.
[0137] In some embodiments, the polynucleotide encoding the 5' flap endonuclease and / or the polynucleotide encoding the 5'-3' exonuclease may be contained in one or more expression cassettes, which may be the same or different expression cassettes. In some embodiments, the expression cassette containing the polynucleotide encoding the 5' flap endonuclease and / or the polynucleotide encoding the 5'-3' exonuclease may be the same as or different from the expression cassette containing the polynucleotide encoding the type II or type V CRISPR-Cas effector protein, the polynucleotide encoding the type II or type V CRISPR-Cas effector protein, and / or the polynucleotide encoding the reverse transcriptase.
[0138] In some embodiments of the present invention, polynucleotides encoding CRISPR-Cas effector proteins (e.g., type II CRISPR-Cas effector protein, type V CRISPR-Cas effector protein), reverse transcriptase, flap endonuclease, 5'-3' exonuclease, and fusion proteins comprising the same, as well as nucleic acid structures, expression cassettes and / or vectors comprising polynucleotides, may be codon-optimized for expression in organisms (e.g., animals (e.g., mammals, insects, fish, etc.), plants (e.g., dicotyledonous plants, monocotyledonous plants), bacteria, archaea, viruses, etc.). In some embodiments, polynucleotides, expression cassettes and / or vectors may be codon-optimized for expression in plants, possibly dicotyledonous or monocotyledonous plants. Exemplary mammals to which the present invention may be useful include, but are not limited to, primates (humans and non-humans (e.g., chimpanzees, baboons, monkeys, gorillas, etc.)), cats, dogs, ferrets, gerbils, hamsters, cattle, pigs, horses, goats, donkeys, or sheep. In some embodiments, the polynucleotides, expression cassettes, and / or vectors may be codon-optimized for expression in fungi, including but not limited to zygomycetes (Zygomycota), ascomycota (Ascomycota), basidiomycota (Basidiomycota), and deuteromycota (fungi imperfecti), and in some cases the fungi may be ascomycetes, and in some cases yeast (e.g., budding yeast (Saccharomyces cerevisiae)).
[0139] In some embodiments, the polynucleotides, nucleic acid structures, expression cassettes, or vectors of the present invention optimized for expression in living organisms may be about 70% to 100% identical (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%) to nucleic acid structures, expression cassettes, or vectors that encode the same but are not codon-optimized for expression in plants.
[0140] In some embodiments, polynucleotides, nucleic acid structures, expression cassettes, and vectors may be provided to carry out the methods of the present invention. Accordingly, in some embodiments, a codon-optimized expression cassette for expression in a living organism is provided, comprising (a) a polynucleotide encoding a promoter sequence in a 5' to 3' orientation, (b) a codon-optimized type V CRISPR-Cas nuclease (e.g., Cpf1(Cas12a), dCas12a, etc.) or type II CRISPR-Cas nuclease (e.g., Cas9, dCas9, etc.) for expression in a living organism, (c) a linker sequence, and (d) a polynucleotide encoding a codon-optimized reverse transcriptase for expression in a living organism. In some embodiments, the living organism is an animal, plant, fungus, archaea, or bacterium. In some embodiments, the organism is a plant, and the polynucleotide encoding the type V CRISPR-Cas nuclease is codon-optimized for expression in plants, and the promoter sequence is a plant-specific promoter sequence (e.g., ZmUbi1, MtUb2, RNA polymerase II (Pol II)).
[0141] In some embodiments, polynucleotides, nucleic acid structures, expression cassettes, and vectors may be provided to carry out the methods of the present invention. Accordingly, in some embodiments, a codon-optimized expression cassette for expression in plants is provided, comprising (a) a polynucleotide encoding a plant-specific promoter sequence (e.g., ZmUbi1, MtUb2, RNA polymerase II (Pol II)) in a 5' to 3' orientation, (b) a plant codon-optimized polynucleotide encoding a type II or type V CRISPR-Cas effector protein (e.g., Cpf1 (Cas12a), dCas12a, etc.), (c) a linker sequence, and (d) a plant codon-optimized polynucleotide encoding a reverse transcriptase.
[0142] In some embodiments, the polypeptide of the present invention may be a fusion protein comprising one or more polypeptides linked to one another via a linker. In some embodiments, the linker may be an amino acid or a peptide linker. In some embodiments, the peptide linker may have a length of about 2 to about 100 amino acids (residues), as described herein. In some embodiments, the peptide linker may be, for example, a GS linker.
[0143] In some embodiments, the present invention provides a codon-optimized expression cassette for expression in plants, comprising (a) a polynucleotide encoding a plant-specific promoter sequence (e.g., ZmUbi1, MtUb2), and (b) an extended guide nucleic acid sequence, wherein the extended guide nucleic acid comprises an extended portion having a primer binding site at its 3' end and an edit portion to be incorporated into the target nucleic acid (e.g., an edit portion in a reverse transcriptase template) (e.g., 5'-3'-crRNA-RTT-PBS) (e.g., a tag nucleic acid; e.g., tagRNA), and optionally the extended guide nucleic acid is contained within the expression cassette, and optionally the extended guide nucleic acid is operably ligated to a Pol II promoter. In some embodiments, if the extended portion of the guide nucleic acid is attached to the CRISPR RNA at the 5' end of the crRNA, the extended portion comprises a primer binding site at its 5' end and an edit portion to be incorporated into the target nucleic acid (e.g., a reverse transcriptase template) at its 3' end (5'-3'-PBS-RTT-crRNA).
[0144] In some embodiments, the expression cassettes of the present invention may be codon-optimized for expression in dicotyledonous plants or monocotyledonous plants. In some embodiments, the expression cassettes of the present invention may be used in a method for modifying a target nucleic acid in a plant or plant cell, the method comprising introducing one or more expression cassettes of the present invention into a plant or plant cell to modify the target nucleic acid in the plant or plant cell and to produce a plant or plant cell containing the modified target nucleic acid. In some embodiments, the method may further comprise regenerating the plant cell containing the modified target nucleic acid to produce a plant containing the modified target nucleic acid.
[0145] In some embodiments, the expression cassettes of the present invention may be codon-optimized for expression in animals, e.g., mammals. In some embodiments, the expression cassettes of the present invention may be used in a method for modifying a target nucleic acid in animal cells (e.g., mammalian cells), the method comprising introducing one or more expression cassettes of the present invention into animal cells to modify the target nucleic acid in the animal cells and to produce animal cells containing the modified target nucleic acid.
[0146] The CRISPR Cas9 polypeptide or CRISPR Cas9 domain useful in the present invention (e.g., type II CRISPR Case effector protein) may be any known or subsequently identified Cas9 nuclease. In some embodiments, the CRISPR Cas9 polypeptide may be, for example, a Cas9 polypeptide derived from the genus Streptococcus (e.g., S. pyogenes, S. thermophilus) (e.g., spCas9), or a Cas9 polypeptide derived from the genera Lactobacillus, Bifidobacterium, Candleria, Leuconostoc, Oenococcus, Pediococcus, Weissella, and / or Olsenella.
[0147] Cas12a is a type V Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas effector protein or domain. Cas12a differs from the more well-known type II CRISPR Cas9 effector protein in several respects. For example, Cas9 recognizes a G-rich protospacer adjacent motif (PAM) (3'-NGG) located on the 3' side of its guide RNA (gRNA, sgRNA) binding site (protospacer, target nucleic acid, target DNA), while Cas12a recognizes a T-rich PAM (5'-TTN, 5'-TTTN) located on the 5' side of the target nucleic acid. In fact, the orientation in which Cas9 and Cas12a bind to their guide RNAs is largely reversed with respect to their N-terminus and C-terminus. Furthermore, the Cas12a effector protein uses a single guide RNA (gRNA, CRISPR array, crRNA) instead of the dual guide RNA (sgRNA (e.g., crRNA and tracrRNA)) found in the natural Cas9 system, and Cas12a processes its own gRNA. In addition, the nuclease activity of Cas12a generates staggered DNA double-strand breaks instead of blunt ends produced by the nuclease activity of Cas9, and Cas12a relies on a single RuvC domain to cleave both DNA strands, whereas Cas9 utilizes both an HNH domain and a RuvC domain for cleavage.
[0148] The CRISPR Cas12a effector protein or domain useful in the present invention may be any known or later identified Cas12a nuclease (formerly known as Cpf1) (see, for example, U.S. Patent No. 9,790,490, which, for the disclosure of the Cpf1 (Cas12a) sequence, is incorporated herein by reference). The terms “Cas12a,” “Cas12a polypeptide,” or “Cas12a domain” refer to an RNA guide effector protein containing Cas12a or a fragment thereof, comprising the Cas12a guide nucleic acid binding domain and / or the Cas12a active, inactive, or partially active DNA cleavage domain. In some embodiments, the Cas12a useful in the present invention may contain mutations within the nuclease active site (e.g., the RuvC site of the Cas12a domain). Cas12a effector proteins or domains that have mutations in their nuclease active site and therefore lack nuclease activity are generally called dead or inactivated Cas12a (e.g., dCas12a).
[0149] In some embodiments, the Cas12a effector polypeptide, which can be optimized or otherwise modified (e.g., inactivated) according to the present invention, may include, but is not limited to, any one amino acid sequence of SEQ ID NOs. 1-20 (e.g., SEQ ID NOs. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20), or SEQ ID NOs. 148, 149, 150, or 151, or the polynucleotide encoding them.
[0150] In some embodiments, a Cas9 effector polypeptide, which may be optimized or otherwise modified (e.g., inactivated) according to the present invention, may include, but is not limited to, the amino acid sequence of either SEQ ID NO: 106 or SEQ ID NO: 107, or the polynucleotide encoding it. In some embodiments, a Cas9 effector polypeptide, which may be optimized or otherwise modified (e.g., inactivated) according to the present invention, may include the amino acid sequence encoded by any one of the nucleic acid sequences of SEQ ID NOs: 108 to 122.
[0151] As used herein, “guide nucleic acid,” “guide RNA,” “gRNA,” “CRISPR RNA / DNA,” “crRNA,” or “crDNA” means a nucleic acid comprising at least one spacer sequence that is complementary to (and hybridizes with) a target DNA (e.g., a protospacer), and at least one repeat sequence corresponding to a particular CRISPR-CAS effector protein (for example, in the case of a type V CRISPR-Cas effector protein, the repeat or a fragment or part thereof is derived from the type V Cas12a CRISPR-Cas system; in the case of a type II CRISPR-Cas effector protein, the repeat or a fragment or part thereof is derived from the type II Cas9 CRISPR-Cas system). Therefore, repeats of the CRISPR-Cas system useful in the present invention include, for example, Cas9, C2c3, Cas12a (also called Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Casl, CaslB, Cas2, Cas3, Cas3', Cas3'', Cas4, Cas 5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csx12), Cas10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, C The CRISPR-Cas effector proteins or fragments thereof may correspond to sxl7, Csxl4, Csx10, Csx16, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4(dinG), and / or Csf5, where the repeat sequence may be ligated to the 5' and / or 3' ends of the spacer sequence. The design of the guide nucleic acid of the present invention may be based on a type I, type II, type III, type IV, or type V CRISPR-Cas system. In some embodiments, the design of the guide nucleic acid of the present invention is based on a type V CRISPR-Cas system. In some embodiments, the design of the guide nucleic acid of the present invention is based on a type II CRISPR-Cas system.
[0152] In some embodiments, the guide nucleic acid (e.g., crRNA, e.g., Cas12a crRNA, Cas12b crRNA, Cas9 crRNA, etc.) may include a repeat sequence (full length or a portion thereof ("handle"); e.g., a pseudoknot-like structure) and a spacer sequence in a 5' to 3' orientation. In some embodiments, the extended guide nucleic acid (e.g., tagRNA, e.g., Cas12a extended guide nucleic acid, Cas12b extended guide nucleic acid, Cas9 extended guide nucleic acid, etc.) may include a repeat sequence (full length or a portion thereof ("handle"); e.g., a pseudoknot-like structure), a spacer sequence, and a 3' or 5' extended portion (e.g., tagRNA extended portion) containing a primer binding site and a reverse transcriptase template (RT template) (RTT) in a 5' to 3' orientation.
[0153] In some embodiments, the guide nucleic acid may include multiple repeat-spacer sequences (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more repeat-spacer sequences) (e.g., repeat-spacer-repeat, e.g., repeat-spacer-repeat-spacer-repeat-spacer-repeat-spacer-repeat-spacer, etc.). The guide nucleic acid of the present invention is synthetic, artificial, and not found in nature. The guide nucleic acid may be fairly long and may be used as other RNA structures suspended from an aptamer or spacer (as in the MS2 mobilization strategy). In some embodiments, as described herein, the guide nucleic acid may include a template and primer binding site for editing. In some embodiments, the guide nucleic acid may include a region or sequence complementary to the editing template (reverse transcriptase template) at its 5' or 3' end, thereby mobilizing the editing template to the target nucleic acid (i.e., the extended guide nucleic acid). In some embodiments, the guide nucleic acid may include a region or sequence (primer binding site) at its 5' or 3' end that is complementary to the primer on the target nucleic acid, thereby recruiting the primer binding site to the target nucleic acid (i.e., the extended guide nucleic acid).
[0154] As used herein, “repetitive sequence” refers to any repetitive sequence of a wild-type CRISPR-Cas locus (e.g., Cas9, Cas12a, C2c1, etc.) or a repetitive sequence of a synthetic crRNA that functions with the CRISPR-Cas nuclease encoded by the nucleic acid structure of the present invention. Repetitive sequences useful to the present invention may be any known or later identified repetitive sequences of a CRISPR-Cas locus (e.g., type I, type II, type III, type IV, type V, or type VI), or synthetic repeats designed to function in type I, II, III, IV, V, or VI CRISPR-Cas systems. Thus, in some embodiments, the repetitive sequence may be identical or substantially identical to a repetitive sequence from the wild-type type I CRISPR-Cas locus, type II CRISPR-Cas locus, type III CRISPR-Cas locus, type IV CRISPR-Cas locus, type V CRISPR-Cas locus and / or type VI CRISPR-Cas locus. In some embodiments, the repeat sequences useful in the present invention may be known or later identified repeat sequences from the type V CRISPR-Cas locus, or synthetic repeats designed to function in the type V CRISPR-Cas system. The repeat sequences may include hairpin and / or stem-loop structures. In some embodiments, the repeat sequences may form pseudoknot-like structures (i.e., "handles") at their 5' ends. Thus, in some embodiments, the repeat sequences may be identical or substantially identical to repeat sequences derived from the wild-type type V CRISPR-Cas locus or the wild-type type II CRISPR-Cas locus. The repeat sequences from the wild-type CRISPR-Cas locus can be determined through established algorithms, such as using CRISPRfinder provided through CRISPRdb (see Grissa et al. Nucleic Acids Res. 35 (Web Server issue): W52-7 or BMC Informatics 8:172 (2007) (doi: 10.1186 / 1471-2105-8-172)).In some embodiments, a repeat sequence or a portion thereof is ligated at its 3' end to the 5' end of a spacer sequence, thereby forming a repeat-spacer sequence (e.g., guide RNA, crRNA).
[0155] In some embodiments, the repeat sequence contains, essentially consists of, or comprises at least 10 nucleotides (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50-100 nucleotides, or any range or value therein, e.g., about) depending on whether a particular repeat and a guide RNA containing the repeat are processed or not. In some embodiments, the repeat sequence contains, is essentially, or consists of about 10 to about 20, about 10 to about 30, about 10 to about 45, about 10 to about 50, about 15 to about 30, about 15 to about 40, about 15 to about 45, about 15 to about 50, about 20 to about 30, about 20 to about 40, about 20 to about 50, about 30 to about 40, about 40 to about 80, about 50 to about 100 or more nucleotides.
[0156] The repetitive sequence ligated to the 5' end of the spacer sequence may contain a portion of the repetitive sequence (for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more consecutive nucleotides of the wild-type repetitive sequence). In some embodiments, a portion of the repeat sequence ligated to the 5' end of the spacer sequence may be about 5 to about 10 consecutive nucleotides long (e.g., about 5, 6, 7, 8, 9, 10 nucleotides) and have at least 90% identity (e.g., at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) with respect to the same region (e.g., the 5' end) of the wild-type CRISPR-Cas repeat nucleotide sequence. In some embodiments, a portion of the repeat sequence may include a pseudoknot-like structure (e.g., a "handle") at its 5' end.
[0157] As used herein, “spacer sequence” is a nucleotide sequence (e.g., a protospacer) that is complementary to the target nucleic acid (e.g., target DNA). The spacer sequence may be fully complementary to the target nucleic acid or substantially complementary (e.g., at least about 70% (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or more)). Therefore, in some embodiments, the spacer sequence may have one, two, three, four, or five mismatches with respect to the target nucleic acid, and these mismatches may be consecutive or discontinuous. In some embodiments, the spacer sequence may have 70% complementarity with respect to the target nucleic acid. In some embodiments, the spacer nucleotide sequence may have 80% complementarity with respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect to respect. In some embodiments, the spacer sequence is 100% complementary to respect to respect to respect to respect to respect to respect to respect to respect. In some embodiments, the spacer sequence may be about 15 to about 30 nucleotides in length (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides, or any range or value therein). Thus, in some embodiments, the spacer sequence may have complete or substantial complementarity over a region of the target nucleic acid (e.g., protospacer) that is at least about 15 to about 30 nucleotides in length. In some embodiments, the spacer is about 20 nucleotides long. In some embodiments, the spacer is about 23 nucleotides long.
[0158] In some embodiments, the 5' region of the guide RNA spacer sequence may be identical to the target DNA, while the 3' region of the spacer may be substantially complementary to the target DNA (e.g., CRISPR-Cas type V), or the 3' region of the guide RNA spacer sequence may be identical to the target DNA, while the 5' region of the spacer may be substantially complementary to the target DNA (e.g., CRISPR-Cas type II), and therefore the overall complementarity of the spacer sequence to the target DNA may be less than 100%. Thus, in a guide of a CRISPR-Cas type V system, for example, the first nucleotides 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 in the 5' region (i.e., seed region) of a 20-nucleotide spacer sequence may be 100% complementary to the target DNA, while the remaining nucleotides in the 3' region of the spacer sequence may be substantially complementary to the target DNA (e.g., at least about 70% complementary). In some embodiments, the first 1-8 nucleotides at the 5' end of the spacer sequence (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8 nucleotides, and any range within that) may be 100% complementary to the target DNA, while the remaining nucleotides in the 3' region of the spacer sequence may be substantially complementary to the target DNA (e.g., at least about 50% (e.g., 50%, 55%, 6)). 0%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% (or greater) (complementary).
[0159] As a further example, in a type II CRISPR-Cas guide, for example, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 nucleotides of the 3' region (i.e., seed region) of a 20-nucleotide spacer sequence may be 100% complementary to the target DNA, while the remaining nucleotides of the 5' region of the spacer sequence may be substantially complementary to the target DNA (e.g., at least about 70%). In some embodiments, the first 1 to 10 nucleotides of the 3' end of the spacer sequence (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 nucleotides, and any range therein) may be 100% complementary to the target DNA, while the remaining nucleotides of the 5' region of the spacer sequence may be substantially complementary to the target DNA (e.g., at least about 50%). 5%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more, or any range or value within that range.
[0160] In some embodiments, the seed region of the spacer may be about 8 to about 10 nucleotides in length, about 5 to about 6 nucleotides in length, or about 6 nucleotides in length.
[0161] In some embodiments, the extended guide nucleic acid of the present invention may be an extended guide nucleic acid, a first extended guide nucleic acid, and / or a second extended guide nucleic acid. In some embodiments, an extended guide nucleic acid useful in the present invention may include (a) a CRISPR nucleic acid (e.g., CRISPR RNA, CRISPR DNA, crRNA, crDNA) and / or a CRISPR nucleic acid and a tracr nucleic acid; and (b) an extended portion comprising a primer binding site and a reverse transcriptase template (RT template), wherein the RT template encodes a modification to be incorporated into the target nucleic acid as described herein (e.g., an edit portion located at any position in the RT template relative to the position of the protospacer adjacent motif (PAM) of the target nucleic acid, possibly an edit portion located from nucleotide position -1 to nucleotide position 19, nucleotide position 10 to nucleotide position 17, or nucleotide position 12 to nucleotide position 15). In some embodiments, the CRISPR nucleic acid may be type II or type V CRISPR nucleic acid, and / or the tracr nucleic acid may be any tracr corresponding to a suitable type II or type V CRISPR nucleic acid. The extended guide nucleic acid may also be called a targeted allele guide nucleic acid, targeted allele guide DNA, or targeted allele guide RNA (tagRNA). In some embodiments, the CRISPR nucleic acid useful in the present invention may be type V CRISPR nucleic acid. In some embodiments, the tracr nucleic acid useful in the present invention may be type V CRISPR tracr nucleic acid. In some embodiments, the CRISPR nucleic acid useful in the present invention may be type II CRISPR nucleic acid tracr.In some embodiments, CRISPR nucleic acids and / or tracr nucleic acids are, for example, Cas9, C2c3, Cas12a (also known as Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Casl, CaslB, Cas2, Cas3, Cas3', Cas3'', Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csx12), C These may originate from as10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, Csx10, Csx16, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4(dinG) and / or Csf5 systems.
[0162] In some embodiments, the extended portion of the extension guide may include an RT template and a primer binding site oriented from 5' to 3' (when the extension guide is ligated to the 3' end of the CRISPR nucleic acid). In some embodiments, the extended portion of the extension guide may include a primer binding site and an RT template (RTT) oriented from 5' to 3' (when the extension guide is ligated to the 5' end of the CRISPR nucleic acid). In some embodiments, the RT template has a length from about 1 nucleotide to about 100 nucleotides (for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 7 5, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides, and any range or value within them), for example, the length of any range or value within them, such as from about 35 nucleotides to about 100 nucleotides, from about 35 nucleotides to about 80 nucleotides, from about 35 nucleotides to about 75 nucleotides, from about 40 nucleotides to about 75 nucleotides, from about 45 nucleotides to about 75 nucleotides, from about 45 nucleotides to about 60 nucleotides. In some embodiments, the length of the RT template may be at least 30 nucleotides, and possibly about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides to about 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides, or any range or value within that range.In some embodiments, the length of the RT template may be approximately 836, 40, 44, 47, 50, 52, 55, 63, 72, or 74 nucleotides. The edit portion is contained within the length of the RTT. The edit portion may be located anywhere within the RTT, and its position may be described relative to the position of the protospacer adjacent motif (PAM) of the target nucleic acid. In some embodiments, the RT template may include an edit portion located at nucleotide positions -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 27, 18, or 19. In some embodiments, the RT template may include an edit portion located at nucleotide positions 4 through 17 of the RT template relative to the position of the protospacer adjacent motif (PAM) of the target nucleic acid (e.g., positions 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17). In some embodiments, the RT template may include edits located at nucleotide positions 10 through 17 of the RT template relative to the protospacer adjacent motif (PAM) of the target nucleic acid (e.g., positions 10, 11, 12, 13, 14, 15, 16, or 17). In some embodiments, the RT template may include edits located at nucleotide positions 12 through 15 of the RT template relative to the protospacer adjacent motif (PAM) of the target nucleic acid (e.g., positions 12, 13, 14, or 15).
[0163] As used herein, the “primer binding site” (PBS) of the extended portion of an extended guide nucleic acid (e.g., tagRNA) refers to a sequence of consecutive nucleotides that can bind to a region on the target nucleic acid or to a “primer,” i.e., is complementary to the target nucleic acid primer. For example, when a CRISPR Cas effector protein (e.g., type II or type V, e.g., Cas9 or Cas12a) nicking / cutting DNA, the 3' end of the cleaved DNA acts as a primer for the PBS portion of the extended guide nucleic acid. The PBS is designed to be complementary to the 3' end of the target nucleic acid strand and may be designed to bind to either the target or non-target strand. The primer binding site may be fully complementary to the primer, or substantially complementary to the primer on the target nucleic acid (e.g., at least 70% complementary (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more)).In some embodiments, the length of the primer binding site of the extension portion ranges from about 1 nucleotide to about 100 nucleotides (for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides, or any value or range thereof), or approximately 4 to approximately 85 nucleotides, approximately 10 to approximately 80 nucleotides, approximately 20 to approximately 80 nucleotides, approximately 25 to approximately 80 nucleotides, approximately 30 to approximately 80 nucleotides, approximately 40 to approximately 80 nucleotides, approximately 45 to approximately 80 nucleotides, approximately 45 to approximately 75 nucleotides, or approximately 45 to approximately 60 nucleotides, or any range or value thereof. In some embodiments, the length of PBS may be at least 30 nucleotides, possibly about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides to about 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides, or any range or value within that range. In some embodiments, the length of PBS may be about 8, 16, 24, 32, 40, 48, 56, 64, 72, or 80 nucleotides.
[0164] In some embodiments, the RTT has a length of about 35 to about 75 nucleotides, and the PBS has a length of about 30 to about 80 nucleotides, and in some cases the PBS may include lengths of about 8, 16, 24, 32, 40, 48, 56, 64, 72, or 80 nucleotides, and the RTT may include lengths of about 36, 40, 44, 47, 50, 52, 55, 63, 72, or 74 nucleotides, or any combination thereof of the length of the RTT and / or the length of the PBS.
[0165] In some embodiments, the extended guide nucleic acid (e.g., extended guide nucleic acid, first extended guide nucleic acid, second extended guide nucleic acid) may include a structured RNA motif, and in some cases, the structured RNA motif may be located at the 3' end of the extended guide nucleic acid. In some embodiments, the structured RNA motif may include, but is not limited to, AsCpf1BB (SEQ ID NO: 189), Box B (SEQ ID NO: 190), Pseudoknot (Decoy) (SEQ ID NO: 95, SEQ ID NO: 203), Pseudoknot (tEvoPreQ1) (SEQ ID NO: 191), fmpknot (SEQ ID NO: 192), mpknot (SEQ ID NO: 193), MS2 (SEQ ID NO: 194), PP7 (SEQ ID NO: 195), SLBP (SEQ ID NO: 196), TAR (SEQ ID NO: 197), and / or ThermoPh (SEQ ID NO: 198). In some embodiments, the structured RNA motif may be a pseudoknot, and in some cases, the pseudoknot is located at the 3' end of the extended guide nucleic acid. A pseudoknot is an RNA structural motif formed by base pairing of a single-stranded region of RNA in a hairpin loop with a set of complementary nucleotides in other parts of the RNA chain. In some embodiments, the pseudoknot useful in the present invention may be a naturally occurring pseudoknot or a synthetic pseudoknot. As used herein, the term pseudoknot includes, but is not limited to, hairpins, multiloops, kissing loops, coaxial stacking, triplexes, pseudoknot-like structures, pseudoknotted hairpins and / or decoy pseudoknotted hairpins or other RNA structural motifs. In some embodiments, the pseudoknot may be located at the 3' end of the extended guide nucleic acid. In some embodiments, if the extended guide contains 5'-3' crRNA-RTT-PBS, the pseudoknot may be located at 5' of the RTT or 3' of the PBS. In some embodiments, the pseudoknot may be located at the 3' end of the extended guide nucleic acid. In some embodiments, if the expansion guide includes an expansion (expanded portion) at the 5' end of the crRNA, the pseudoknot may be located at 3' of the RTT or 5' of the PBS.In some embodiments, pseudoknots useful for expansion guidance may include, but are not limited to, a tEvoPreQ1 pseudoknot containing the nucleic acid sequence UAAUUUCUACUAAGUGUAGAU (SEQ ID NO: 158), an EvoPreQ1 pseudoknot containing the nucleic acid sequence TTGACGCGGTTCTATCTAGTTACGCGTTAAACCAACUAGAAA (SEQ ID NO: 191), or a pseudoknot containing the nucleic acid sequence TAAGTCTCCATAGAATGGAGG (SEQ ID NO: 95) and / or UAAGUCUCCAUAGAAUGGAGG (SEQ ID NO: 203). The expansion guide nucleic acid of the present invention may be contained in an expression cassette, and in some cases, the expression cassette is contained in a vector.
[0166] In some embodiments, the expansion portion of the expansion guide may be fused to either the 5' or 3' end of a type II or type V CRISPR nucleic acid (e.g., 5' to 3' orientation: repeat-spacer-expansion portion, or expansion portion-repeat-spacer), and / or to the 5' or 3' end of a tracr nucleic acid. In some embodiments, when the expansion portion is located at 5' of the crRNA, the type V CRISPR-Cas effector protein is modified to reduce (or eliminate) self-processing RNAse activity. In some embodiments, the type V CRISPR-Cas effector protein modified to reduce (or eliminate) self-processing RNAse activity may also be utilized when the expansion portion is located at 3' of the crRNA.
[0167] In some embodiments, the extended portion of the extended guide nucleic acid can be linked to type II or V CRISPR nucleic acid and / or type II or V tracrRNA via a linker. In some embodiments, the linker has a length of about 1 to about 100 nucleotides or more (for example, a length of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 , 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides, and any range thereof (for example, lengths of approximately 2 to approximately 40, approximately 2 to approximately 50, approximately 2 to approximately 60, approximately 4 to approximately 40, approximately 4 to approximately 50, approximately 4 to approximately 60, approximately 5 to approximately 40, approximately 5 to approximately 50, approximately 5 to approximately 6 0, approximately 9-40, approximately 9-50, approximately 9-60, approximately 10-40, approximately 10-50, approximately 10-60, approximately 40-100, approximately 50-100, or approximately 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides to approximately 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, It may be 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 or more nucleotides (for example, nucleotides with a length of approximately 105, 110, 115, 120, 130, 140, 150 or more).
[0168] As used herein, “target nucleic acid,” “target DNA,” “target nucleotide sequence,” “target region,” or “target region in genome” refers to a region of the genome of an organism that is fully complementary (100% complementary) or substantially complementary (e.g., at least 70% complementary (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more)) to the spacer sequence in the guide RNA of the present invention (e.g., the spacer is substantially complementary to the target strand of the target nucleic acid). Useful target regions for the CRISPR-Cas system can be located immediately 3' (e.g., type V CRISPR-Cas system) or immediately 5' (e.g., type II CRISPR-Cas system) of the PAM sequence within the genome of an organism (e.g., a plant genome). The target region can be selected from any region of at least 15 consecutive nucleotides located immediately adjacent to the PAM sequence on the target strand (e.g., nucleotides 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, etc.).
[0169] The term "protospacer sequence" refers to a portion of the target nucleic acid / target DNA (e.g., the genome (e.g., nuclear genome, plastid genome, mitochondrial genome), or a target region in an extragenomic sequence such as a plasmid or minichromosome) that is completely or substantially complementary (and hybridizes) with the target double-stranded DNA, particularly the spacer sequence of a CRISPR repeat-spacer sequence (e.g., guide RNA, CRISPR array, crRNA). Thus, the protospacer sequence is complementary to the target strand of the target nucleic acid. In some embodiments, the target nucleic acid may have a first strand and a second strand (double-stranded DNA). In some embodiments, the term "first strand" as used herein with respect to the target nucleic acid may refer to the target strand or bottom strand. In some embodiments, the term "second strand" as used with respect to the target nucleic acid is a strand that is complementary to the first strand (e.g., the top strand or non-target strand).
[0170] In the art and as used herein, “target strand” refers to the strand of double-stranded DNA to which the spacer is complementary and to which the CRISPR-Cas effector protein is recruited, while “non-target strand” refers to the strand opposite to the target strand in a double-stranded nucleic acid. In some embodiments of the present invention, the non-target strand of the double-stranded nucleic acid is the strand opposite to the strand to which the CRISPR-Cas effector protein is recruited, and is nicked by the CRISPR-Cas effector protein and edited by reverse transcriptase. In some embodiments, the target strand of the double-stranded nucleic acid is the same strand to which the CRISPR-Cas effector protein is recruited, and is nicked by the CRISPR-Cas effector protein and edited by reverse transcriptase.
[0171] In the case of type V CRISPR-Cas (e.g., Cas12a) and type II CRISPR-Cas (Cas9) systems, the protospacer sequence is adjacent to the protospacer adjacency motif (PAM) (e.g., immediately adjacent). In the case of type IV CRISPR-Cas systems, the PAM is located at the 5' end of the non-target strand and at the 3' end of the target strand (see below for an example). [ka]
[0172] In type II CRISPR-Cas systems (e.g., Cas9), the PAM is located 3' immediately after the target region. In type I CRISPR-Cas systems, the PAM is located 5' of the target strand. No PAM is known for type III CRISPR-Cas systems. Makarova et al. (Nature Reviews Microbiology 13:722-736 (2015)) describe the nomenclature for all classes, types, and subtypes of CRISPR systems. Guide structures and PAMs are described by R. Barrangou (Genome Biol. 16:247 (2015)).
[0173] Canonical Cas12a PAMs are T-rich. In some embodiments, the canonical Cas12a PAM sequence may be 5'-TTN, 5'-TTTN, or 5'-TTTV. In some embodiments, the canonical Cas9 (e.g., Streptococcus pyogenes) PAM may be 5'-NGG-3'. In some embodiments, non-canonical PAMs may be used, but they may be less effective.
[0174] Further PAM sequences may be determined by those skilled in the art by established experimental and computational approaches. For example, experimental approaches include targeting sequences adjacent to all possible nucleotide sequences and identifying sequence members that are not targeted, for example, by transformation of the target plasmid DNA (Esvelt et al. 2013. Nat Methods 10:1116-1121, Jiang et al. 2013. Nat. Biotechnol. 31:233-239). In some embodiments, computational approaches may include performing BLAST searches of native spacers to identify the original target DNA sequence within a bacteriophage or plasmid, and aligning these sequences to determine conserved sequences adjacent to the target sequence (Briner and Barrangou. 2014. Appl. Environ. Microbiol. 80:994-1001, Mojica et al. 2009. Microbiology 155:733-740).
[0175] In some embodiments, the present invention further provides a method for modifying a target nucleic acid, comprising contacting the target nucleic acid at a first site with (a)(i) a first CRISPR-Cas effector protein; and (ii) a first extended guide nucleic acid (e.g., a first extended CRISPR RNA, a first extended CRISPR DNA, a first extended crRNA, a first extended crDNA); and (b)(i) a second CRISPR-Cas effector protein, (ii) a first reverse transcriptase; and (ii) a first guide nucleic acid, thereby modifying the target nucleic acid. In some embodiments, the method of the present invention may further comprise contacting a target nucleic acid with (a) a third CRISPR-Cas effector protein; and (b) a second guide nucleic acid, wherein the third CRISPR-Cas effector protein nicks a site on the first strand of the target nucleic acid located about 10 to about 125 base pairs (5' or 3') from a second site on the second strand nicked by the second CRISPR-Cas effector protein, thereby improving mismatch repair. In some embodiments, the method of the present invention may further include contacting a target nucleic acid with (a) a fourth CRISPR-Cas effector protein, (b) a second reverse transcriptase, and (c) a second extended guide nucleic acid (e.g., a second extended CRISPR RNA, a second extended CRISPR DNA, a second extended crRNA, a second extended crDNA), where the second extended guide nucleic acid targets a site on the first strand of the target nucleic acid (the spacer is substantially complementary to / bound to a site on the first strand of the target nucleic acid), thereby modifying the target nucleic acid. The CRISPR-Cas effector proteins useful in the present invention (e.g., the first, second, third, and fourth) may be any combination of any type I, type II, type III, type IV, or type V CRISPR-Cas effector proteins described herein.In some embodiments, the CRISPR-Cas effector protein is Cas9, C2c3, Cas12a (also called Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Casl, CaslB, Cas2, Cas3, Cas3', Cas3'', Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also called Csnl and Csx12), This can be Cas10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, Csx10, Csx16, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4(dinG) and / or Csf5.
[0176] In some embodiments, an extension guide nucleic acid useful for a first CRISPR-Cas effector protein may include an extension portion comprising (a) a CRISPR nucleic acid (CRISPR RNA, CRISPR DNA, crRNA, crDNA); and (b) a primer binding site and a reverse transcriptase template (RT template), wherein the RT template encodes modifications to be incorporated into the target nucleic acid as described herein (for example, encoding edits located at any position in the RT template relative to the position of the protospacer adjacent motif (PAM) of the target nucleic acid, possibly from nucleotide position -1 to nucleotide position 19, from nucleotide position 10 to nucleotide position 17, or from nucleotide position 12 to nucleotide position 15).
[0177] In some embodiments, the CRISPR nucleic acid of the extended guide nucleic acid includes a spacer sequence that can bind to a first site on the first strand of the target nucleic acid (having substantial homology).
[0178] In some embodiments, the guide nucleic acid useful for the CRISPR-Cas effector protein includes a CRISPR nucleic acid (CRISPR RNA, CRISPR DNA, crRNA, crDNA). In some embodiments, the CRISPR nucleic acid of the first guide nucleic acid includes a spacer sequence that binds to a second site on the first strand of the target nucleic acid located upstream (3') of a first site on the first strand of the target nucleic acid.
[0179] In some embodiments, the second CRISPR-Cas effector protein may be a CRISPR-Cas fusion protein containing a CRISPR-Cas effector protein domain fused to a reverse transcriptase.
[0180] In some embodiments, the second CRISPR-Cas effector protein may be a CRISPR-Cas fusion protein containing a CRISPR-Cas effector protein domain fused to a peptide tag, and the reverse transcriptase may be a reverse transcriptase fusion protein containing a reverse transcriptase domain fused to an affinity polypeptide capable of binding to the peptide tag.
[0181] In some embodiments, the first guide nucleic acid may be ligated to an RNA recruitment motif, and the reverse transcriptase may be a reverse transcriptase fusion protein comprising a reverse transcriptase domain fused to an affinity polypeptide capable of binding to the RNA recruitment motif.
[0182] In some embodiments, the target nucleic acid may be further contacted with a 5'-3' exonuclease, and optionally the 5'-3' exonuclease may be fused with a first CRISPR-CAS effector protein. In some embodiments, the 5'-3' exonuclease may be a fusion protein comprising a 5'-3' exonuclease fused to a peptide tag, and the first CRISPR-Cas effector protein may be a fusion protein comprising a CRISPR-Cas effector protein domain fused to an affinity polypeptide capable of binding to the peptide tag. In some embodiments, the 5'-3' exonuclease may be a fusion protein containing a 5'-3' exonuclease fused to an affinity polypeptide capable of binding to the RNA recruitment motif, and the extended guide nucleic acid is linked to the RNA recruitment motif.
[0183] In some embodiments, the present invention further provides contacting a target nucleic acid with one or more single-stranded DNA-binding proteins (ssDNA BPs). The single-stranded DNA-binding proteins (ssDNA BPs) may be useful for stabilizing the single-stranded DNA produced in the methods of the present invention. While we do not wish to be bound by any particular theory, ssDNA BPs may protect the DNA strand from degradation or prevent it from becoming unavailable for RT-mediated priming and polymerization. Single-stranded DNA-binding proteins useful in the present invention may include, but are not limited to, those obtained from exemplary ssDNA BPs, and may include, but are not limited to, those derived from humans, bacteria, or phages. In some embodiments, the ssDNA BP includes, but is not limited to, hRad51 (possibly hRad51_S208E_A209D) (SEQ ID NO: 123), hRad52 (SEQ ID NO: 124), BsRecA (SEQ ID NO: 125), EcRecA (SEQ ID NO: 126), T4ssB (SEQ ID NO: 127), and / or Brex27 (SEQ ID NO: 128). In some embodiments, the target nucleic acid may be contacted with one or more ssDNA BPs, where the ssDNA BPs may be fused to the C-terminus or N-terminus of a CRISPR-Cas effector protein (e.g., CRISPR-Cas effector protein, first CRISPR-Cas effector protein, second CRISPR-Cas effector protein, third CRISPR-Cas effector protein, and / or fourth CRISPR-Cas effector protein). ssDNA BP can be fused to the C-terminus or N-terminus of a CRISPR-Cas effector protein / domain. In some embodiments, ssDNA BP is fused to a type II CRISPR-Cas effector protein / domain and / or a type V CRISPR-Cas effector protein / domain.
[0184] In some embodiments, the methods of the present invention further include reducing double-strand breaks by introducing a chemical inhibitor of non-homologous end joining (NHEJ), transiently knocking down the expression of NHEJ proteins by introducing CRISPR-guided nucleic acids or siRNAs that target NHEJ proteins, or introducing a polypeptide that prevents NHEJ. In some embodiments, the polypeptide that prevents NHEJ may include, but is not limited to, a Gam protein, and in some cases the Gam protein may be the Escherichia phage Mu Gam protein (e.g., SEQ ID NO: 147).
[0185] In some embodiments, an extended guide nucleic acid is provided, which comprises (i) a type V CRISPR nucleic acid or a type II CRISPR nucleic acid (type II or V CRISPR RNA, type II or V CRISPR DNA, type II or V crRNA, type II or V crDNA), and / or a type V CRISPR nucleic acid or a type II CRISPR nucleic acid and a tracr nucleic acid (e.g., type II or V tracrRNA, type II or V tracrDNA); and (ii) an extended portion comprising a primer binding site and a reverse transcriptase template (RT template) (RTT). In some embodiments, the extended guide nucleic acid further comprises a structured RNA motif, which may be located at the 3' end of the extended guide nucleic acid. In some embodiments, the structured RNA motif may include, but is not limited to, AsCpf1BB (SEQ ID NO: 189), Box B (SEQ ID NO: 190), Pseudoknot (Decoy) (SEQ ID NO: 95, SEQ ID NO: 203), Pseudoknot (tEvoPreQ1) (SEQ ID NO: 191), fmpknot (SEQ ID NO: 192), mpknot (SEQ ID NO: 193), MS2 (SEQ ID NO: 194), PP7 (SEQ ID NO: 195), SLBP (SEQ ID NO: 196), TAR (SEQ ID NO: 197), and / or ThermoPh (SEQ ID NO: 198). In some embodiments, the structured RNA motif is a pseudoknot, which may be located at the 3' end of an extended guide nucleic acid. In some embodiments, the pseudoknot useful in the present invention may be a naturally occurring pseudoknot or a synthetic pseudoknot. In this specification, a pseudoknot may also be referred to as a pseudoknot-like structure, a pseudoknotted hairpin, and / or a decoy pseudoknotted hairpin. In some embodiments, the pseudoknot may be located at the 3' end of the expansion guide nucleic acid. In some embodiments, if the expansion guide contains a 5'-3' crRNA-RTT-PBS, the pseudoknot may be located at the 5' of the RTT or the 3' of the PBS. In some embodiments, if the expansion guide contains an expansion (expanded portion) at the 5' end of the crRNA, the pseudoknot may be located at the 3' of the RTT or the 5' of the PBS.In some embodiments, the pseudoknot may be located at the 5' end of the extended guide nucleic acid, followed by PBS in the 5'-3' orientation, then RTT, a native pseudoknot in the crRNA (e.g., in a repetitive sequence), and then a complementary region (e.g., a spacer sequence).
[0186] In some embodiments, pseudoknots useful for expansion guidance may include, but are not limited to, a tEvoPreQ1 pseudoknot containing the nucleic acid sequence of SEQ ID NO: 158, an EvoPreQ1 pseudoknot containing the nucleic acid sequence of SEQ ID NO: 191, and / or a pseudoknot containing the nucleic acid sequence of SEQ ID NO: 95 or SEQ ID NO: 203. The expansion guide nucleic acid of the present invention may be contained in an expression cassette, which may optionally be contained in a vector.
[0187] In some embodiments, a complex is provided comprising (a) a type II CRISPR-Cas effector protein or a type V CRISPR-Cas effector protein; (b) a reverse transcriptase; and (c) an extended guide nucleic acid (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA; e.g., tagDNA, tagRNA).
[0188] In some embodiments, the type II or type V CRISPR-Cas effector protein of the complex may be a fusion protein comprising a type II or type V CRISPR-Cas effector protein domain fused to a peptide tag. In some embodiments, the type II or type V CRISPR-Cas effector protein of the complex may be a fusion protein comprising a type II or type V CRISPR-Cas effector protein domain fused to an affinity polypeptide capable of binding to a peptide tag. In some embodiments, the type II or type V CRISPR-Cas effector protein of the complex may be a fusion protein comprising a type II or type V CRISPR-Cas effector protein domain fused to an affinity polypeptide capable of binding to an RNA recruitment motif.
[0189] In some embodiments, the reverse transcriptase of the complex may be a fusion protein comprising a reverse transcriptase domain fused to a peptide tag. In some embodiments, the reverse transcriptase of the complex may be a fusion protein comprising a reverse transcriptase domain fused to an affinity polypeptide capable of binding to a peptide tag. In some embodiments, the reverse transcriptase of the complex may be a fusion protein comprising a reverse transcriptase domain fused to an affinity polypeptide capable of binding an RNA recruiting polypeptide. In some embodiments, the complex may further comprise guide nucleic acids (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA). In some embodiments, the complex may further comprise extended guide nucleic acids (e.g., extended CRISPR RNA, extended CRISPR DNA, extended crRNA, extended crDNA).
[0190] In some embodiments, the expansion guide nucleic acid of the complex may further include a pseudoknot. In some embodiments, the pseudoknot included in the expansion guide nucleic acid of the complex may be located at the 3' end of the expansion guide nucleic acid. In some embodiments, the pseudoknot useful in the expansion guide nucleic acid of the complex of the present invention may be a naturally occurring pseudoknot or a synthetic pseudoknot. Hereinafter, the pseudoknot may also be called a pseudoknot-like structure, a pseudoknot-modified hairpin, and / or a decoy pseudoknot-modified hairpin. In some embodiments, the pseudoknot may be located at the 3' end of the expansion guide nucleic acid. In some embodiments, if the expansion guide includes 5'-3' crRNA-RTT-PBS, the pseudoknot may be located at 5' of the RTT or 3' of the PBS. In some embodiments, the pseudoknot may include, but is not limited to, a tEvoPreQ1 pseudoknot containing the nucleic acid sequence of SEQ ID NO: 158, an EvoPreQ1 pseudoknot containing the nucleic acid sequence of SEQ ID NO: 191, or a pseudoknot containing the nucleic acid sequence of SEQ ID NO: 95 or SEQ ID NO: 203.
[0191] In some embodiments, the complex of the present invention may be contained in an expression cassette, and in some cases, the expression cassette may be contained in a vector. In some embodiments, the expression cassette containing the complex of the present invention may be codon-optimized for expression in organisms described herein, and in some cases, the organism may be an animal such as a human, a plant, a fungus, an archaea, a bacterium, or a virus.
[0192] The present invention further provides a codon-optimized expression cassette for expression in an organism, comprising (a) a polynucleotide encoding a promoter sequence in a 5' to 3' orientation; (b) a polynucleotide encoding a codon-optimized V-type CRISPR-Cas nuclease (e.g., Cpf1(Cas12a), dCas12a, etc.) or a II-type CRISPR-Cas nuclease (e.g., Cas9, dCas9, etc.) for expression in an organism; (c) a linker sequence; and (d) a polynucleotide encoding a codon-optimized reverse transcriptase for expression in an organism, wherein the organism may be an animal such as a human, a plant, a fungus, an archaea, a bacterium, or a virus. Furthermore, a codon-optimized expression cassette for expression in plants is provided, comprising (a) a polynucleotide encoding a plant-specific promoter sequence (e.g., ZmUbi1, MtUb2, RNA polymerase II (Pol II)) oriented 5' to 3'; (b) a plant codon-optimized polynucleotide encoding a type V CRISPR-Cas nuclease (e.g., Cpf1 (Cas12a), dCas12a, etc.); (c) a linker sequence; and (d) a plant codon-optimized polynucleotide encoding a reverse transcriptase. In some embodiments, the linker sequence may be an amino acid or peptide linker as described herein. In some embodiments, the reverse transcriptase in the expression cassette may be fused to one or more ssRNA-binding domains (RBDs).
[0193] The present invention further provides a codon-optimized expression cassette for expression in plants, comprising (a) a polynucleotide encoding a plant-specific promoter sequence (e.g., ZmUbi1, MtUb2), and (b) an extended RNA guide sequence, wherein the extended guide nucleic acid comprises an extended portion (e.g., a reverse transcriptase template) having a primer binding site and an edit portion incorporated into the target nucleic acid at its 3' end, and optionally the extended guide nucleic acid is included in the expression cassette, and optionally the extended guide nucleic acid is operably ligated to a Pol II promoter.
[0194] In some embodiments, the expression cassette comprises an extended guide nucleic acid further containing a structured RNA motif, which may be located at the 3' end of the extended guide nucleic acid. In some embodiments, the structured RNA motif may include, but is not limited to, AsCpf1BB (SEQ ID NO: 189), Box B (SEQ ID NO: 190), Pseudoknot (Decoy) (SEQ ID NO: 95, SEQ ID NO: 203), Pseudoknot (tEvoPreQ1) (SEQ ID NO: 191), fmpknot (SEQ ID NO: 192), mpknot (SEQ ID NO: 193), MS2 (SEQ ID NO: 194), PP7 (SEQ ID NO: 195), SLBP (SEQ ID NO: 196), TAR (SEQ ID NO: 197), and / or ThermoPh (SEQ ID NO: 198). In some embodiments, the structured RNA motif is a pseudoknot, which may be located at the 3' end of the extended guide nucleic acid. In some embodiments, pseudoknots useful in the extension guide may include, but are not limited to, pseudoknots containing the nucleic acid sequences of SEQ ID NO: 158, SEQ ID NO: 191, SEQ ID NO: 95, and / or SEQ ID NO: 203.
[0195] In some embodiments, the plant-specific promoter useful in the expression cassette of the present invention may be bound to an intron or is a promoter region containing an intron (e.g., ZmUbi1 containing an intron; MtUb2 containing an intron).
[0196] In some embodiments, the expression cassette may be codon-optimized for expression in dicotyledonous plants. In some embodiments, the expression cassette may be codon-optimized for expression in monocotyledonous plants.
[0197] In some embodiments, the present invention provides a method for modifying a target nucleic acid in a plant or plant cell, comprising introducing one or more expression cassettes of the present invention into a plant or plant cell, thereby modifying a target nucleic acid in the plant or plant cell, and generating a plant or plant cell containing the modified target nucleic acid. In some embodiments, the method of the present invention further comprises regenerating a plant from a plant cell containing the modified target nucleic acid to generate a plant containing the modified target nucleic acid. In some embodiments, the method of the present invention comprises contacting the target nucleic acid at a temperature of about 20°C to 42°C (e.g., about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42°C, and any value or range therein).
[0198] In some embodiments, the present invention provides cells comprising one or more polynucleotides, guide nucleic acids, nucleic acid structures, expression cassettes, or vectors of the present invention.
[0199] When used in combination with a guide nucleic acid, the polynucleotide / nucleic acid structure / expression cassette of the present invention may be used to modify a target nucleic acid. The target nucleic acid may be contacted with the polynucleotide / nucleic acid structure / expression cassette of the present invention before, simultaneously with, or after contact of the target nucleic acid with the guide nucleic acid. In some embodiments, the polynucleotide and guide nucleic acid of the present invention may be contained in the same expression cassette or vector, and therefore the target nucleic acid may be contacted with the polynucleotide and guide nucleic acid of the present invention simultaneously. In some embodiments, the polynucleotide and guide nucleic acid of the present invention may be contained in different expression cassettes or vectors, and therefore the target nucleic acid may be contacted with the polynucleotide of the present invention before, simultaneously with, or after contact with the guide nucleic acid.
[0200] Using the polynucleotides and methods of the present invention, target nucleic acids of any organism, including but not limited to eukaryotes or prokaryotes, such as plants, animals, bacteria, archaea, fungi, and / or viruses, may be modified (e.g., mutations, e.g., base editing, cleavage, nicking, etc.). Using the polynucleotides of the present invention, any animal or its cells, including but not limited to insects, fish, birds, amphibians, reptiles, and / or mammals, may be modified (e.g., mutations, e.g., base editing, cleavage, nicking, etc.). Exemplary mammals to which the present invention may be useful include, but are not limited to, primates (humans and non-humans (e.g., chimpanzees, baboons, monkeys, gorillas, etc.)), cats, dogs, ferrets, gerbils, hamsters, cattle, pigs, horses, goats, donkeys, or sheep. In some embodiments, the fungal target organism may include, but is not limited to, zygomycetes, ascomycetes, basidiomycetes, and imperfect fungi (imperfect fungi). In some embodiments, the fungal target organism may be an ascomycete, and in some cases, a yeast. In some embodiments, the fungal target organism may be from the genus Saccharomyces, and in some cases, a budding yeast.
[0201] Any target nucleic acid of any plant or plant part can be modified using the polynucleotides of the present invention (e.g., mutation, e.g., base editing, cleavage, nicking, etc.). Any plant (or group of plants, e.g., genera or higher-order classification) including angiosperms, gymnosperms, monocots, dicots, C3, C4, CAM plants, bryophytes, ferns and / or ferns, microalgae, and / or macroalgae can be modified using the nucleic acid structures of the present invention. Plants and / or plant parts useful to the present invention may be plants and / or plant parts of any plant species / variety / cultivar. The term "plant part" as used herein is not limited to, but includes, embryos, pollen, ovules, seeds, leaves, stems, shoots, flowers, branches, fruits, kernels, spikes, cobs, exocoria, stems, roots, root tips, anthers, and plant cells (including intact plant cells, plant protoplasts, plant tissues, plant cell tissue cultures, plant callus, plant masses, etc. in plants and / or plant parts). As used herein, “shoot” refers to the above-ground part of a plant, including leaves and stems. Furthermore, as used herein, “plant cell” refers to the structural and physiological unit of a plant, which includes a cell wall and may also refer to a protoplast. A plant cell may be in the form of an isolated single cell, a cultured cell, or a more highly organized unit, such as part of a plant tissue or plant organ.
[0202] Non-limiting examples of plants useful for the present invention include turfgrasses (e.g., bluegrass, bentgrass, ryegrass, and the genus *Phragmites australis*), reeds, broad-leaved sedges, *Miscanthus*, *Arundo*, switchgrass, vegetable crops (artichoke, kohlrabi, yellow radish, chives, asparagus, lettuce (e.g., salad greens, leaf lettuce, and tachi-chisha), maranga, melons (e.g., muskmelon, watermelon, Crenshaw melon, honeydew melon, and cantaloupe), and brassica crops (e.g., Brussels sprouts, cabbage, cauliflower, broccoli, and colander). (Corn, kale, Chinese cabbage, bok choy), cardoni, carrots, Chinese cabbage, okra, onions, celery, parsley, chickpeas, parsnips, chicory, pepper, potatoes, cucurbits (e.g., mallow, cucumber, zucchini, squash, pumpkin, honeydew melon, watermelon, cantaloupe), radishes, dried onions, rutabaga, eggplant, pokeweed, shallots, endive, garlic, spinach, leeks, squash, greens, beets (sugar beets and fodder beets), sweet potatoes, corn (Examples include herbs, horseradish, tomatoes, turnips, and spices), fruit crops such as apples, apricots, cherries, nectarines, peaches, pears, plums, prunes, cherries, quince, figs, nuts (e.g., chestnuts, pecans, pistachios, hazelnuts, peanuts, walnuts, macadamia nuts, almonds, etc.), citrus fruits (e.g., clementines, kumquats, oranges, grapefruits, tanger mandarins, oranges, lemons, limes, etc.), blueberries, black raspberries, boysenberries, cranberries, and more. Lantz, gooseberry, loganberry, raspberry, strawberry, blackberry, grapes (for wine and eating), avocado, banana, kiwi, persimmon, pomegranate, pineapple, tropical fruit, pear-shaped fruit, melon, mango, papaya, and lychee, crops such as clover, alfalfa, timothy, evening primrose, meadowfoam, corn (for feed, sweet corn, popcorn), hops, jojoba, buckwheat, safflower, quinoa, wheat, rice, barley, rye, millet, sorghum, oats, rye wheat, sorghum, tobacco,Kapok, legumes (beans (e.g., green beans and dried beans), lentils, peas, soybeans), oil plants (rapeseed, canola, mustard, poppy, olive, sunflower, coconut, castor oil plants, cocoa beans, peanuts, oil palm), duckweed, Arabidopsis genus, fiber plants (cotton, flax, hemp, jute), cannabis (e.g., hemp (Cannabis sativa), Indian hemp (Cannabis indica), and Cannabis ruderalis (Cannabis Examples include plants such as ruderalis, laurel (cinnamon, camphor), or coffee, sugarcane, tea, and natural rubber plants, as well as / or flowerbed plants, such as flowering plants, cacti, succulents, and / or ornamental plants (e.g., roses, tulips, violets), as well as trees, such as forest trees (broad-leaved and evergreen plants, such as conifers, such as elm, ash, oak, maple, fir, spruce, cedar, pine, birch, cypress, eucalyptus, willow), as well as shrubs and other seedlings. In some embodiments, the nucleic acid structures of the present invention and / or expression cassettes and / or vectors encoding them may be used to modify corn, soybeans, wheat, canola, rice, tomatoes, pepper, sunflowers, raspberries, blackberries, black raspberries, and / or cherries.
[0203] The present invention further includes a kit for carrying out the method of the present invention. The kit of the present invention may include reagents, buffers, and apparatus for mixing, measuring, sorting, labeling, etc., as well as instructions suitable for modifying target nucleic acids.
[0204] In some embodiments, the present invention provides a kit comprising one or more nucleic acid constructs of the present invention and / or expression cassettes and / or vectors containing them, and optional instructions for their use. In some embodiments, the kit may further comprise a CRISPR-Cas guide nucleic acid (or extended guide nucleic acid) (corresponding to a CRISPR-Cas effector protein encoded by the polynucleotides of the present invention) and / or an expression cassette and / or vector containing it. In some embodiments, the guide nucleic acid / extended guide nucleic acid may be provided on the same expression cassette and / or vector as one or more polynucleotides of the present invention. In some embodiments, the guide nucleic acid / extended guide nucleic acid may be provided on a separate expression cassette or vector from the one or more polynucleotides of the present invention.
[0205] In some embodiments, the kit may further include a nucleic acid structure encoding a guide nucleic acid, the construct including a cloning site for cloning a nucleic acid sequence identical to or complementary to the target nucleic acid sequence into the guide nucleic acid backbone.
[0206] In some embodiments, the nucleic acid structure of the present invention may be mRNA capable of encoding one or more introns within the encoded polynucleotide. In some embodiments, the expression cassette and / or vector comprising one or more polynucleotides of the present invention may further encode one or more selection markers useful for identifying transformants (e.g., nucleic acids encoding antibiotic resistance genes, herbicide resistance genes, etc.).
[0207] Next, the present invention will be described with respect to the following embodiments. It should be recognized that these embodiments are not intended to limit the claims to the present invention, but rather to illustrate specific embodiments. Any variation of the illustrated methods that a person skilled in the art could imagine is intended to fall within the scope of the present invention. [Examples]
[0208] Allelic, RNA-encoded DNA substitution (REDRAW) utilizes the V-type Cas effector, an enzyme that polymerizes a DNA:RNA hybrid from a free DNA 3' end (annealing site, AS) and an extended guide nucleic acid (i.e., a targeted allele guide RNA (tagRNA)). These three macromolecules work in conjunction to perform the following tasks: i) position the CRISPR enzyme at the genomic site of interest using the CRISPR effector and the crRNA portion of the tagRNA; ii) nicking or cleaving the DNA to generate a free 3' end; iii) providing a portion of the tagRNA to anneal to the free 3' end of the DNA; iv) providing a portion of the tagRNA that serves as a template for RNA-dependent DNA polymerase; and v) terminating reverse transcription by either enzyme collision, spontaneous termination, or encounter with a stable hairpin.
[0209] We tested the REDRAW system using a non-targeted strand (NTS) nickase version of LbCas12a_R1138A and Moloney mouse leukemia virus (M-MuLV) RT. LbCas12a_R1138A was expected to be an NTS nickase based on its alignment with the previously described AsCas12a_R1226A mutation. We demonstrate in Figure XXX that LbCas12a_R1138A is indeed a nickase. The LbCas12a used was either RNAse(+) or had a mutation (H759A) that inhibited RNAse activity. The LbCas12a_R1138A_H759A mutant was used to prevent self-processing of tagRNA during 5' extension or when incorporating a 3' hairpin (e.g., a pseudoknot containing a hairpin element).
[0210] The tested tagRNAs included crRNAs containing either a 5' or 3' extension. Various annealing site lengths were tested to allow for the formation of shorter or longer DNA:RNA hybrids from the nicked non-target strand. RNA templates of varying lengths were also tested. Finally, two different hairpin designs—pseudoknotted hairpin design and decoy pseudoknotted hairpin design—were also incorporated into the LbCas12a crRNA sequence.
[0211] [Example 1] LbCas12a_R1138A Nickase Assay A nucleic acid structure (SEQ ID NO: 57) containing LbCas12a, followed by nucleoplasmin NLS, and a 6× histidine tag (GeneWiz) was synthesized and cloned into the pET28a vector between NcoI and XhoI to produce pWISE450 (SEQ ID NO: 58). To facilitate cloning, an additional glycine was added to the sequence between Met-1 and Ser-2. This extra glycine has been excluded in the numbering presented here. Next, the R1138A mutation was generated using the QuickChange II site-directed mutagenesis kit (Agilent) according to the manufacturer's instructions. These expression plasmids were used to transform BL21(DE3)Star E. coli competent cells (ThermoFisher Scientific).
[0212] BL21(DE3) Star cells were cultured in Luria medium and 50 ug / ml kanamycin at 37°C until an optical density A600=0.5 was obtained. Isopropyl β-d-1-thiogalactopyranoside (IPTG) was added to 0.5 mM, and protein induction was carried out overnight at 18°C. Cells were pelleted at 5,000 × g. Purification was achieved using two columns, a HisTrap column followed by a MonoS column (GE Healthcare), according to the manufacturer's protocol.
[0213] CRISPR RNA (crRNA) is sequenced by Synthego. [ka] Synthesized using (guide sections are shown in bold).
[0214] The plasmid that is cut is [ka] This is pUC19 with the following sequence inserted, where the bolded portion of the sequence is the PAM sequence recognized by LbCas12a, and the remainder (in normal font) is the protospacer sequence. The pUC19 plasmid was transformed into XL1-Blue (Agilent) (E. coli) and then purified using the Qiagen plasmid spin minikit.
[0215] The nuclease assay was performed by mixing LbCas12a_R1138:crRNA:plasmid in a 10:10:1 ratio and incubating in New England Biolabs buffer 2.1 at 37°C for 15 minutes, followed by heat inactivation at 80°C for 20 minutes, and loading onto a 1% TAE agarose gel embedded with SYBR-Safe stain (Invitrogen) to stain the DNA. As shown in the in vitro assay in Figure 4, LbCas12a_R1138A is a nickase. As shown in lanes 2 and 3, the supercoiled 2.8kB plasmid migrated with an apparent size of 2.0kB until double-strand breaks were induced by wild-type LbCas12a (lane 3) (lane 2). The mutant enzyme LbCas12a_R1138A mainly produced a nicked product that migrated with an apparent size of 5.0kB. Lanes 4-6 show that the ratio does not change even when the concentration of the mutant enzyme is increased until overall nuclease digestion of the plasmid occurs using extremely high concentrations of the enzyme (256 nM).
[0216] Designing and building REDRAW editor plasmids - bacterial screening A REDRAW (RNA-encoded DNA substitution of an allele) expression construct was synthesized by solid-phase synthesis and cloned between the NcoI restriction site and the XhoI restriction site of the expression vector pET28a(+). The REDRAW expression vector contains a ColE1 origin of replication, a kanamycin resistance marker, and a REDRAW editor under the control of the T7 promoter and terminator. The REDRAW editor contains Cas12a nickase (R1138A) or Rnase-inactivated Cas12a nickase (R1138A, H759A) fused to Mu-LV reverse transcriptase MuLV(5M) with XTEN or 5R linker (see, e.g., SEQ ID NO: 97) (mouse leukemia virus reverse transcriptase with five mutations: D200N+L603W+T330P+T306K+W313F) (Anzalone et al. Nature 576(7785):149-157(2019)). All REDRAW editor sequences are optimized for E. coli codons. The tested REDRAW editor configurations are shown in Figure 5. The two configurations provided in Figure 5 have Cas12a at the N-terminus of the reverse transcriptase, and the other two configurations have Cas12a at the C-terminus of the reverse transcriptase. The tested configuration was constructed using a Cas12a mutant with an additional H759A mutation to prevent processing of tagRNA including the 5' extension.
[0217] Design and construction of tagRNA plasmids - bacterial screening The tagRNA (target allele guide RNA) library sequences were designed using an algorithm that assembled Cas12a spacer and scaffold sequences along with reverse transcriptase templates and primer binding sites specific to each target. The design parameters shown in Table 1 span a wide range of primer binding sites and reverse transcriptase template lengths. The desired alterations shown in Table 3 are designed to confer antibiotic resistance after successful editing.
[0218] [Table 1]
[0219] Figure 6 shows the composition of the tagRNA in the first library. Both the 5' and 3' extensions, including RTT and PBS, were included in the library.
[0220] The second library was designed in a similar manner to the first library, but with the additional evaluation of whether the presence of a hairpin located exactly 3' of the spacer in the 3' tagRNA extension configuration improved REDRAW editing. The design parameters shown in Table 2 again broadly examine the lengths of the primer binding site (PBS) and reverse transcriptase template (RTT), but focus on the RTT length regions that proved functional from the first library. Both the 5' and 3' extensions containing the RTT and PBS were included in the library. Furthermore, mutants containing a decoy hairpin were also included in the second tagRNA library. Since a hairpin similar to the scaffold sequence of the natural LbCas12a but not recognized and cleaved by the Cas12a protein was desired, an existing hairpin with an architecture similar to the LbCas12a hairpin was found in the HIV-1 RNA genome and modified by adding a UA sequence to form a pseudoknot as shown in Figure 7.
[0221] [Table 2]
[0222] Construction of tagRNA plasmids for bacterial screening The base plasmid for the tagRNA library was generated by solid-phase synthesis and cloning of the holder fragment into pTwist Amp Medium Copy (TWIST BIOSCIENCE®). This plasmid contains the p15A origin of replication and an ampicillin resistance marker. The tagRNA is constitutively expressed from a synthetic BbaJ23119 promoter and terminated by a T7 terminator. The first tagRNA library evaluated was synthesized by an external vendor (Genewiz) and cloned into a tagRNA-based vector. For the second library, oligonucleotides were synthesized and cloned into a tagRNA-based vector using the NEB HiFi assembly kit according to the manufacturer's instructions. Library diversity was investigated by colony PCR and Sanger sequencing of 72 clones from the library to confirm that the library contained a wide range of PBS, RTT, and targets, and that there was virtually no bias.
[0223] Reporter plasmid design and construction A base reporter plasmid containing the CloDF13 origin of replication, chloramphenicol resistance marker, and spectinomycin resistance marker (aadA) was constructed by PCR amplified the CloDF13 origin of replication and chloramphenicol resistance marker, and then ligated to the PCR-amplified aadA resistance marker. Next, the wild-type aadA gene was excised between the BamHI and BglII restriction sites, and a synthetic gene block containing stop codons at residue positions Thr61, Leu115, and Asp132 was ligated to construct three reporter plasmids containing aadA variants. All reporter plasmids were validated by Sanger sequencing after construction. Furthermore, reporter plasmids containing aadA variants with stop codons in the coding sequence were validated for both spectinomycin and streptomycin sensitivity before being used in REDRAW tagRNA screening experiments.
[0224] Targeting REDRAW editing - bacterial screening In the REDRAW editing experiments, five targets were tested, as shown in Table 3 below. In all cases, two genomic targets and three plasmid targets were used. Successful REDRAW editing with any of the targets resulted in resistance to antibiotics (nalidixic acid or streptomycin), linking the survival of the host organism (E. coli) to the success of REDRAW editing.
[0225] [Table 3]
[0226] REDRAW tagRNA experiment - bacterial screening The host organism for all bacterial REDRAW tagRNA screening experiments was *E. coli* BL21(DE3). Before performing the selection experiments, chemically competent BL21(DE3) was transformed using each REDRAW expression construct according to the manufacturer's instructions and plated onto LB agar plates containing kanamycin. Subsequently, single colonies were taken from the transformation plates, and batches of electrocompetent cells were prepared according to a previously developed method (Sambrook and Russell (Transformation of E. coli by electroporation. Cold Spring Harbor Protocols 2006.1(2006):pdb-prot3933)). Next, competent cells containing each REDRAW expression construct were electroporated with 10 ng of each reporter plasmid, recovered at 37°C and 225 rpm SOC for 1 hour, and plated onto LB agar plates supplemented with kanamycin and chloramphenicol. Then, single colonies were taken from these plates from the transformation plates, and batches of electrocompetent cells were prepared again (Sambrook and Russell (Transformation of E. coli by electroporation. Cold Spring Harbor Protocols 2006.1(2006):pdb-prot3933)). Table 4 below summarizes the batches of electrocompetent cells prepared for testing the first tagRNA library.
[0227] [Table 4]
[0228] Selection experiments were first performed by electroporating 100 ng of tagRNA library into 50 μL of electrocompetent cells in each batch. Transformation was restored at 37°C for 1 hour with shaking at 225 rpm. After 1 hour of restoration, 1 μL of the restored material was taken out, mixed with 99 μL of LB, and plated onto an LB agar plate containing the appropriate antibiotic to check the transformation efficiency. Subsequently, the remaining amount of each transformant was added to 29 mL of LB + antibiotic (LB Kan / Carb for genome selection, LB Kan / Carb / Cam for plasmid selection) and 0.5 mM IPTG. The expression cultures were grown overnight at 37°C with shaking at 225 rpm.
[0229] The following day, the OD600 of each expression culture was measured. For each expression culture, 1 OD was plated onto five plates (approximately 0.2 OD per plate) containing the REDRAW expression vector (Kan), tagRNA plasmid (Carb), antibiotic against the reporter plasmid, 0.5 mM IPTG, and an additional selective antibiotic (nalidixic acid or streptomycin). The plates were incubated overnight at 37°C, and growth was observed the following morning. If no colonies were observed, the plates were incubated for a further 24 hours at 37°C.
[0230] Colonies observed on the selection plate were collected, streaked onto a plate containing the appropriate antibiotic, and colony PCR was performed to amplify the target gene for editing and the tag RNA for Sanger sequencing. Sanger sequencing was performed on the colony PCR products using Genewiz.
[0231] The evaluation of the second library was performed in the same manner as the first tagRNA library, with one modification. Instead of preparing 20 batches of electrocompetent cells, one large batch of electrocompetent BL21(DE3) cells containing the second tagRNA library was prepared. Subsequently, the electrocompetent cells containing the tagRNA library were transformed with either REDRAW expression constructor (100 ng) or REDRAW expression constructor + reporter plasmid (100 ng each). All subsequent steps were repeated in the same manner.
[0232] Evaluation of REDRAW editing using a first tagRNA library - bacterial screening The number of colonies obtained in the selection experiment of the first tagRNA library is summarized in Table 5 below. No colonies were observed in any of the genome selections (selections 1-8). Colonies were observed in each plasmid selection.
[0233] [Table 5]
[0234] For selections 9, 12, 15, and 18 (aadA Thr61 target), bacterial flora was observed. Colonies isolated from these plates were false positives. For selections 10, 11, 13, 14, 16, and 17 (aadA Leu115 target and aadA Asp132 target), a small number of colonies were observed on the plates. Colonies on these plates possessed both amplified tagRNA and target by colony PCR, confirming that editing had occurred, and were sent for Sanger sequencing to identify the tagRNA involved in the editing. All evaluated colonies from selections 11, 14, 17, and 20 (aadA Asp132 target) were false positives. Multiple colonies from selection 10 (aadA Leu115 target) possessed the designed edit region and associated tagRNA. The sequencing results of the edited targets are shown in Figure 8, demonstrating TGA→CTG editing and restoration of antibiotic resistance in the crippled aadA gene.
[0235] The identified sequences of the tagRNAs involved in editing are associated with the editing region shown in Figure 8: 5'- GTTTCAAAGATTAAATAATTTCTACTAAGTGTAGATTACGGCTCCGCAGTGGATGGCGGTAATTTCTACTAAGTGTAGATGCGGCGCGTTGTTTCATCAAGGCGTACGGTCACCGTAACCAGCAAATCAATATCACTGTGTGGCTTCAGGCCGCCATCCACTGCGG - 3' (SEQ ID NO: 87).
[0236] The protein composition of Selection 10 is as follows: SV40-nCas12a-XTEN-MMLV-RT-SV40.
[0237] Evaluation of REDRAW editing using a second tagRNA library - Results of genome selection The number of colonies obtained from the genome selection experiment of the second tagRNA library is summarized in Table 6 below. Colonies were observed on the rpsL selection plate.
[0238]
Table 6
[0239] For Selections 2.1 - 2.4 and 2.9 - 2.12 (gyrA genomic target), no colonies were observed on the plates. For Selections 2.5 - 2.8 and 2.13 - 2.16 (rpsL genomic target), a few colonies were observed on these plates. The colonies on these plates were streaked again to confirm resistance to all antibiotics. Next, colonies from these plates were used to generate tagRNA and target PCR products for Sanger sequencing. Sanger sequencing was used to confirm the editing that occurred and to identify the tagRNA involved in the editing. The colonies from Selections 2.6 - 2.8 and 2.13 - 2.16 were all false positives. One colony from Selection 2.5 had the designed edit from AAA to CGT that confers streptomycin resistance (see Figure 9).<000090Evaluation of REDRAW editing using a second tagRNA library - Plasmid selection results The number of colonies obtained from the plasmid selection experiment of the second tagRNA library is summarized in Table 7 below.
[0243] [Table 7] JPEG2023549339000012.jpg67170
[0244] Colonies were observed on plates of Leu115 and Asp132 selections. Selections 2.18, 2.19, 2.22, 2.25, 2.28, 2.31, 2.39, and 2.40 formed colonies on the selection plates. These colonies were streaked again to confirm resistance to all antibiotics. They were then used to produce PCR products of tagRNA and targets for Sanger sequencing. Sanger sequencing was used to confirm the edits performed and identify the tagRNAs involved in the editing. Colonies from selections 2.18, 2.19, 2.22, 2.28, 2.39, and 2.40 were all false positives. As shown in Figures 10 and 11, four colonies from selection 2.25 and two colonies from selection 2.31 had the designed edits and associated tagRNAs. Four colonies from selection 2.25 had identical edits and tagRNAs. The two colonies from selection 2.31 also had identical edits and tagRNAs.
[0245] The identified tagRNA sequences associated with the editing of Figure 10 from Selection 2.25 are as follows: 5'- TAATTTCTACTAAGTGTAGATTACGGCTCCGCAGTGGATGGCGGTAAGTCTCCATAGAATGGAGGACAGCGCGGAGAATCTCGCTCTCTCCAGGGGAAGCCGAAGTTTCCAAAAGGTCGTTGATCAAAGCGCGGCGCGTTGTTTCATCAAGGCGTACGGTCACCGTAACCAGCAAATCAATATCACTGTGTGGCTTCAGGCCGCCATCCACTGCGGAT- 3' Sequence number 93.
[0246] The protein composition of Selection 2.25 is as follows: SV40-nCas12a-XTEN-MMLV-RT-SV40
[0247] The identified tagRNA sequences associated with the editing of Figure 11 from Selection 2.31 are as follows: 5'-TAATTTCAACTAAGTGTAGATTACGGCTCCGCAGTGGATGGCGGTAAGTCTCCATAGAATGGAGGGCGGAGAATCTCGCTCTCCAGGGGAAGCCGAAGTTTCCAAAAGGTCGTTGATCAAAGCGCGGCGCGTTGTTTCATCAAGGCGTACGGTCACCGTAACCAGCAAATCAATATCACTGTGTGGCTTCAGGCCGCCATCCACTGCGGAT - 3' SEQ ID NO:94.
[0248] The protein composition of Selection 2.31 is as follows: SV40-MMLV-RT-XTEN-nLbCas12a(H759)-SV40.
[0249] Summary of REDRAW editing observed in bacterial cells Table 8 below summarizes examples of REDRAW editing observed in E. coli. For each example, the protein composition (REDRAW editor), edited target, tagRNA extension position (5' or 3' of the Cas12a hairpin and guide), PBS length, and RTT length are described.
[0250] [Table 8]
[0251] [Example 2] Precision editing activity in human cells A further approach using the active form of Cas12a in combination with reverse transcriptase is shown in Figure 12 and outlined below. Cas12a, which possesses nuclease activity, is recruited to this site through the interaction between the spacer and the target site. Cas12a performs double-strand cleavage. In some cases, an exonuclease is provided to break down the non-template strand from 5' to 3'. Priming is performed using tagRNA. The primer binding site (PBS) is located to the right of the cleavage site and encodes a sequence complementary to the template DNA. • Reverse transcriptase (MMuLV-RT(5M)) extends from the priming site or primer on the target nucleic acid (dashed line = extension), encoding the desired change in the newly synthesized chain. • Mismatch repair and DNA ligation resolve DNA intermediates, generating a new, edited DNA strand.
[0252] method: The extended guide RNA was designed to target two genomic sites in HEK293T cells, DMNT1 and FANCF1. Various combinations of primer-binding site (PBS) and reverse transcriptase template (RTT) lengths were assayed. The guide RNA encodes two base changes in the PAM region of the target guide, which correspond to TT to AA at positions -2 and -3 (counting TTTV PAM as positions -4 to -1). The guide extension was fused to either the 5' or 3' end of the guide RNA.
[0253] The plasmid encoding the RNAse-inactivated mutant LbCas12a (H758A), reverse transcriptase (MMuLV-RT(5M)), and optionally an exonuclease (one of T5 exonuclease, T7 exonuclease, RecE, RecJ), and an extended guide RNA was transfected into HEK293T cells cultured at 70% confluence using Lipofectamine™ 3000 according to the manufacturer's protocol. Three days later, the cells were harvested and gene editing was quantified by next-generation sequencing.
[0254] Results: We observed precise editing as intended at both targeted sites. Depending on the guide design, we observed up to 0.5% editing at the FANCF1 site (Figure 13) and up to 1.7% editing at the DMNT1 site (Figure 14). The use of exonuclease improved the editing efficiency for some guide designs.
[0255] [Table 9]
[0256] [Table 10]
[0257] [Table 11] JPEG2023549339000017.jpg94170
[0258] The effect of exonuclease transfection on the activity of precise editing at the DMNT1 site is shown in Figure 15 (normalized to without exonuclease treatment; pUC19 = 1). Exonuclease improves editing for some guide configurations.
[0259] [Example 3] Variations in the REDRAW protein architecture The method of the present invention (i.e., REDRAW) is provided by (1) overexpressing reverse transcriptase (RT(5M)) in cells; and (2) fusing a SunTag (GCN4, e.g., SEQ ID NO: 23, SEQ ID NO: 24) to a CRISPR-CAS effector protein (e.g., LbCpf1) to an antibody (e.g., a single-strand variable fragment (scFv) antibody) that binds to the SunTag fused to the CRISPR-Cas effector protein, thereby enabling editing of the editing site. The study was conducted using different protein architectures / constructs of LbCas12a and RT(5M), including (3) a construct in which RT(RT(5M)) is recruited; and (4) a construct in which reverse transcriptase (RT(5M)) is fused to the N-terminus or C-terminus of a CRISPR-Cas effector protein (e.g., LbCpf1(LbCas12a)), e.g., LbCpf1(H759A)) (e.g., RT(5M)-LbCpf1(H759A)-RT(5M))). The results are shown in Figure 16. Using four different tagRNA constructs, all constructs showed evidence of RT(5M) and tagRNA-dependent REDRAW activity. In this example, active recruitment by SunTag did not enhance activity. Overexpression of untagged constructs allows for sufficient intracellular protein concentrations, and therefore, under these conditions, it may not be the rate-limiting condition for generating precise editing.
[0260] MS2 / MCP series In addition to the architectures tested above, the MS2 / MCP system was also evaluated for use in the constructs and methods of the present invention. The MS2 hairpin RNA structure binds to the MCP protein. The MS2 hairpin can be attached to the tagRNA. In this example, the MS2 hairpin structure was added to the 3' end of the tagRNA and the MCP was fused to RT(5M) to recruit RT(5M) to the target site.
[0261] LbCas12a H759A with RT(5M) was transiently expressed without MCP (trans control) or with MCP-RT(5M) (fusion construct). This architecture was tested using two tagRNAs, tagRNA5 and tagRNA6. We also compared different tagRNA versions in which the 3' ends of tagRNA5 and tagRNA6 were modified with an MS2 sequence. The results are shown in Figure 37. Comparing MCP-RT(5M) and RT(5M), the efficiency of precise editing was not improved with MS2 tagRNA and MCP-RT(5M). Since the RT concentration is not the rate-limiting factor under these experimental conditions, the MCP fusion may not enhance the efficiency of precise editing. However, an increase in editing efficiency was observed with tagRNAs having MS2 at the 3' end. The MS2 structure at the 3' end of the tagRNA may stabilize the tagRNA and reduce its degradation.
[0262] [Example 4] 5'-3' exonuclease for use in the method of the present invention (REDRAW) 5'-3' exonucleases can be useful in the methods of the present invention by degrading DNA at both ends of double-strand breaks. Thus, 5'-3' exonucleases can (1) enable stronger RNA-DNA double-strand formation (substrates for RT-mediated polymerization) by degrading the strand that normally forms the extended DNA strand, and / or (2) allow cells to preferentially use DNA synthesized by RT for DNA repair by degrading the region that would otherwise be overwritten by RT. See, for example, the schematic diagram in Figure 17.
[0263] The exonucleases tested in this example include those listed in Table 11.
[0264] [Table 12]
[0265] The 5'-3' exonuclease was fused to the C-terminus of LbCas12a(H759A). The fusion construct was transfected into HEK293T cells with a plasmid expressing a reverse transcriptase (5M) construct and appropriate tagRNAs encoding precise mutations. Cells were harvested 3 days after transfection and DNA was analyzed using high-throughput sequencing (HTS). The results are shown in Figure 18. Here, RT is expressed in trans (unrecruited), and the 5'-3' exonuclease is fused to the C-terminus of LbCpf1 H759A. Compared to the construct without the exonuclease (LbCpf1 H759A only), the fusion of T7_Exo, in particular, improves the precision editing of REDRAW in three of the four tagRNAs tested.
[0266] Figure 19 provides an additional 5'-3' exonuclease test using the method of the present invention (REDRAW) under the same conditions as described above. Specifically, Figure 19 shows the percentage of refinement by REDRAW using either the 5'-3' exonuclease sbcB (SEQ ID NO: 134) or the 5'-3' exonuclease Exo (SEQ ID NO: 135), respectively, fused to the C-terminus of the Cas polypeptide (LbCpf1). RT(5M) (SEQ ID NO: 97) is expressed in trans (unrecruited). In contrast to T7_Exo (SEQ ID NO: 132), exonucleases sbcB and Exo did not improve REDRAW.
[0267] The 5'-3' exonuclease was also tested in trans using the method of the present invention. The results are shown in Figure 20. LbCpf1 and RT(5M) (SEQ ID NO: 97) are provided as a fusion protein. The right side of Figure 20 shows the result of fusion of RT to the N-terminus of LbCpf1 (RT(5M)-LbCpf1(H759A)), and the left side of the figure shows the result of fusion of RT to the C-terminus of LbCpf1 (LbCpf1(H759A)-RT(5M)). Figure 20 shows that when the 5'-3' exonuclease is expressed in trans without fusion to LbCpf1, the editing rate does not increase compared to treatment without the 5'-3' exonuclease. Therefore, the benefit of using the 5'-3' exonuclease in the method of the present invention is observed when the 5'-3' exonuclease is fused to a CRISPR-Cas effector protein.
[0268] [Example 5] Mutations that regulate the DNA binding affinity of Cas12a used in REDRAW By reducing the DNA binding affinity of the CRISPR-Cas effector protein, it is hypothesized that the CRISPR-Cas effector protein can more effectively dissociate from the target site, thereby inducing double-strand DNA breaks. This allows for the rapid formation of an intermediate that promotes sequence substitution by RT, potentially improving the efficiency of editing by the present invention's method (REDRAW).
[0269] In this example, positively charged residues within Cas12a (LbCas12a) that interact with the DNA backbone were mutated to alanine. Specifically, the following three mutations, K167A, K272A, and K349A (see amino acid position numbering in SEQ ID NO: 1 or 148), were cloned into LbCas12a H759A as single, double, or triple mutants (K167A, K272A, K349A, K167A+K272A, K167A+K349A, K272A+K349A, and K167A+K272A+K349A). In this case, the H759A mutation (SEQ ID NO: 148) was used to inactivate the RNA processing ability of LbCas12a and facilitate the extension of the 5' tagRNA to crRNA.
[0270] LbCas12a containing various combinations of binding affinity mutations was transfected into HEK293T cells along with a plasmid encoding RT(5M) and a tagRNA encoding precise editing. Cells were harvested 3 days after transfection, and DNA was analyzed using high-throughput sequencing (HTS). Specific combinations of mutations were shown to improve the precise editing of the present invention (Figure 21).
[0271] [Example 6] Single-stranded DNA binding protein (ssDNA BP) used in REDRAW The use of single-stranded DNA-binding proteins (ssDNA BPs) can potentially improve REDRAW by stabilizing the ssDNA generated during the reaction, protecting the DNA strand from degradation, and making it available for priming and polymerization via RT. Selected ssDNA BPs were tested using the method of the present invention (see Table 12).
[0272] [Table 13]
[0273] The ssDNA BPs listed in Table 12 were expressed in trans or as fusions with Cas12a, in the presence of RT(5M)(trans). The ssDNA BPs tested were hRad51_s208E_A209D (SEQ ID NO: 123), hRad52 (SEQ ID NO: 124), BsRecA (SEQ ID NO: 125), EcRecA (SEQ ID NO: 126), T4SSB (SEQ ID NO: 127), and Brex27 (SEQ ID NO: 124). The results are shown in Figures 22 and 23. Trans expression of ssDNA BPs did not improve the rate of precise editing compared to the control (pUC19) (see Figure 22). Furthermore, the fusion proteins did not show improvement except for the fusion of the N-terminus and C-terminus of Brex27 and Cas12 (see Figure 23). Brex27 is a peptide known to recruit Rad51 in situ and stabilize its interaction with ssDNA.
[0274] [Example 7] Evaluation of Gam proteins for use in REDRAW The Gam protein may help reduce indel formation during REDRAW by preventing NHEJ. Gam binds to double-strand DNA breaks and prevents DNA end processing. Gam may be used to reduce indel formation during cytosine base editing.
[0275] To evaluate the usefulness of the Gam protein in the method of the present invention, the Gam protein (Escherichia phage Mu Gam protein) (SEQ ID NO: 147) was fused to either the CRISPR-Cas effector protein (LbCas12a H759A) (SEQ ID NO: 148) or RT(5M) (SEQ ID NO: 53). LbCas12a H759A, RT(5M), and plasmids encoding tagRNAs that encode precise mutations were transfected into HEK293T cells. Target DNA was analyzed using high-throughput sequencing after 3 days. The results are shown in Figures 24 and 25.
[0276] In Figure 24, reverse transcriptase (RT) is expressed in trans as either its native sequence (e.g., RT(5M)) or fused with a Gam protein at its N-terminus (e.g., Gam-RT(5M)). These constructs are expressed concurrently with LbCas12a(H759A) or LbCas12a(H759A) having a Gam protein fused at its N-terminus (e.g., Gam-LbCas12a H759A). In Figure 25, the Gam protein is provided in trans as a fusion protein with reverse transcriptase (N-terminal fusion; Gam-RT(5M)) and / or a fusion protein with a CRISPR-Cas effector polypeptide (e.g., Gam-LbCas12a H759A). The results show that while the Gam protein can be used to reduce indel formation in some cases, the overall efficiency of editing using the method of the present invention is not improved by including the Gam protein.
[0277] [Example 8] Evaluation of the length of the primer binding site (PBS) and the reverse transcriptase template (RTT). The effect of length on editing was evaluated by varying the RTT and PBS lengths in the tagRNA of the present invention. LbCas12a, RT(5M), and tagRNA with various RTT and PBS lengths were transfected into HEK293T cells, and the editing rate 3 days after transfection was analyzed using high-throughput sequencing (HTS). The results are shown in Figure 26. The upper and lower panels of Figure 26 show the results using two different spacers (upper panel: pwsp143(GCTCAGCAGGCACCTGCCTCAGC)(SEQ ID NO: 136), lower panel: pwsp139(CTGATGGTCCATGTCTGTTACTC)(SEQ ID NO: 137)). The results differed depending on the spacer used, but many different lengths showed good editing efficiency for both RTT and PBS. One optimal combination of PBS length and RTT length may be 48 nucleotides and 52 nucleotides, respectively.
[0278] [Example 9] Evaluation of the placement of the editorial region within tagRNA. The efficiency of REDRAW can vary depending on where the desired edit site is located within the tagRNA reverse transcriptase template (RTT). In this example, we evaluated the effect of the edit site within the RTT on the rate of editing. In Figure 27, the edit site location and results are shown in bold. The upper and lower panels provide different RTT sequences with altered edit sites (RTT in the upper panel: SEQ ID NO: 187; RTT in the lower panel: SEQ ID NO: 188). The "Edit Site" column in both the upper and lower panels of Figure 27 shows the reverse complementary sequence of the first 26 bases of the RTT, which corresponds to the PAM sequence (TTTC) and a 23-base spacer sequence. We aligned double mutations along the RTT such that the spacer used for REDRAW would no longer be complementary once the desired edit was introduced into the DNA. We placed the edit site at many locations within the RTT to determine the effectiveness of the editing. In several examples, placing the edit area at positions corresponding to nucleotides 12-15 in the RTT sequence (where the TTTN PAM for LbCas12a is defined as positions -4, -3, -2, and -1, respectively) resulted in a very high level of editing.
[0279] [Example 10] REDRAW editing using different CRISPR-Cas effector proteins REDRAW was assumed to be compatible with alternative CRISPR-Cas effector proteins capable of generating double-strand DNA breaks. In this example, LbCas12a and cas9 (SpCas9), BhCas12b, and AsCas12a (EnAsCas12a) demonstrate that alternative CRISPR-Cas effector proteins can be successfully used in the method of the present invention (REDRAW).
[0280] Cas9 HEK293T cells were transformed and expressed using RT(5M), tagRNA encoding precise editing, and two forms of Cas9 (Cas9 (nuclease), nCas9(D10A) (nickase)). Cells were harvested 3 days after transfection, and target amplicons were sequenced using high-throughput sequencing (HTS). The lengths of PBS and RTT were varied, and extensions were added to both the 3' and 5' ends of the guide RNA (labeled "3' extension" or "5' extension" in Figure 28). The tagRNA extensions used targeted four different target sites (spacer: pwsp10: GAGTCCGAGCAGAAGAAGAA (SEQ ID NO: 140); pwsp621: GCATTTTCAGGAGGAAGCGA (SEQ ID NO: 141); pwsp15: GTCATCTTAGTCATTACCTG (SEQ ID NO: 142); pwsp11: GGAATCCCTTCTGCAGCACC (SEQ ID NO: 143)). The results are shown in Figure 28. Using both Cas9 and nCas9(D10A), precise editing via RT was observed with multiple different spacer sequences, but the nuclease version performed best. Furthermore, both 3' and 5' tagRNA extensions were effective in REDRAW, but the 3' extension of the extension guide RNA performed best.
[0281] BhCas12b HEK293T cells were transformed and expressed using RT(5M), a tagRNA encoding precision editing, and BhCas12b v4 (a manipulated high-efficiency version of BhCas12b). Cells were harvested 3 days after transfection, and target amplicons were sequenced using high-throughput sequencing (HTS). The lengths of PBS and RTT were varied, and extensions were added to both the 3' and 5' ends of the guide RNA (labeled 3' and 5' in Figure 29). The tagRNA extensions used targeted three different target sites (spacers: PWsp1099: ACGTACTGATGTTAACAGCTGA (SEQ ID NO: 144); PWsp1098: GGTCAGCTGTTAACATCAGTAC (SEQ ID NO: 145); PWsp1094: TCCAGCCCGCTGGCCCTGTAAA (SEQ ID NO: 146)). The results are shown in Figure 29. Precise editing via RT was observed using BhCas12b v4 and several different spacer sequences. When using BhLbCas12b, certain combinations of RTT and PBS lengths resulted in higher editing than other combinations. Generally, with BhLbCas12b, 3' extension of the tagRNA resulted in more consistent editing than 5' extension, although editing was detected using both forms of tagRNA.
[0282] EnAsCas12a AsCas12a is a homolog of LbCas12a, and EnAsCas12a is an engineered version of AsCas12a. The H800A mutation in EnAsCas12a corresponds to the H759A mutation in LbCas12a, which is a mutation that inactivates the crRNA processing ability of Cas12a.
[0283] HEK293T cells were transformed and expressed using RT(5M), a tagRNA encoding precise editing, and EnAsCas12a H800A (EnAsCpf1 H800A). In this example, the reverse transcriptase was provided as a fusion protein with EnAsCas12a (C-terminal fusion (EnAsCas12a-RT) and N-terminal fusion (RT-EnAsCas12a)). Cells were harvested 3 days after transfection, and the target amplicons were sequenced using high-throughput sequencing (HTS). Precise RT-dependent and tagRNA-dependent editing was observed when using EnAsCas12a with multiple different tagRNA sequences. The tagRNA extension used targeted a single site (spacer: CCTCACTCCTGCTCGGTGAATTT (SEQ ID NO: 171)).
[0284] The results are shown in Figure 30, which demonstrate that, in the presence of various tagRNAs, fusions of RT with the N-terminus and C-terminus of EnAsCas12a all result in precise editing. When EnAsCas12a without RT fusion was used as a control, editing was either absent or very low.
[0285] [Example 11] Editing in yeast In addition to demonstrating that human cells can be edited using the method of the present invention, we similarly evaluated it in budding yeast, a eukaryote. Budding yeast is an attractive organism for evaluating the method of the present invention for several reasons, including: (1) budding yeast utilizes the NHEJ repair process; genome double-strand breaks are not lethal, unlike in prokaryotes (e.g., E. coli) often used in directional evolution experiments; (2) yeast grows relatively quickly, allowing for rapid testing and adjustment of many of the conditions for the method of the present invention (REDRAW); (3) thousands of yeast strains are readily available; and (4) large libraries of biomolecules (proteins, RNA, etc.) can be investigated in yeast.
[0286] In this example, the budding yeast strain W303-1a (hereinafter referred to as "ScW303-1a") was selected. The genotype of ScW303-1a is MATa ade2-1 ura3-1 his3-11 trp1-1 leu2-3 leu2-112 can1-100. The editing targets of this strain include ADE2, CAN1, HIS3, LYS2, TRP1, and URA3. Sanger sequencing was used to confirm the locus sequences of each PCR product. All sequenced loci were as expected, except for ADE2. The ADE2 locus was expected to have a stop codon at Gln64; however, sequencing showed that a tyrosine codon was present at Gln64 instead of a stop codon. As a result, a special strain with a modified ADE2 locus was constructed, and REDRAW was tested at that locus. The modified strain was named ScDS21.6. Table 13 provides the genomic targets selected for testing in yeast.
[0287] [Table 14]
[0288] Examples of spacers for targeting these areas include: PWsp1643 (ADE2 target): 5'-GCATACGATGGAAGAGGTAACTT-3' (SEQ ID NO: 159) PWsp1894 (ADE2 target): 5'-GCATACGATTAAAGAGGTAACTT-3' (SEQ ID NO: 160) PWsp1665 (URA3-1 target): 5'-CAAATAGTCCTCTTTCAACAATA-3' (SEQ ID NO: 161) Examples of primer binding site sequences: 48bp primer binding site ADE2 target: 5'-CGTTGTAAAGAATAAGGAAATGATTCCGGAAGCTTTGGAAGTACTGAA-3'(Sequence ID 162) 48bp primer binding site URA3-1 target: 5'-ATAATGTCAGATCCTGTAGAGACCACATCATCCACGGTTCTATACTGT-3'(Sequence ID 163) Examples of reverse transcriptase template sequences: (A)ADE2 target: 40-bp RTT:5'-TGAAGTCGAGGACTTTGGCATACGATGGAAGAGGTAACTT-3'(Sequence ID 164) 50-bp RTT:5'-CCATTCGTCTTGAAGTCGAGGACTTTGGCATACGATGGAAGAGGTAACTT-3'(Sequence ID 165) 72-bp RTT:5'-TGTTGGAAGAGATTTGGGTTTTCCATTCGTCTTGAAGTCGAGGACTTTGGCATACGATGGAAGAGGTAACTT-3'(Sequence ID 166) (B) URA3-1 target 47-bp RTT:5'-CTACCTTAGCATCCCTTCCCTTTGCAAATAGTCCTCTCTCAACAATA-3'(Sequence ID 167) 55-bp RTT:5'-TTCACCCTCTACCTTAGCATCCCTTCCCTTTGCAAATAGTCCTCTCTCAACAATA-3'(Sequence ID 168) 63-bp RTT:5'-CTGTAACGTTCACCCTCTACCTTAGCATCCCTTCCCTTTGCAAATAGTCCTCTCTCAACAATA-3'(Sequence ID 169) Example of an LbCas12a crRNA scaffold: 5'-TAATTTCTACTAAGTGTAGAT-3'(SEQ ID NO: 170)
[0289] The protein expression vector pESC-LEU was used for the following reasons: (1) it contains the yeast selection marker LEU2 which is compatible with the ScW303-1a strain; (2) protein expression can be strongly controlled by the GAL promoter system in the plasmid; (3) high levels of protein expression are possible because the yeast origin of replication 2μ has a high copy rate; and (4) all vector manipulation and cloning can be performed in E. coli before working with yeast because it also contains the E. coli origin of replication (pUC origin) and the selection marker AmpR.
[0290] The following configurations were used for the CRISPR-Cas effector protein and reverse transcriptase: • LbCas12a+C-terminal fused MMLV-RT(5M)(SEQ ID NO: 155) • LbCas12a+N-terminal fused MMLV-RT(5M)(SEQ ID NO: 157) The LbCas12a fusion was placed under the control of the inducible GAL1 promoter (pol II promoter), while the crRNA and tagRNA were expressed using the constitutive SNR52 promoter (pol III promoter).
[0291] Furthermore, the following tagRNA configurations were tested with two LbCas12a and RT configurations: (1) absence of a 3' pseudoknot, and (2) presence of either (a) a pseudoknot called the "decoy" pseudoknot (see Figure 7, SEQ ID NO: 203) or (b) a pseudoknot called the tEvoPreQ1 pseudoknot (SEQ ID NO: 158). In addition, the lengths of three different reverse transcriptase templates (RTTs) (47, 55, 64 nucleotides, or 40, 50, 72 nucleotides) were tested using a fixed-length 48-nucleotide primer-binding site (PBS). These configurations are shown in Table 15.
[0292] [Table 15]
[0293] REDRAW was first tested in budding yeast by transforming either the yeast strain ScDS21.6 (ADE2 target site) or the yeast strain ScW303-1a (URA3 target site) with the vector of interest using the PEG / LiAc heat shock method. The transformants were plated onto synthetic complete medium (SC-LEU + 2% Glu) lacking leucine and containing 2% glucose as a carbon source. After approximately 48-72 hours, a single colony was taken and placed in 3 mL of liquid SC-LEU + 2% raffinose (SC-LEU + 2% Raff). The cells were incubated at 28°C for approximately 36 hours with shaking at 200 rpm. 600 The cells were cultured until the OD was ~1.8. Next, the 1.5 OD cells were spun down by centrifugation at room temperature and returned to 3 mL of protein expression medium, SC-LEU + 1% raffinose + 1% galactose (SC-LEU + 1% Raffinose + 1% Gal). The expression culture was incubated at 28°C for 4 hours with shaking at 200 rpm. The expression culture was then removed from the shaking incubator and centrifuged. The supernatant was then removed by pipette and 3 mL of SC-LEU + 2% Glu was added. The cells were then grown at 28°C and 200 rpm for a further 90 minutes. After 90 minutes, the OD of the culture was... 600 We confirmed that each culture contained approximately 1 OD of yeast cells (approximately 1 × 10⁶). 7 The yeast cells were pelleted in a centrifuge at room temperature. The supernatant was removed, and each culture was resuspended in 200 μL of sterile water. To select the edited colonies, approximately half of the resuspended culture (0.5 OD) (approximately 5 × 10⁶) was used. 6One half of the yeast cells were plated onto synthetic complete plates lacking either adenine (SC-ADE) or uracil (SC-URA), and the other half onto SC-LEU plates (non-selective, to see how many cells were present during a measured OD of approximately 0.5). These plates were cultured at 28°C for approximately 3 days. Colonies were then counted and recorded. Colonies were selected from the SC-ADE / SC-URA plates or SC-LEU (negative control) plates, and target loci were amplified using colony PCR. Analysis of the target loci using Sanger sequencing confirmed that the intended editing had occurred (2-bp change in ADE2: AA156 TAA->GGA and 1-bp change in URA3-1: AA 234 GGA->GAA).
[0294] Each combination of LbCas12a and RT composition / tagRNA was tested at two different target sites in yeast, and the results are shown in Figures 31 and 32. Figure 31 shows the results of editing the URA3-1 target gene (URA3-1: 1-bp change (AA 234 GGA->GAG) (editing repairs adenine nutrient requirement)), with the upper panel showing LbCas12-RT C-terminal fusion and the lower panel showing RT-LbCas12 N-terminal fusion. Figure 32 shows the results of editing the ADE2 target gene (ADE2: 2-bp change (AA 156 TAA->GGA) (editing repairs uracil nutrient requirement)), with the upper panel showing LbCas12-RT C-terminal fusion and the lower panel showing RT-LbCas12 N-terminal fusion. All configurations were able to edit the URA3-1 gene and generate viable colonies (repair of adenine nutrient requirements), but the most efficient configuration involved a pseudoknot and a 55-nucleotide RTT (Figure 31). The RT, LbCas12a C-terminal fusion was most efficient with a "decoy" pseudoknot, and the RT, LbCas12a N-terminal fusion was most efficient with a tEvoPreQ1 pseudoknot (see Figure 31). Editing of yeast ADE2 showed similar results, with the RT, LbCas12a C-terminal fusion being most efficient with a "decoy" pseudoknot, and the RT, LbCas12a N-terminal fusion being most efficient with a tEvoPreQ1 pseudoknot (Figure 32). In the case of ADE2, editing was most efficient with a 50-nucleotide RTT.
[0295] Therefore, this embodiment demonstrates that the method of the present invention can precisely edit yeast at either target site, and that for these two targets, using either the C-terminal fusion RT configuration or the N-terminal fusion RT configuration was slightly more efficient than using the N-terminal fusion RT configuration. Pseudoknots were confirmed to improve the editing efficiency of REDRAW in each configuration tested. Furthermore, in the absence of tagRNA and REDRAW editor, no growth was observed in the selection plate (SC-ADE or SC-URA), indicating that these REDRAW assays in yeast are highly stringent and the escape frequency is below the detection limit.
[0296] [Example 12] Evaluation of ssRNA-binding proteins in editing Single-stranded RNA-binding proteins (ssRNA BPs) are proteins that interact nonspecifically with ribonucleic acid. By expressing ssRNA-binding proteins during editing using the method of the present invention, the exposed tagRNA component (extended guide nucleic acid) can be stabilized against degradation by endogenous proteins. To test this, several RNA-binding proteins were expressed by fusing them to the N-terminus of RT(5M)-LbCas12a(H759A).
[0297] Figure 33 shows the results of precise editing using the ssRNA-binding proteins defensin (SEQ ID NO: 152) and ORF5 (SEQ ID NO: 153). The defensin and ORF5 of ssRNA BP were fused to the N-terminus of an RT-LbCas12 fusion protein (e.g., RT-LbCas12a), respectively. Editing is shown by comparison with the same RT-Cas12a fusion protein that was not fused with an ssRNA-binding protein at its N-terminus. It was shown that using an ssRNA-binding protein for one of the two tagRNAs (extended guide nucleic acids) tested improved precise editing.
[0298] [Example 13] Evaluation of reverse transcriptase polypeptides with different mutations Reverse transcriptase RT(5M) was engineered by introducing five mutations into the wild-type RT sequence (Anzalone et al. Nature 576:149-157 (2019)). To evaluate whether the method of the present invention could be further optimized by using RT domains with different or additional mutations compared to RT(5M), several reverse transcriptase (RT) proteins with different mutations and combinations of mutations, some with and some without the core mutation of RT(5M), were fused at the N-terminus of LbCas12a(H759A). The RT domains tested included RT(L139P, D200N, W388R, E607K), RT(L139P, D200N, T306K, W313F, W388R, E607K), RT(5M, F155Y, H638G), RT(5M, Q221R, V223M), and RT(5M, D524N). The RT(M) mutation includes D200N+L603W+T330P+T306K+W313F, referring to the amino acid numbering of SEQ ID NO: 172 (see SEQ ID NO: 53). The reference RT for amino acid numbering of sequences without the RT(5M) mutation is SEQ ID NO: 172. The reference RT for amino acid numbering of sequences containing the RT(5M) mutation is SEQ ID NO: 53. In both cases, the RT was fused to the N-terminus of LbCas12a(H759A).
[0299] The results are shown in Figure 34. Compared to RT(5M) (left), several other RT domains with different mutation combinations were able to improve the precision of editing compared to RT(5M). This result is influenced by the tagRNA (extended guide nucleic acid) used.
[0300] [Example 14] Evaluation of 3' structured RNA motifs incorporated into the 3' end of tagRNA. Experiments were conducted to evaluate whether structured RNA incorporated into the 3' end of tagRNA could further stabilize the tagRNA and protect it from possible degradation. For this purpose, several RNA sequences known to form 3-D structures, including hairpins and pseudoknots, were attached to different tagRNAs.
[0301] [Table 16]
[0302] [Table 17]
[0303] The results of incorporating various 3' structured RNAs into the composition of the present invention are provided in Figure 35. In this experiment, RT(5M)-LbCas12a H759A with various tagRNAs, some with and some without 3' RNA structures, was expressed in HEK293T cells. After 3 days, the cells were harvested and the efficiency of precision editing was analyzed by high-throughput sequencing. We observed that almost all 3' RNA structures on the tagRNAs are compatible with the method of the present invention (e.g., REDRAW). We did not observe any increase in REDRAW efficiency by using 3' RNA structures in HEK293T cells.
[0304] [Example 15] Evaluation of the use of chromatin-modulating peptide fusions Genome-editing proteins can be occluded by nucleosomes, leading to reduced activity within living cells. Chromatin regulatory proteins / peptides may help address such effects by promoting chromatin exchange, histone modification, and epigenetic modification, thereby enhancing access by programmable DNA-binding proteins such as Cas9 or Cas12a.
[0305] To evaluate this possibility, consider CHD1 (e.g., SEQ ID NO: 199), H1G (e.g., SEQ ID NO: 200), HB1 (e.g., SEQ ID NO: 201), and HN1 (e.g., SEQ ID NO: 202) (e.g., Ding et al., CRISPR J. 2019). Chromatin regulatory peptides (see Feb;2:51-63) were fused to selected constructs of the present invention in various fusion directions as follows: HN1-RT(5M)-LBCas12a(H759A), HN1-RT(5M)-LBCas12a(H759A)-HB1, HN1-RT(5M)-LBCas12a(H759A)-H1G, HN1-RT(5M)-LBCas12a(H759A)-CHD1, HN1-RT(5M)-H1G-LBCas12a(H759A), and HN1-RT(5M)-CHD1-LBCas12a(H759A).
[0306] The results of precise editing using the constructs of the present invention and chromatin regulatory peptides are provided in Figure 36. Compared to constructs without additional fusion (e.g., RT(5M)-LbCas12a H759A), most constructs did not result in an increase in precise editing activity. In HN1-RT(5M)-LbCas12a(H759A)-HB1, a slight increase in precise editing activity was observed when two of the tagRNAs, tagRNA5 and tagRNA6, were used.
[0307] [Example 16] Evaluation of simultaneous nicking of the non-template chain of the construct of the present invention. For example, intermediates in genome editing events, including base editing, prime editing, and REDRAW, may be mismatched DNA double helixes where one strand of DNA is edited by an enzyme (the desired edit) and the other strand contains the wild-type sequence. Resolving such mismatches to perform the desired edit can be crucial to ensure that the desired edit is persistent within the cell.
[0308] Nicking the DNA strand opposite the strand containing the edit is thought to facilitate a process that makes the edit permanent by utilizing the cell's mismatch repair (MMR). In eukaryotes, MMR resolves the base mismatch by identifying the DNA strand containing the nick (which suggests it is a newly synthesized strand and therefore "highly" likely to contain the "mistake"), removing that strand, and resynthesizing perfectly complementary DNA. In this way, DNA containing the wild-type sequence is removed, and new DNA that is perfectly complementary to the DNA containing the desired edit is created. This approach has been used to improve the editing efficiency of base editors (Komor et al. Nature 533:420-424 (2016)) and prime editors (Anzalone et al. Nature 576:149-157 (2019)).
[0309] We attempted a similar evaluation using the construct and method of the present invention (REDRAW). In REDRAW, editing is performed on the DNA template strand (the DNA strand hybridized by crRNA). Therefore, we wanted to determine whether nicking the non-template strand near the editing region during the editing process would improve the efficiency of precise editing in REDRAW.
[0310] Fu et al. previously reported that crRNAs containing various mismatches at base positions 12–15 can cause Cas12a to act as a non-template strand nickase rather than a nuclease (TTTV PAM is denoted as positions -4, -3, -2, and -1) (Fu et al, Nat Microbiol. 2019 May;4(5):888-897). To investigate whether such an approach is effective in increasing the precision editing achieved by the present invention's method and constructs, crRNAs containing various mismatches (extended guide nucleic acids, as opposed to tagRNAs) were prepared and used to edit target DNA together with the present invention's constructs. The results are shown in Table 18.
[0311] [Table 18]
[0312] Compared to processing with crRNA without nicking, crRNAs containing single, double, or triple mismatches at positions 12–15 led to improved editing efficiency. In summary, co-expression of crRNA containing appropriate mismatches (in addition to tagRNA) can be used to induce nicks on the non-template strand, thereby enhancing the precision editing efficiency of the method of the present invention.
[0313] The foregoing is an example of the present invention and should not be construed as an limitation thereof. The present invention is defined by the following claims, and equivalents of the claims should also be included therein.
Claims
1. Target nucleic acid (a) a type V CRISPR-Cas effector protein or a type II CRISPR-Cas effector protein; (b) a reverse transcriptase, and (c) an extended guide nucleic acid comprising a structured RNA motif; wherein the target nucleic acid is modified by contacting the target nucleic acid with a
2. 2. The method of claim 1, wherein the structured RNA motif is located at the 3' end of the extended guide nucleic acid.
3. 2. The method of claim 1, wherein the structured RNA motif is AsCpf1BB (SEQ ID NO: 189), box B (SEQ ID NO: 190), pseudoknot(decoy) (SEQ ID NO: 95, SEQ ID NO: 203), pseudoknot(tEvoPreQ1) (SEQ ID NO: 191), fmpknot (SEQ ID NO: 192), mpknot (SEQ ID NO: 193), MS2 (SEQ ID NO: 194), PP7 (SEQ ID NO: 195), SLBP (SEQ ID NO: 196), TAR (SEQ ID NO: 197), and / or ThermoPh (SEQ ID NO: 198).
4. The method of claim 1 , wherein the structured RNA motif is a pseudoknot.
5. The method of claim 4, wherein the pseudoknot is a tEvoPreQ1 pseudoknot comprising the nucleic acid sequence of SEQ ID NO: 158 or an EvoPreQ1 pseudoknot comprising the nucleic acid sequence of SEQ ID NO:
191.
6. The method of claim 4, wherein the pseudoknot comprises the nucleic acid sequence of SEQ ID NO:95 or SEQ ID NO:
203.
7. The extended guide nucleic acid, (i) a type V or type II CRISPR nucleic acid (crRNA, crDNA), and / or a type V or type II CRISPR nucleic acid and a tracr nucleic acid (e.g., type II or type V tracrRNA, type II or type V tracrDNA); and (ii) an extension portion comprising a primer binding site and a reverse transcriptase template (RT template) (RTT); wherein the RTT is about 35 to about 75 nucleotides in length, the PBS is about 30 to about 80 nucleotides in length, and optionally the PBS is about 8, 16, 24, 32, 40, 48, 56, 64, 72, or 80 nucleotides in length, and the RTT is about 36, 40, 44, 47, 50, 52, 55, 63, 72, or 74 nucleotides in length; The method of claim 1 further comprising:
8. 2. The method of claim 1, wherein the Type V or Type II CRISPR-Cas effector protein is a fusion protein and / or the reverse transcriptase is a fusion protein, wherein the Type V or Type II CRISPR-Cas fusion protein, the reverse transcriptase fusion protein and / or the extended guide nucleic acid are fused to one or more components that recruit the reverse transcriptase to the Type V or Type II CRISPR-Cas effector protein, optionally wherein one or more of the components recruit via protein-protein interactions, protein-RNA interactions, and / or chemical interactions, and wherein the Type V or Type II CRISPR-Cas fusion protein is fused to a chromatin modulating peptide.
9. 9. The method of claim 8, wherein the chromatin modulating peptide is fused to the C-terminus and / or N-terminus of the type V or type II CRISPR-Cas fusion protein.
10. 9. The method of claim 8, wherein the type V or type II CRISPR-Cas fusion protein is fused to a reverse transcriptase at its N-terminus, and the chromatin modulating peptide is fused to the N-terminus of the reverse transcriptase.
11. The method of claim 8, wherein the chromatin regulatory peptides are CHD1, H1G, HB1, and HN1.
12. The method described in claim 11, wherein CHD1 is sequence number 199, H1G is sequence number 200, HB1 is sequence number 201, and HN1 is sequence number 202.
13. 2. The method of claim 1, wherein the reverse transcriptase is fused to one or more single-stranded RNA binding domains (RBDs), thereby improving the thermostability, processivity and template affinity of the reverse transcriptase.
14. 14. The method of claim 13, wherein the one or more single-stranded RNA binding domains are fused to the N-terminus of the reverse transcriptase, and optionally the reverse transcriptase is further fused at its C-terminus to the N-terminus of the Type II CRISPR-Cas effector protein and / or the Type V CRISPR-Cas effector protein.
15. 10. The method of claim 1, further comprising contacting the target nucleic acid with a single-stranded DNA binding protein (ssDNA binding protein).
16. 16. The method of claim 15, wherein the ssDNA binding protein is fused to a type IIV CRISPR-Cas effector protein or a type V CRISPR-Cas effector protein.
17. 17. The method of claim 16, wherein the ssDNA binding protein is fused to the C-terminus of a type II or type V CRISPR-Cas effector protein.
18. 17. The method of claim 16, wherein the ssDNA binding protein is fused to the N-terminus of a type II or type V CRISPR-Cas effector protein.
19. 16. The method of claim 15, wherein the ssDNA binding protein is hRad51 (optionally hRad51_S208E_A209D), hRad52, BsRecA, EcRecA, T4ssB and / or Brex27.
20. 2. The method of claim 1, further comprising reducing double-stranded breaks by introducing a chemical inhibitor of non-homologous end joining (NHEJ), by introducing a CRISPR guide nucleic acid or siRNA targeting an NHEJ protein to transiently knock down expression of an NHEJ protein, or by introducing a polypeptide that prevents NHEJ, wherein the polypeptide that prevents NHEJ is a Gam protein, and the Gam protein is fused to the reverse transcriptase and / or the CRISPR-Cas effector protein, and optionally the Gam protein is fused to the N-terminus of the reverse transcriptase and / or the CRISPR-Cas effector protein.
21. 21. The method of claim 20, wherein the Gam protein is an Escherichia phage Mu Gam protein, and optionally the Gam protein comprises the amino acid sequence of SEQ ID NO: 147.
